Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds and cell targeting molecules for site-specific conjugation
By introducing unique or ectopic amino acid residues into Shiga toxin A subunit polypeptide for site-specific ligation, the problem of controlling site-specific and homogeneity during traditional biomolecular conjugation is solved, and high efficiency and low Cost cell-targeted molecular delivery and therapeutic effects.
Patent Information
- Application Number
- CN201780085716.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2016-12-07
- Filing Date
- 2017-12-07
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2037-12-07
AI Technical Summary
The prior art has challenges in controlling site specificity, homogeneity, yield and cost-effectiveness in biomolecular conjugation, especially when using traditional chemical reactions, it is difficult to obtain efficient, low-cost homogeneous bioconjugation. Things.
By introducing unique or ectopic amino acid residues into Shiga toxin A subunit polypeptides, using these residues for site-specific ligation, forming cell-targeting molecules and their compositions with optimized properties to achieve cargo selection Sexual delivery and targeted therapy.
It achieves the acquisition of high homogeneity of bioconjugates at low cost and high efficiency, improves the delivery accuracy and therapeutic effect of cell-targeted molecules, and reduces production costs.
Smart Images

Figure CN110494443B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to cell targeting molecules and / or components of cell targeting molecules comprising site-specific amino acid residues for attachment to other molecules (such as, for example, for covalent attachment to cargo molecules for delivery via the cell targeting molecule). Certain embodiments of the cell targeting molecules of the invention comprise a Shiga toxin effector polypeptide, linker and / or immunoglobulin-type polypeptide of the invention, optionally conjugated to another molecule (such as, for example, an agent that alters the cell targeting molecule and / or a cargo for delivery). The cell targeting molecules of the invention and compositions thereof have uses, for example, for selective delivery of cargo to cells expressing a target, and as diagnostic and / or therapeutic molecules for the treatment of a variety of diseases, disorders and conditions, including genetic disorders, genetic predispositions, infections, cancers, tumors, growth abnormalities and / or immune disorders. Background Art
[0002] The following includes information that may be useful in understanding the invention described herein. No admission is made that any of the information provided herein is prior art or relevant to the presently described or claimed invention, or that any publication or document specifically or implicitly referenced herein is prior art.
[0003] Shiga toxin effector polypeptides can be combined with immunoglobulin domains, ligands and other targeting moieties to generate cell targeting molecules (see, e.g., WO 2014 / 164693; WO 2015 / 113005; WO 2015 / 113007; WO 2015 / 138435; WO 2015 / 138452; WO 2015 / 191764; US 20160177284; WO 2016 / 126950). Shiga toxin A subunit effector polypeptides are polypeptides derived from Shiga toxin A subunit members of the Shiga toxin family that are capable of exhibiting one or more Shiga toxin functions (see, e.g., Cheung M et al., Mol Cancer 9:28 (2010) WO 2014 / 164693; WO 2015 / 113005; WO 2015 / 113007; WO 2015 / 191764; WO 2016 / 126950). The Shiga toxin A subunit is stable and retains one or more functions of the toxin even when mutated, truncated, and / or fused to other molecules (see, e.g., WO 2014 / 164693; WO 2015 / 113005; WO 2015 / 113007; WO 2015 / 138452; WO 2015 / 191764; US20160177284; WO 2016 / 126950). The functions of Shiga toxin include, for example, increasing cellular internalization, directing subcellular routing from the endosomal compartment to the cytosol through a series of well-characterized intracellular compartments, avoiding intracellular degradation, catalytically inactivating ribosomes, and achieving cytostatic and / or cytotoxic effects. Furthermore, Shiga toxin effector polypeptides have been recognized to possess unique characteristics that facilitate cell-internalized molecules for targeted therapy (see, e.g., WO 2014 / 164680; US20150259428; WO 2016 / 126950).
[0004] Bioconjugates are useful formats for developing therapeutic or diagnostic biomolecules, such as, for example, by linking bioactive agents to targeting agents, solubility modifiers, pharmacokinetic modifiers, immunogenicity modifiers, and pharmacodynamic modifiers. Bioconjugates have been shown to have novel uses compared to the unconjugated components of the conjugate, such as, for example, cell type-specific targeting of drugs with antibody-drug conjugates or cell type-specific targeting of toxins with immunotoxins and ligand-toxin fusions. In addition, bioconjugates with novel uses and / or desirable improved characteristics can be rationally designed. Bioconjugates can be designed to have improved characteristics compared to the unconjugated components of the conjugate, such as, for example, improved pharmacokinetics, pharmacodynamics, safety, tolerability, therapeutic window, solubility, and immunogenicity.
[0005] It is desirable to optimize Shiga toxin effector polypeptide conjugates and cell targeting molecules comprising Shiga toxin effector polypeptides for conjugation to another one or more agents or cargoes to develop therapeutic and / or diagnostic biomolecules. For example, it is desirable to conjugate a cell targeting molecule comprising a Shiga toxin effector polypeptide to one or more molecular cargoes to form a molecule capable of delivering one or more cargoes thereof in a cell-targeted manner. In addition, it is desirable to conjugate a cell targeting molecule comprising a Shiga toxin effector polypeptide to one or more molecular cargoes to form a molecule capable of accurately intracellularly delivering one or more cargoes thereof following a clear subcellular delivery directed by a Shiga toxin effector polypeptide (see, e.g., WO 2015 / 138435, WO 2015 / 138452, and WO 2015 / 191764). In addition, it is desirable to conjugate a cell targeting molecule comprising a Shiga toxin effector polypeptide to an agent, such as, for example, a solubility modifier, a pharmacokinetic modifier, an immunogenicity modifier, and / or a pharmacodynamic modifier.
[0006] Typically, biomolecules are conjugated to other agents or goods using chemical reactions that involve one or more functional groups of biomolecules and the functional groups of agents or goods, or alternatively are designed as the functional groups of the joints bridged between biomolecules and agents or goods. However, traditional conjugation chemistry has several problems that limit its usefulness, such as, for example, controlling conjugation site specificity, managing conjugate stoichiometry, obtaining required homogeneity, low yield, batch consistency and cost-effectiveness (see, for example, Panowski S et al., MAbs 6: 34-45 (2014)). In particular, homogeneity may be the key to conjugated drug manufacturing, because homogeneous products are more likely to perform better in the clinic, because these products generally have better pharmacokinetics and safety. For example, protein conjugates produced from solvent-accessible amino acid residues using traditional methods can produce heterogeneous mixtures of conjugates with different conjugate stoichiometric ratios and different residue position connection sites. Furthermore, an important criterion for the quality of biopharmaceutical conjugates is homogeneity, which may be required for government approval for sale (see, e.g., Kim E, Kim K, Biomol Ther 23:493-509 (2015); Zhou Q, Kim J, Anticancer Agents Med Chem 15:828-36 (2015)). Therefore, it is desirable to control conjugation to protein biomolecules, such as by using methods that force conjugation to a limited number of known residue sites at the desired conjugate stoichiometry. However, even if conjugation is limited to a single product, separation and purification of the conjugate from unconjugated material is inefficient and expensive.
[0007] There is a need in the art to develop Shiga toxin A subunit scaffolds and cell targeting molecules comprising the same for convenient, controlled, and cost-effective, site-specific conjugation of various molecules, such as, for example, cargoes for targeted delivery or molecule-altering agents (to improve the properties of the entire molecule (e.g., therapeutic efficacy, pharmacokinetics, immunogenicity, or therapeutic index after administration of the molecule to a vertebrate)). It would be desirable to have convenient and less expensive methods for obtaining extremely homogeneous bioconjugates of biomolecules comprising Shiga toxin A subunit effector polypeptides, such as, for example, cell targeting molecules for diagnostic and / or therapeutic purposes. Summary of the Invention
[0008] The present invention provides various embodiments of Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell targeting molecules, each of which comprises site-specific amino acid residues for attachment to other molecules, such as, for example, cargo molecules. The present invention also provides various embodiments of Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell targeting molecules, each of which comprises n agents or cargos directly or indirectly attached to site-specific amino acid residues, such as, for example, specific cysteine or lysine residues. In addition, the present invention provides components of cell targeting molecules, which comprise site-specific attachment amino acid residues for attachment to other molecules, such as, for example, cargo molecules for delivery via the cell targeting molecule, or cell targeting molecule-altering agents that confer desired properties to the cell targeting molecule upon administration to a mammal.
[0009] The present invention provides various embodiments of Shiga toxin A subunit polypeptides having unique residues and / or one or more ectopic amino acid residues, wherein each polypeptide is capable of exhibiting one or more Shiga toxin A subunit effector functions, such as, for example, promoting cellular internalization, efficient subcellular delivery, catalytic activity, and cytotoxicity. The present invention provides various embodiments of Shiga toxin A subunit polypeptides having one or more mutations relative to a naturally occurring Shiga toxin that result in one or more unique and / or ectopic amino acid residues, wherein each polypeptide is capable of exhibiting one or more Shiga toxin effector functions.
[0010] The connection of the cell targeting binding region to a polypeptide derived from the Shiga toxin A subunit enables the engineering of cell targeting molecules that utilize one or more unique and / or ectopic amino acid residues as one or more attachment points for attachment of other molecules (such as, for example, molecular cargo for delivery and / or agents that alter the properties of the cell targeting molecule). Thus, certain cell targeting molecules of the present invention and compositions thereof can be used to selectively deliver one or more cargoes to one or more target-expressing cell types in the presence of one or more other cell types. In addition, certain cell targeting molecules of the present invention and compositions thereof can be used to selectively kill cells expressing the target in the presence of one or more other cell types. For example, certain cell targeting molecules of the present invention can be potently cytotoxic to cells expressing the target by their ability to effectively deliver catalytically active Shiga toxin effector polypeptides (which are effectively directed to the cytosol) to the interior of cells expressing the target.
[0011] Certain embodiments of the present invention are Shiga toxin A subunit effector polypeptides comprising one or more mutations relative to wild-type Shiga toxin, resulting in one or more unique sites and / or positions-ectopic amino acid residues. The unique sites and / or ectopic amino acid residues of the Shiga toxin A subunit effector polypeptides of the present invention have uses, for example, for direct or indirect controlled site-specific attachment of other molecules (e.g., linkers, cell targeting moieties, peptides, nucleic acids, proteins, protein-nucleic acid complexes, cytotoxic agents, solubility modifiers, pharmacokinetic modifiers, immunogenicity modifiers, and pharmacodynamic modifiers). In certain embodiments, the Shiga toxin A subunit effector polypeptides of the present invention are capable of exhibiting one or more Shiga toxin A subunit effector functions, such as, for example, promoting cellular internalization, efficient subcellular delivery, catalytic activity, and cytotoxicity. In certain embodiments, the Shiga toxin A subunit effector polypeptides of the present invention are conjugated to another molecule via the unique sites and / or ectopic amino acid residues of the Shiga toxin effector polypeptide. The present invention also provides a cell targeting molecule comprising a Shiga toxin effector polypeptide of the present invention, which is optionally conjugated to another molecule via a unique site and / or ectopic amino acid residue of the Shiga toxin effector polypeptide. In addition, the present invention provides various cell targeting molecules and compositions thereof comprising such a Shiga toxin A subunit polypeptide, wherein each molecule is capable of delivering the Shiga toxin A subunit effector polypeptide to a target cell and the Shiga toxin A subunit is capable of entering the target cell.
[0012] Certain embodiments of the present invention are Shiga toxin A subunit effector polypeptide scaffolds, each of which comprises at least one Shiga toxin A subunit effector polypeptide and a linker, wherein the scaffold comprises a unique amino acid residue. The unique amino acid residues of the Shiga toxin A subunit effector polypeptide scaffolds of the present invention have uses, for example, for direct or indirect controlled site-specific attachment of other molecules (e.g., cell targeting moieties, peptides, nucleic acids, proteins, protein-nucleic acid complexes, cytotoxic agents, solubility modifiers, pharmacokinetic modifiers, immunogenicity modifiers, and pharmacodynamic modifiers). In certain embodiments, the Shiga toxin A subunit effector polypeptide scaffolds of the present invention are capable of exhibiting one or more Shiga toxin A subunit effector functions, such as, for example, promoting cellular internalization, efficient subcellular delivery, catalytic activity, and cytotoxicity. In certain embodiments, the Shiga toxin A subunit effector polypeptide scaffolds of the present invention are conjugated to another molecule via the unique amino acid residues of the Shiga toxin effector polypeptide scaffolds. The present invention also provides cell targeting molecules comprising the Shiga toxin effector polypeptide scaffolds of the present invention, which are optionally conjugated to another molecule at the unique amino acid residue sites of the Shiga toxin effector polypeptide scaffolds. In addition, the present invention provides various cell targeting molecules and compositions thereof comprising such Shiga toxin effector polypeptide scaffolds, wherein each molecule is capable of delivering Shiga toxin A subunit effector polypeptides to target cells and Shiga toxin A subunits are capable of entering target cells.
[0013] Certain embodiments of the present invention are components for cell targeting molecules, such as, for example, linkers or cell targeting binding regions, each of which comprises unique sites and / or ectopically positioned amino acid residues for controlled, direct or indirect site-specific attachment of other molecules. Certain further embodiments are cell targeting binding regions (e.g., immunoglobulin-derived polypeptides), each comprising one or more amino acid residues having functional groups for direct or indirect site-specific attachment of other molecules (e.g., linkers, cell targeting moieties, peptides, nucleic acids, proteins, protein-nucleic acid complexes, cytotoxic agents, solubility modifiers, pharmacokinetic modifiers, immunogenicity modifiers, and pharmacodynamic modifiers). Certain other embodiments of the present invention are linkers comprising one or more site-engineered functional groups for site-specific attachment of other molecules. The present invention also provides cell targeting molecules comprising such components (e.g., cell targeting binding regions and / or linkers of the present invention, optionally attached to another molecule).
[0014] Certain embodiments of the cell targeting molecules of the present invention comprise a Shiga toxin effector polypeptide, a Shiga toxin effector scaffold, a linker and / or an immunoglobulin-type polypeptide of the present invention, optionally conjugated to another molecule (such as, for example, an agent that alters the cell targeting molecule and / or a cargo for delivery). For certain further embodiments, the Shiga toxin A subunit component of the cell targeting molecule is capable of exhibiting one or more Shiga toxin A subunit effector functions, such as, for example, promoting cellular internalization, efficient subcellular delivery, catalytic activity and cytotoxicity. The cell targeting molecules of the present invention and compositions thereof have uses, for example, for selective delivery of cargo to cells expressing a target, and as diagnostic and / or therapeutic molecules for the treatment of a variety of diseases, disorders and conditions, including genetic disorders, genetic predispositions, infections, cancers, tumors, growth abnormalities and / or immune disorders.
[0015] Implementation Group #1 - Shiga Toxin Effector Peptides
[0016] In certain embodiments, the Shiga toxin effector polypeptides of the present invention are derived from the A subunit of at least one member of the Shiga toxin family and comprise a unique amino acid residue relative to all other amino acid residues in the polypeptide. In certain further embodiments, the Shiga toxin effector polypeptide is capable of exhibiting one or more Shiga toxin effector functions. For certain further embodiments, the Shiga toxin effector polypeptide is capable of exhibiting significant levels of one or more Shiga toxin effector functions selected from the following: promoting cellular internalization, directing subcellular trafficking to the cytosol after cell entry, catalytic inactivation of ribosomes, and cytotoxicity. In certain further embodiments, the unique amino acid residue is ectopic. In certain further embodiments, the unique amino acid residue is cysteine, histidine, lysine, or a non-natural amino acid residue. In certain further embodiments, the unique amino acid residue is capable of being incorporated into the Shiga toxin effector polypeptide through the nucleic acid translation process. In certain further embodiments, the Shiga toxin effector polypeptide is covalently linked to a heterologous molecule, such as, for example, a cell targeting binding region, a linker, another exogenous substance, a cargo, or a cell targeting altering agent, via the functional group of the unique amino acid residue. In certain further embodiments, the heterologous molecule is selected from the group consisting of: an antibiotic, an antigen, an antigenic substance, a cytotoxic agent, a radionuclide, a cell targeting molecule altering agent, a detection enhancing agent, a dye, a T cell epitope, a fluorophore, an immunogen, an immunogenic substance, an enzyme, a zymoxin, a lipid, a polymer, polyethylene glycol, a serum albumin binder, a small molecule chemotherapeutic agent, a prodrug, a peptide, a protein, a nucleic acid and / or a protein-nucleic acid complex.
[0017] In certain embodiments, the Shiga toxin effector polypeptides of the present invention comprise one or more amino acid substitutions relative to a wild-type Shiga toxin A subunit having substantial sequence identity; wherein the totality of the amino acid substitutions results in the presence of a unique amino acid residue in the Shiga toxin effector polypeptide compared to all other residues in the Shiga toxin effector polypeptide; and wherein the Shiga toxin effector polypeptide is capable of performing one or more Shiga toxin effector functions. The term "substantial sequence identity" means having at least about 85%, 90%, 95%, 98%, 99% or greater identity (typically 92-99% identity) relative to aligned polypeptide sequences of the same size or when compared to aligned sequences aligned by computer homology programs known in the art. In certain further embodiments, the unique amino acid residue is one of the one or more substituted amino acids, and positional variability may be considered. Positional variability means that the position of the unique amino acid is not the type of amino acid naturally found at that position in a closely aligned wild-type Shiga toxin A subunit or fragment thereof when aligned along the entire length of the Shiga toxin effector polypeptide of the present invention. In certain other embodiments, the unique amino acids are naturally located amino acids relative to a wild-type Shiga toxin A subunit having substantial sequence identity to the Shiga toxin effector polypeptide. The uniqueness may be due to one or more amino acid substitutions that remove one or more other amino acids of the same type.
[0018] In certain embodiments, the Shiga toxin effector polypeptides of the invention are capable of exhibiting one or more Shiga toxin effector functions selected from the group consisting of directing intracellular trafficking of a cell in which the polypeptide is present to the Golgi apparatus, directing intracellular trafficking of a cell in which the polypeptide is present to the endoplasmic reticulum, directing intracellular trafficking of a cell in which the polypeptide is present to the cytosol, directing intracellular trafficking in the presence of a cargo directly or indirectly linked to the polypeptide, inhibition of ribosome function, enzymatic inactivation of ribosomes, and cytotoxicity. In certain further embodiments, the Shiga toxin effector polypeptides are capable of exhibiting ribosome inhibitory activity, IC 50 The value is 10,000 picomoles or less.
[0019] In certain further embodiments, the unique amino acid residue is an unnatural amino acid residue.
[0020] In certain further embodiments, the unique amino acid residues are capable of being incorporated into a Shiga toxin effector polypeptide by translation of the polynucleotide, such as by the action of ribosomes in vitro or by the action of ribosomes in living cells, such as host cells used for protein production.
[0021] In certain further embodiments, the unique amino acid residue is located internally in the Shiga toxin effector polypeptide (e.g., an internally located amino acid residue cannot be a terminal residue of the polypeptide, such as an amino acid residue at the end of the polypeptide having a free primary amine group or carboxyl group). Instead, both the amino and carboxyl groups of internal amino acid residues of the polypeptide participate in peptide bonds with other amino acid residues.
[0022] In certain further embodiments, the unique amino acid residue is selected from the group consisting of cysteine, histidine, lysine, selenocysteine, and pyrroline-carboxy-lysine.
[0023] In certain further embodiments, the Shiga toxin effector polypeptide of the invention comprises or consists essentially of any one of SEQ ID NOs: 5-232.
[0024] In certain further embodiments, the unique amino acid residue is covalently linked via its functional group to a heterologous molecule, such as an antibiotic, an antigen, an antigenic substance, a cytotoxic agent, a radionuclide, a cell targeting molecule altering agent, a detection facilitating agent, a dye, a T cell epitope, a fluorophore, an immunogen, an immunogenic substance, an enzyme, a zymoxin, a lipid, a polymer, polyethylene glycol, a serum albumin binder, a small molecule chemotherapeutic agent, a prodrug, a peptide, a protein, a nucleic acid and / or a protein-nucleic acid complex.
[0025] In certain further embodiments, the Shiga toxin effector polypeptides of the invention comprise one or more amino acid substitutions relative to a wild-type Shiga toxin A subunit having substantial sequence identity to the Shiga toxin effector polypeptide, which result in a positionally-different amino acid residue suitable for chemical conjugation via a chemically reactive group, and wherein the Shiga toxin effector polypeptide is capable of exhibiting one or more Shiga toxin effector functions.
[0026] In certain embodiments, the Shiga toxin effector polypeptides of the invention comprise one or more amino acid substitutions relative to a wild-type Shiga toxin A subunit having substantial sequence identity; wherein the one or more amino acid substitutions result in a positionally-ectopic amino acid residue available for conjugation; and wherein the Shiga toxin effector polypeptide is capable of exhibiting one or more Shiga toxin effector functions. In certain further embodiments, the Shiga toxin effector polypeptides of the invention are capable of exhibiting one or more Shiga toxin effector functions selected from the group consisting of directing intracellular sending to the Golgi apparatus of a cell in which the polypeptide is present, directing intracellular sending to the endoplasmic reticulum of a cell in which the polypeptide is present, directing intracellular sending to the cytosol of a cell in which the polypeptide is present, directing intracellular sending in the presence of a cargo directly or indirectly linked to the polypeptide, inhibiting ribosome function, enzymatically inactivating ribosomes, and cytotoxicity. In certain further embodiments, the Shiga toxin effector polypeptides are capable of exhibiting ribosome inhibitory activity, IC 50 The value is 10,000 picomoles or less.
[0027] In certain further embodiments, the positionally-different amino acid residue is a non-natural amino acid residue.
[0028] In certain further embodiments, the positionally-ectopic amino acid residue is capable of being incorporated into the Shiga toxin effector polypeptide by translation of the polynucleotide, for example, by the action of ribosomes in vitro or by the action of ribosomes in living cells.
[0029] In certain further embodiments, the positionally-ectopic amino acid residue is located internally in the Shiga toxin effector polypeptide.
[0030] In certain further embodiments, the positionally-isotopic amino acid residue is selected from the group consisting of cysteine, histidine, lysine, selenocysteine, and pyrroline-carboxy-lysine.
[0031] In certain further embodiments, the Shiga toxin effector polypeptide of the invention comprises or consists essentially of any one of SEQ ID NOs: 5-124.
[0032] In certain further embodiments, the positionally-differentiated amino acid residue is covalently linked via its functional group to a heterologous molecule, such as an antibiotic, an antigen, an antigenic substance, a cytotoxic agent, a radionuclide, a cell targeting molecule altering agent, a detection enhancing agent, a dye, a T cell epitope, a fluorophore, an immunogen, an immunogenic substance, an enzyme, a zymoxin, a lipid, a polymer, polyethylene glycol, a serum albumin binder, a small molecule chemotherapeutic agent, a prodrug, a peptide, a protein, a nucleic acid and / or a protein-nucleic acid complex.
[0033] In certain embodiments, a Shiga toxin effector polypeptide of the invention comprises or consists essentially of any one of SEQ ID NOs: 5-84, 830, 832, and 1109-1140.
[0034] In certain embodiments, the Shiga toxin effector polypeptide of the present invention (1) is a polypeptide derived from the A subunit of a member of the Shiga toxin family, and (2) comprises an amino acid residue having a functional group that is covalently linked to a heterologous molecule (which is heterologous to the Shiga toxin) through the functional group. For certain further embodiments, the Shiga toxin effector polypeptide is capable of exhibiting Shiga toxin effector function. In certain further embodiments, the amino acid residue is cysteine, histidine, lysine, selenocysteine and pyrroline-carboxyl-lysine. In certain further embodiments, the amino acid residue is ectopic to the wild-type Shiga toxin A subunit - meaning that the amino acid residue is not naturally found at that position in the wild-type Shiga toxin. In certain further embodiments, the amino acid residue is non-natural - meaning that the amino acid is not one of the twenty common amino acids. In certain further embodiments, the amino acid residue is capable of being incorporated into the Shiga toxin effector polypeptide by nucleic acid translation. In certain further embodiments, the Shiga toxin effector polypeptide comprises or consists essentially of a polypeptide as set forth in any one of SEQ ID NOs: 5-84, 830, 832, and 1109-1140. For certain further embodiments, the Shiga toxin effector polypeptide is capable of exhibiting significant intracellular trafficking from endosomal compartments to the Golgi apparatus, endoplasmic reticulum, and / or cytoplasmic compartments. In certain further embodiments, the Shiga toxin effector polypeptide is capable of exhibiting ribosome inhibitory activity (IC 50 In certain further embodiments, the heterologous molecule is selected from the group consisting of: peptides, proteins, nucleic acids, protein-nucleic acid complexes, cytotoxic agents, antibiotics, and detection facilitators. For certain further embodiments, the heterologous molecule is capable of specifically binding to at least one extracellular target biomolecule physically coupled to the cell surface. In certain further embodiments, the heterologous molecule comprises a cell targeting polypeptide. In certain further embodiments, the cell targeting polypeptide comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NARFragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. For certain further embodiments, the heterologous molecule is capable of binding to an extracellular target biomolecule selected from the group consisting of: CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gpA3 3, mucin, TAG-72, carbonic anhydrase IX, folate-binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TRP- 1. TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase-related Antigen, human tyrosinase-related protein 1, HPV-E7, Epstein–Barr virus (Epstein–Barr virus) antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13,In some embodiments, the Shiga toxin effector polypeptide comprises a carboxy-terminal endoplasmic reticulum retention / retrieval signal motif of a KDEL family member ("KDEL," disclosed as SEQ ID NO: 1142). In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173),HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1188) NO:1189). For certain further embodiments, administration of a Shiga toxin effector polypeptide to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell-targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell-targeting molecule to the cytosol of the cell, (3) disruption of ribosomal function of the cell, and (4) killing of the cell. For certain further embodiments, administration of a Shiga toxin effector polypeptide of the invention to a cell expressing a biomolecule target can cause cell death, i.e., kill the cell. In certain further embodiments, the Shiga toxin effector polypeptide comprises a mutation relative to a naturally occurring A subunit of a member of the Shiga toxin family that alters the enzymatic activity of the Shiga toxin effector polypeptide, the mutation being selected from at least one amino acid residue deletion, insertion, or substitution, such as, for example, A231E, N75A, Y77S, Y114S, E167D, R170A, R176K, and / or W203A in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. In certain further embodiments, the mutation is selected from at least one amino acid residue deletion, insertion, or substitution that reduces or eliminates catalytic activity but retains at least one other Shiga toxin effector function, such as, for example, inducing cellular internalization and / or directing subcellular trafficking. In certain further embodiments, the mutation reduces or eliminates the cytotoxicity of the Shiga toxin effector polypeptide.
[0035] In certain embodiments, the Shiga toxin effector polypeptide of the present invention (1) is a polypeptide derived from the A subunit of a member of the Shiga toxin family, and (2) comprises an ectopic amino acid residue having a functional group suitable for chemical conjugation to a heterologous molecule (which is heterologous to the Shiga toxin) through the functional group; and wherein the Shiga toxin effector polypeptide is capable of exhibiting a Shiga toxin effector function. In certain further embodiments, the ectopic amino acid residue is a basic and / or strongly nucleophilic amino acid residue, and is optionally cysteine, histidine, lysine, selenocysteine, or pyrroline-carboxyl-lysine. In certain further embodiments, the ectopic amino acid residue is non-natural - meaning that the amino acid is not one of the twenty common amino acids. In certain further embodiments, the ectopic amino acid residue is capable of incorporation into the Shiga toxin effector polypeptide by nucleic acid translation. In certain further embodiments, the Shiga toxin effector polypeptide comprises or consists essentially of a polypeptide as set forth in any one of SEQ ID NOs: 5-84, 830, 832, and 1109-1140. For certain further embodiments, the Shiga toxin effector polypeptide can exhibit significant intracellular trafficking from endosomal compartments to the Golgi apparatus, endoplasmic reticulum, and / or cytoplasmic compartments. For certain further embodiments, the Shiga toxin effector polypeptide can exhibit ribosome inhibitory activity (IC 50 In certain further embodiments, the Shiga toxin effector polypeptide is linked to the heterologous molecule via an ectopic amino acid residue. In certain further embodiments, the heterologous molecule is selected from the group consisting of: a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection facilitator. For certain further embodiments, the heterologous molecule is capable of specifically binding to at least one extracellular target biomolecule physically coupled to the cell surface. In certain further embodiments, the heterologous molecule comprises a cell targeting polypeptide. In certain further embodiments, the cell targeting polypeptide comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NARFragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. For certain further embodiments, the heterologous molecule is capable of binding to an extracellular target biomolecule selected from the group consisting of: CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gpA33 , mucin, TAG-72, carbonic anhydrase IX, folate binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase-related antigen, Human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54, CD63,In certain further embodiments, the Shiga toxin effector polypeptide comprises a carboxy-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173), HIEL (SEQ ID NO:1174), HNEL (SEQID NO:1175)、HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1189). For certain further embodiments, administration of a Shiga toxin effector polypeptide to a cell physically coupled to an extracellular target biomolecule results in one or more of: (1) internalization of the cell-targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell-targeting molecule to the cytosol of the cell, (3) disruption of ribosomal function of the cell, and (4) killing of the cell. For certain embodiments of the Shiga toxin effector polypeptides of the present invention, administration of a Shiga toxin effector polypeptide to a cell expressing a target, the cell-targeting molecule is capable of causing cell death, i.e., killing the cell. In certain further embodiments, the Shiga toxin effector polypeptide comprises a mutation relative to a naturally occurring A subunit of a member of the Shiga toxin family that alters the enzymatic activity of the Shiga toxin effector polypeptide, the mutation being selected from at least one amino acid residue deletion, insertion, or substitution, such as, for example, A231E, N75A, Y77S, Y114S, E167D, R170A, R176K, and / or W203A in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. In certain further embodiments, the mutation is selected from at least one amino acid residue deletion, insertion, or substitution that reduces or eliminates catalytic activity but retains at least one other Shiga toxin effector function, such as, for example, inducing cellular internalization and / or directing subcellular trafficking. In certain further embodiments, the mutation reduces or eliminates the cytotoxicity of the Shiga toxin effector polypeptide.
[0036] In certain embodiments, the Shiga toxin effector polypeptide of the present invention is a polypeptide derived from the A subunit of a member of the Shiga toxin family, and comprises an internal ectopic amino acid residue having a functional group suitable for chemical conjugation to a heterologous molecule (which is heterologous to the Shiga toxin) through the functional group; and wherein the Shiga toxin effector polypeptide is capable of exhibiting a Shiga toxin effector function. Internal refers to the incorporation of an ectopic amino acid residue into a single continuous polypeptide at a position that does not represent an amino-terminal residue and a carboxyl-terminal residue. In certain further embodiments, the ectopic amino acid residue is a basic and / or strongly nucleophilic amino acid residue, and is optionally cysteine, histidine, lysine, selenocysteine or pyrroline-carboxyl-lysine. In certain further embodiments, the ectopic amino acid residue is non-natural - meaning that the amino acid is not one of the twenty common amino acids. In certain further embodiments, the ectopic amino acid residue is capable of incorporation into the Shiga toxin effector polypeptide by nucleic acid translation. In certain further embodiments, the Shiga toxin effector polypeptide comprises or consists essentially of a polypeptide as set forth in any one of SEQ ID NOs: 5-84, 830, 832, and 1109-1140. For certain further embodiments, the Shiga toxin effector polypeptide is capable of exhibiting significant intracellular trafficking from endosomal compartments to the Golgi apparatus, endoplasmic reticulum, and / or cytoplasmic compartments. For certain further embodiments, the Shiga toxin effector polypeptide is capable of exhibiting ribosome inhibitory activity (IC 50 In certain further embodiments, the Shiga toxin effector polypeptide is linked to the heterologous molecule via an ectopic amino acid residue. In certain further embodiments, the heterologous molecule is selected from the group consisting of: a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection facilitator. For certain further embodiments, the heterologous molecule is capable of specifically binding to at least one extracellular target biomolecule physically coupled to the cell surface. In certain further embodiments, the heterologous molecule comprises a cell targeting polypeptide. In certain further embodiments, the cell targeting polypeptide comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NARFragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. For certain further embodiments, the heterologous molecule is capable of binding to an extracellular target biomolecule selected from the group consisting of: CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gpA33 , mucin, TAG-72, carbonic anhydrase IX, folate binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase-related antigen, Human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54, CD63,In certain further embodiments, the immunoglobulin-type binding region comprises a peptide or polypeptide as set forth in any one of SEQ ID NOs: 844-1100. In certain further embodiments, the Shiga toxin effector polypeptide comprises a carboxyl-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173),HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1188) NO:1189). For certain further embodiments, administration of a Shiga toxin effector polypeptide to a cell physically coupled to an extracellular target biomolecule results in one or more of: (1) internalization of the cell-targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell-targeting molecule to the cytosol of the cell, (3) disruption of ribosomal function of the cell, and (4) killing of the cell. For certain embodiments of the Shiga toxin effector polypeptides of the present invention, administration of a Shiga toxin effector polypeptide to a cell expressing the target can cause cell death, i.e., kill the cell. In certain further embodiments, the Shiga toxin effector polypeptide comprises a mutation relative to a naturally occurring A subunit of a member of the Shiga toxin family that alters the enzymatic activity of the Shiga toxin effector polypeptide, the mutation being selected from at least one amino acid residue deletion, insertion, or substitution, such as, for example, A231E, N75A, Y77S, Y114S, E167D, R170A, R176K, and / or W203A in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. In certain further embodiments, the mutation is selected from at least one amino acid residue deletion, insertion, or substitution that reduces or eliminates catalytic activity but retains at least one other Shiga toxin effector function, such as, for example, inducing cellular internalization and / or directing subcellular trafficking. In certain further embodiments, the mutation reduces or eliminates the cytotoxicity of the Shiga toxin effector polypeptide.
[0037] In certain embodiments, the Shiga toxin effector polypeptides of the invention are fused to linkers known to the skilled artisan.
[0038] In certain embodiments, a Shiga toxin effector polypeptide of the invention is fused directly or indirectly to a binding region capable of specifically binding an extracellular target biomolecule.
[0039] In certain embodiments, the Shiga toxin effector polypeptide of the present invention further comprises a Shiga toxin A1 fragment-derived region having a carboxyl terminus, and further comprises a disrupted furin cleavage motif at the carboxyl terminus of the A1 fragment region (see, e.g., WO 2015 / 191764; WO 2016 / 126950). In certain further embodiments, the Shiga toxin effector polypeptide of the present invention further comprises a molecular portion located at the carboxyl terminus of the Shiga toxin A1 fragment region (see, e.g., WO 2015 / 191764; WO 2016 / 126950).
[0040] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise at least one inserted or embedded heterologous T cell epitope (see, e.g., WO 2015 / 113005; WO 2016 / 126950).
[0041] In certain embodiments, the Shiga toxin effector polypeptides of the invention are deimmunized. In certain embodiments, the Shiga toxin effector polypeptides of the invention exhibit reduced antigenicity and / or immunogenic potential following administration to chordates compared to a reference molecule (such as, for example, a wild-type Shiga toxin effector polypeptide) (see, e.g., SEQ ID NOs: 1-3).
[0042] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise at least one, two, or three disrupted endogenous B cell and / or CD4+ T cell epitope regions. In certain further embodiments, the Shiga toxin effector polypeptides further comprise at least one disrupted endogenous B cell and / or CD4+ T cell epitope region that does not overlap with at least one inserted or embedded heterologous epitope (see, e.g., WO 2016 / 126950). In certain embodiments, the Shiga toxin effector polypeptide comprises a disruption in a B cell and / or T cell epitope region of a naturally located Shiga toxin A subunit region selected from the group consisting of: 1-15 of SEQ ID NO: 1 or SEQ ID NO: 2; 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 94-115 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 141-153 of SEQ ID NO: 1 or SEQ ID NO: 2; 140-156 of SEQ ID NO: 3; 179-190 of SEQ ID NO: 1 or SEQ ID NO: 2; 179-191 of SEQ ID NO: 3; NO: 3; 204 of SEQ ID NO: 1 or SEQ ID NO: 2; 205 of SEQ ID NO: 1 or SEQ ID NO: 2 and 210-218 of SEQ ID NO: 3; 240-260 of SEQ ID NO: 1 or SEQ ID NO: 2; 243-257 of SEQ ID NO: 1 or SEQ ID NO: 2; 254-268 of SEQ ID NO: 1 or SEQ ID NO: 2; 262-278 of SEQ ID NO: 3; 281-297 of SEQ ID NO: 3; 285-293 of SEQ ID NO: 1 or SEQ ID NO: 2; 4-33 of SEQ ID NO: 1 or SEQ ID NO: 2; 34-78 of SEQ ID NO: 1 or SEQ ID NO: 2; 77-103 of SEQ ID NO: 1 or SEQ ID NO: 2; 128-168 of SEQ ID NO: 1 or SEQ ID NO: 2; 160-183 of SEQ ID NO: 1 or SEQ ID NO: 2; 236-258 of SEQ ID NO: 2; and 274-293 of SEQ ID NO: 1 or SEQ ID NO: 2; or the equivalent region in the Shiga toxin A subunit or a derivative thereof.In certain further embodiments, there is no disruption of carboxy-terminal truncation of amino acid residues that overlap with part or all of the at least one disrupted endogenous B-cell and / or T-cell epitope and / or epitope region.
[0043] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise a mutation relative to wild-type Shiga toxin A subunit in a B cell immunogenic amino acid residue selected from the group consisting of naturally located Shiga toxin A subunit amino acid residues: L49, D197, D198, R204, and R205.
[0044] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise an embedded or inserted heterologous T cell epitope that disrupts an endogenous B cell and / or T cell epitope region selected from the group consisting of: (i) 1-15 of SEQ ID NO: 1 or SEQ ID NO: 2; 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; and 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or the equivalent regions in the Shiga toxin A subunit or derivatives thereof, without the following disruptions: amino-terminal truncation of a sequence that overlaps with part or all of at least one of the disrupted epitope regions; (ii) 94-115 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; NO:2; 141-153 of SEQ ID NO:2; 140-156 of SEQ ID NO:3; 179-190 of SEQ ID NO:1 or SEQ ID NO:2; 179-191 of SEQ ID NO:3; 204 of SEQ ID NO:3; 205 of SEQ ID NO:1 or SEQ ID NO:2; and 210-218 of SEQ ID NO:3; (iii) 240-260 of SEQ ID NO:3; 243-257 of SEQ ID NO:1 or SEQ ID NO:2; 254-268 of SEQ ID NO:1 or SEQ ID NO:2; 262-278 of SEQ ID NO:3; 281-297 of SEQ ID NO:3; and 285-293 of SEQ ID NO:1 or SEQ ID NO:2; or the equivalent regions in the Shiga toxin A subunit or its derivatives.
[0045] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise mutations relative to wild-type Shiga toxin A subunit in a B-cell and / or T-cell epitope region selected from the group consisting of: (i) 1-15 of SEQ ID NO: 1 or SEQ ID NO: 2; 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; and 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or the equivalent regions in a Shiga toxin A subunit or derivatives thereof, without disruption of: an amino-terminal truncation of a sequence overlapping with part or all of at least one of the disrupted epitope regions; (ii) 94-115 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; NO:2; 141-153 of SEQ ID NO:2; 140-156 of SEQ ID NO:3; 179-190 of SEQ ID NO:1 or SEQ ID NO:2; 179-191 of SEQ ID NO:3; 204 of SEQ ID NO:3; 205 of SEQ ID NO:1 or SEQ ID NO:2; and 210-218 of SEQ ID NO:3; (iii) 240-260 of SEQ ID NO:3; 243-257 of SEQ ID NO:1 or SEQ ID NO:2; 254-268 of SEQ ID NO:1 or SEQ ID NO:2; 262-278 of SEQ ID NO:3; 281-297 of SEQ ID NO:3; and 285-293 of SEQ ID NO:1 or SEQ ID NO:2; or the equivalent regions in the Shiga toxin A subunit or a derivative thereof, without the following disruptions: amino-terminal truncation of sequences that overlap with part or all of at least one disrupted epitope region.
[0046] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise a disruption in at least one endogenous epitope region of a naturally located Shiga toxin A subunit selected from the group consisting of: 94-115 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; 141-153 of SEQ ID NO: 1 or SEQ ID NO: 2; 140-156 of SEQ ID NO: 3; 179-190 of SEQ ID NO: 1 or SEQ ID NO: 2; 179-191 of SEQ ID NO: 3; 204 of SEQ ID NO: 3; 205 of SEQ ID NO: 1 or SEQ ID NO: 2; or 210-218 of SEQ ID NO: 3.
[0047] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise disruption of at least four, five, six, seven, eight or more endogenous B cell and / or T cell epitope regions (see, e.g., WO 2015 / 113007; WO 2016 / 126950).
[0048] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise one or more endogenous B cell and / or T cell epitope regions comprising a plurality of amino acid residue substitutions relative to wild-type Shiga toxin A subunit (see, e.g., WO 2015 / 113007; WO 2016 / 126950).
[0049] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise at least one, two, three, or four disruptions comprising multiple amino acid residue substitutions in endogenous B cell and / or T cell epitope regions relative to wild-type Shiga toxin A subunit (see, e.g., WO 2015 / 113007; WO 2016 / 126950).
[0050] In certain embodiments, the Shiga toxin effector polypeptide of the invention further comprises at least one disruption comprising at least one, two, three, four, five, six, seven, eight or more amino acid residue substitutions relative to a wild-type Shiga toxin A subunit, and optionally wherein at least one substitution occurs at a naturally located Shiga toxin A subunit amino acid residue selected from the group consisting of: 1 of SEQ ID NO: 1 or SEQ ID NO: 2; 4 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 6 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 8 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 9 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 11 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 12 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 33 of SEQ ID NO: 1 or SEQ ID NO: 2; 43 of SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 2; 44 of SEQ ID NO: 1 or SEQ ID NO: 2; 45 of SEQ ID NO: 1 or SEQ ID NO: 2; 46 of SEQ ID NO: 1 or SEQ ID NO: 2; 47 of SEQ ID NO: 1 or SEQ ID NO: 2; 48 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 49 of SEQ ID NO: 1 or SEQ ID NO: 2; 50 of SEQ ID NO: 1 or SEQ ID NO: 2; 51 of SEQ ID NO: 1 or SEQ ID NO: 2; 53 of SEQ ID NO: 1 or SEQ ID NO: 2; 54 of SEQ ID NO: 1 or SEQ ID NO: 2; 55 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 56 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 57 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 58 of SEQ ID NO:3; 59 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 60 of SEQ ID NO:1 or SEQ ID NO:2; 61 of SEQ ID NO:1 or SEQ ID NO:2;SEQ ID NO: 1 or SEQ ID NO: 62; SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 3; SEQ ID NO: 1 or SEQ ID NO: 62; SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 3 ... NO:3; 112 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 141 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 147 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 154 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 179 of SEQ ID NO:1 or SEQ ID NO:2; 180 of SEQ ID NO:1 or SEQ ID NO:2; 181 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 183 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 184 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 185 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 186 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 187 of SEQ ID NO:1 or SEQ ID NO:2; 188 of SEQ ID NO:1 or SEQ ID NO:2; 189 of SEQ ID NO: 2; 197 of SEQ ID NO: 3; 198 of SEQ ID NO: 1 or SEQ ID NO: 2; 204 of SEQ ID NO: 3; 205 of SEQ ID NO: 1 or SEQ ID NO: 2; 247 of SEQ ID NO: 1 or SEQ ID NO: 2;247 of SEQ ID NO:3; 248 of SEQ ID NO:1 or SEQ ID NO:2; 250 of SEQ ID NO:3; 251 of SEQ ID NO:1 or SEQ ID NO:2; 264 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 265 of SEQ ID NO:1 or SEQ ID NO:2; and 286 of SEQ ID NO:1 or SEQ ID NO:2; or the equivalent amino acid residues in the Shiga toxin A subunit or a derivative thereof. In certain further embodiments, at least two disruptions each comprise at least one amino acid residue replacement relative to a wild-type Shiga toxin A subunit selected from the group consisting of: 1 of SEQ ID NO: 1 or SEQ ID NO: 2; 4 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 8 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 9 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 11 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 33 of SEQ ID NO: 1 or SEQ ID NO: 2; 43 of SEQ ID NO: 1 or SEQ ID NO: 2; 45 of SEQ ID NO: 1 or SEQ ID NO: 2; 47 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 48 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 49 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 53 of SEQ ID NO: 1 or SEQ ID NO: 2; 54 of SEQ ID NO: 1 or SEQ ID NO: 2; 55 of SEQ ID NO: 1 or SEQ ID NO: 2; 56 of SEQ ID NO: 1 or SEQ ID NO: 2; 57 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 58 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 59 of SEQ ID NO: 1 or SEQ ID NO: 2; 60 of SEQ ID NO: 1 or SEQ ID NO: 2 SEQ ID NO: 1 or SEQ ID NO: 2; 55 of SEQ ID NO: 1 or SEQ ID NO: 2; 58 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 59 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 60 of SEQ ID NO: 1 or SEQ ID NO: 2; 61 of SEQ ID NO: 1 or SEQ ID NO: 2; 62 of SEQ ID NO: 1 or SEQ ID NO: 2; 94 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 96 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 109 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 110 of SEQ ID NO: 1 or SEQ ID NO: 2;SEQ ID NO: 1 or SEQ ID NO: 3 112; SEQ ID NO: 1 or SEQ ID NO: 3 147; SEQ ID NO: 1 or SEQ ID NO: 3 179; SEQ ID NO: 1 or SEQ ID NO: 3 180; SEQ ID NO: 1 or SEQ ID NO: 2 181; SEQ ID NO: 1 or SEQ ID NO: 2 183; SEQ ID NO: 1 or SEQ ID NO: 3 184; SEQ ID NO: 1 or SEQ ID NO: 2 185; SEQ ID NO: 1 or SEQ ID NO: 2 186; SEQ ID NO: 1 or SEQ ID NO: 3 187; SEQ ID NO: 1 or SEQ ID NO: 2 188; SEQ ID NO: 1 or SEQ ID NO: 2 189; SEQ ID NO: 3 204; SEQ ID NO: 1 or SEQ ID NO: 2 205 of SEQ ID NO: 2; 247 of SEQ ID NO: 1 or SEQ ID NO: 2; 247 of SEQ ID NO: 3; 250 of SEQ ID NO: 3; 264 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 265 of SEQ ID NO: 1 or SEQ ID NO: 2; and 286 of SEQ ID NO: 1 or SEQ ID NO: 2; or the equivalent amino acid residues in the Shiga toxin A subunit or a derivative thereof.
[0051] In certain embodiments, the Shiga toxin effector polypeptide of the invention further comprises disruptions of at least three endogenous B-cell and / or T-cell epitope regions selected from the group consisting of: (i) 1-15 of SEQ ID NO: 1 or SEQ ID NO: 2; 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; and 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or the equivalent region in the Shiga toxin A subunit or a derivative thereof, wherein none of the disruptions is an amino-terminal truncation of amino acid residues that overlap with part or all of at least one of the disrupted endogenous B-cell and / or T-cell epitope regions; (ii) 94-115 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; NO:2; 141-153 of SEQ ID NO:2; 140-156 of SEQ ID NO:3; 179-190 of SEQ ID NO:1 or SEQ ID NO:2; 179-191 of SEQ ID NO:3; 204 of SEQ ID NO:3; 205 of SEQ ID NO:1 or SEQ ID NO:2; and 210-218 of SEQ ID NO:3; (iii) 240-260 of SEQ ID NO:3; 243-257 of SEQ ID NO:1 or SEQ ID NO:2; 254-268 of SEQ ID NO:1 or SEQ ID NO:2; 262-278 of SEQ ID NO:3; 281-297 of SEQ ID NO:3; and 281-298 of SEQ ID NO:1 or SEQ ID NO:2 NO: 285-293; or the equivalent region in the Shiga toxin A subunit or a derivative thereof, wherein there is no disruption of: a carboxyl-terminal truncation of amino acid residues that overlap partially or completely with at least one disrupted endogenous B cell and / or T cell epitope and / or epitope region.
[0052] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise disruptions of at least two endogenous B-cell and / or T-cell epitope regions, wherein each disruption comprises one or more amino acid residue substitutions, and wherein the endogenous B-cell and / or T-cell epitope regions are selected from the group of naturally located Shiga toxin A subunit regions consisting of: 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or the equivalent regions in the Shiga toxin A subunit or a derivative thereof.
[0053] In certain embodiments, the Shiga toxin effector polypeptides of the invention further comprise at least one disruption comprising one or more amino acid residue substitutions relative to the wild-type Shiga toxin A subunit selected from the group consisting of: D to A, D to G, D to V, D to L, D to I, D to F, D to S, D to Q, D to M, D to R, E to A, E to G, E to V, E to L, E to I, E to F, E to S, E to Q, E to N, E to D, E to M, E to R, F to A, F to G, F to V, F to L, F to I, G to A, G to P, H to A, H to G, H to V, H to L, H to I, H to F, H to M, I to A, I to V, I to G , I to C, K to A, K to G, K to V, K to L, K to I, K to M, K to H, L to A, L to V, L to G, L to C, N to A, N to G, N to V, N to L, N to I, N to F, P to A, P to G, P to F, R to A, R to G, R to V, R to L, R to I, R to F, R to M, R to Q, R to S, R to K, R to H, S to A, S to G, S to V, S to L, S to I, S to F, S to M, T to A, T to G, T to V, T to L, T to I, T to F, T to M, T to S, V to A, V to G, Y to A, Y to G, Y to V, Y to L, Y to I, Y to F, Y to M, and Y to T. In certain further embodiments, the one or more amino acid residue substitutions relative to wild-type Shiga toxin A subunit are selected from the group consisting of: D to A, D to G, D to V, D to L, D to I, D to F, D to S, D to Q, E to A, E to G, E to V, E to L, E to I, E to F, E to S, E to Q, E to N, E to D, E to M, E to R, G to A, H to A, H to G, H to V, H to L, H to I, H to F, H to M, K to A, K to G, K to V, K to L, K to I, K to M, K to H, L to A, L to G, N to A, N to G, N to V, N to L, N to I, N to F, P to A, P to G, P to F, R to A, R to G, R to V, R to L, R to I, R to F, R to M, R to Q, R to S, R to K, R to H, S to A, S to G, S to V, S to L, S to I, S to F, S to M, T to A, T to G, T to V, T to L, T to I, T to F, T to M, T to S, Y to A, Y to G, Y to V, Y to L, Y to I, Y to F and Y to M.
[0054] In certain embodiments, the at least one disruption comprises one or more amino acid residue replacements relative to wild-type Shiga toxin A subunit selected from the group consisting of: K1 to A, G, V, L, I, F, M, and H; T4 to A, G, V, L, I, F, M, and S; D6 to A, G, V, L, I, F, S, Q, and R; S8 to A, G, V, I, L, F, and M; T9 to A, G, V, I, L, F, M, and S; S9 to A, G, V, L, I, F, and M; K11 to A, G, V, L, I, F, , M, and H; T12 to A, G, V, I, L, F, M, S, and K; S12 to A, G, V, I, L, F, and M; S33 to A, G, V, L, I, F, M, and C; S43 to A, G, V, L, I, F, and M; G44 to A or L; S45 to A, G, V, L, I, F, and M; T45 to A, G, V, L, I, F, and M; G46 to A and P; D47 to A, G, V, L, I, F, S, M, and Q; N48 to A, G, V, L, M, and F; L49 to A, V, C, and G;
[0055] Y49 to A, G, V, L, I, F, M, and T; F50 to A, G, V, L, I, and T; A51; D53 to A, G, V, L, I, F, S, and Q; V54 to A, G, I, and L; R55 to A, G, V, L, I, F, M, Q, S, K, and H; G56 to A and P; I57 to A, G, V, and M; L57 to A, V, C, G, M, and F; D 58 to A, G, V, L, I, F, S, and Q; P59 to A, G, and F; E60 to A, G, V, L, I, F, S, Q, N, D, M, T, and R; E61 to A, G, V, L, I, F, S, Q, N, D, M, and R; G62 to A; R84 to A, G, V, L, I, F, M, Q, S, K, and H; V88 to A and G; I88 to A, V, C and G; D94 to A, G, V, L, I, F, S and Q; S96 to A, G, V, I, L, F and M; T104 to A, G, V, L, I, F, M; and N; A105 to L; T107 to A, G, V, L, I, F, M and P; S107 to A, G, V, L, I, F, M and P; L108 to A, V, C and G; S109 to A, G, V, I, L, F and M; T109 to A, G, V, I, L, F, M and S; G110 to A; S112 to A, G, V, L, I, F and M; D111 to A, G, V, L, I, F, S, Q and T; S112 to A, G, V, L, I, F and M; D141 to A, G, V, L, I, F, S and Q; G147 to A; V154 to A and G.R179 to A, G, V, L, I, F, M, Q, S, K, and H; T180 to A, G, V, L, I, F, M, and S; T181 to A, G, V, L, I, F, M, and S; D183 to A, G, V, L, I, F, S, and Q; D184 to A, G, V, L, I, F, S, and Q; L185 to A, G, V, and C; S186 to A, G, V, I, L, F, and M; G187 to A; R188 to A, G, V, L, I, F, M, Q, S, K, and H; S189 to A, G, V, I, L, F, and M; D197 to A, G, V, L, I, F, S, and Q; D198 to A, G, V, L, I , F, S, and Q; R204 to A, G, V, L, I, F, M, Q, S, K, and H; R205 to A, G, V, L, I, F, M, Q, S, K, and H; S247 to A, G, V, I, L, F, and M; Y247 to A, G, V, L, I, F, and M; R248 to A, G, V, L, I, F, M, Q, S, K, and H; R250 to A, G, V, L, I, F, M, Q, S, K, and H; R251 to A, G, V, L, I, F, M, Q, S, K, and H; D264 to A, G, V, L, I, F, S, and Q; G264 to A; and T286 to A, G, V, L, I, F, M, and S.
[0056] For certain further embodiments, when a Shiga toxin effector polypeptide of the present invention is administered as a component of a cell targeting molecule to a cell expressing a target of an extracellular target biomolecule, the Shiga toxin effector polypeptide can cause cell death. For certain further embodiments, the cell is a target biomolecule positive cell. For certain further embodiments, the cell is physically coupled to a plurality of extracellular target biomolecules. For certain further embodiments, the Shiga toxin effector polypeptide of the present invention, as a component of a cell targeting molecule, can exhibit a half maximal inhibitory concentration (CI) of 300 nM or less when introduced into the cell. 50 ) values, and / or are capable of exhibiting significant levels of Shiga toxin cytotoxicity.
[0057] Implementation Group #2 - Shiga Toxin Effector Peptide Scaffold
[0058] In certain embodiments, the Shiga toxin effector polypeptide scaffold of the present invention comprises i) a Shiga toxin effector polypeptide and ii) an additional protein structure, wherein the additional protein structure comprises amino acid residues not present in the Shiga toxin effector polypeptide, e.g., unique amino acid residues and / or amino acid residues having functional groups unique to the Shiga toxin effector polypeptide component of the Shiga toxin effector polypeptide scaffold (also referred to herein as a Shiga toxin effector polypeptide region or a Shiga toxin effector region). The Shiga toxin effector polypeptide is derived from the A subunit of at least one member of the Shiga toxin family and need not comprise any cell targeting domain of the Shiga holotoxin or any portion of the Shiga toxin B subunit. In certain further embodiments, the Shiga toxin effector polypeptide scaffold is capable of exhibiting one or more Shiga toxin effector functions. For certain further embodiments, the Shiga toxin effector polypeptide scaffold is capable of exhibiting significant levels of one or more Shiga toxin effector functions selected from the group consisting of: promoting cellular internalization, directing subcellular delivery to the cytosol upon entry into the cell, catalytic inactivation of ribosomes, and cytotoxicity.
[0059] In certain embodiments, the Shiga toxin effector polypeptide scaffold of the present invention comprises (i) a protein structure having unique amino acids and not comprising a Shiga toxin effector polypeptide and (ii) a Shiga toxin effector polypeptide that does not comprise the unique amino acids and is capable of exhibiting one or more Shiga toxin effector functions; wherein the protein structure and the Shiga toxin effector polypeptide are covalently linked together.
[0060] In certain further embodiments, the Shiga toxin effector polypeptide scaffolds of the present invention are capable of exhibiting one or more Shiga toxin effector functions selected from the group consisting of directing intracellular trafficking to the Golgi apparatus in the presence of the polypeptide scaffold, directing intracellular trafficking to the endoplasmic reticulum in the presence of the polypeptide scaffold, directing intracellular trafficking to the cytosol in the presence of the polypeptide scaffold, directing intracellular trafficking in the presence of a cargo directly or indirectly linked to the polypeptide scaffold, inhibition of ribosome function, enzymatic inactivation of ribosomes, and cytotoxicity. In certain further embodiments, the Shiga toxin effector polypeptide scaffolds are capable of exhibiting ribosome inhibitory activity, IC 50 The value is 10,000 picomoles or less.
[0061] In certain further embodiments, the unique amino acid residue is an unnatural amino acid residue.
[0062] In certain further embodiments, unique amino acid residues are capable of being incorporated into a Shiga toxin effector polypeptide scaffold by translation of the polynucleotide, for example, by the action of ribosomes in vitro or by the action of ribosomes in living cells.
[0063] In certain further embodiments, the unique amino acid residues are located internally within the Shiga toxin effector polypeptide scaffold.
[0064] In certain further embodiments, the unique amino acid residue is selected from the group consisting of cysteine, histidine, lysine, selenocysteine, and pyrroline-carboxy-lysine.
[0065] In certain further embodiments, the Shiga toxin effector polypeptide scaffold of the invention comprises or consists essentially of any one of SEQ ID NOs: 762-767.
[0066] In certain embodiments of the Shiga toxin effector polypeptide scaffolds of the present invention, the unique amino acid residue is cysteine, histidine, lysine, or an uncommon / non-natural amino acid residue. In certain further embodiments, the unique amino acid residue can be incorporated into the Shiga toxin effector polypeptide scaffold through the nucleic acid translation process.
[0067] In certain embodiments of the Shiga toxin effector polypeptide scaffolds of the invention, additional protein structures are fused to the Shiga toxin effector polypeptide. In certain further embodiments, the Shiga toxin effector polypeptide scaffolds can be produced by nucleic acid translation.
[0068] In certain embodiments, the Shiga toxin effector polypeptide scaffold is covalently linked to a heterologous molecule, such as, for example, a cell targeting binding region, a linker, another exogenous substance, a cargo, a cell targeting altering agent, through a functional group of unique amino acid residues. In certain further embodiments, the heterologous molecule is selected from the group consisting of an antibiotic, an antigen, an antigenic substance, a cytotoxic agent, a radionuclide, a cell targeting molecule altering agent, a detection facilitating agent, a dye, a T cell epitope, a fluorophore, an immunogen, an immunogenic substance, an enzyme, a zymoxin, a lipid, a polymer, polyethylene glycol, a serum albumin binder, a small molecule chemotherapeutic agent, a prodrug, a peptide, a protein, a nucleic acid, and / or a protein-nucleic acid complex.
[0069] In certain embodiments, the Shiga toxin effector polypeptide scaffold of the invention comprises a Shiga toxin effector polypeptide of the invention. In certain further embodiments, the Shiga toxin effector polypeptide is selected from any one of SEQ ID NOs: 233-756.
[0070] In certain embodiments, the Shiga toxin effector polypeptide scaffold of the present invention comprises i) a Shiga toxin effector polypeptide of the present invention and ii) a linker. In certain further embodiments of the Shiga toxin effector polypeptide scaffold of the present invention, the Shiga toxin effector polypeptide component of the scaffold is selected from any one of SEQ ID NOs: 233-756, and the Shiga toxin effector polypeptide further comprises a linker. In certain further embodiments of the Shiga toxin effector polypeptide scaffold of the present invention, the Shiga toxin effector polypeptide component of the scaffold is selected from any one of SEQ ID NOs: 233-756, and the Shiga toxin effector polypeptide scaffold further comprises a linker selected from any one of SEQ ID NOs: 757-761.
[0071] In certain embodiments of the Shiga toxin effector polypeptide scaffolds of the invention, the linker comprises a peptide or polypeptide fused to the carboxyl terminus of the Shiga toxin effector polypeptide.
[0072] In certain embodiments, the Shiga toxin effector polypeptide scaffold comprises only one cysteine, lysine, selenocysteine and / or pyrroline-carboxyl-lysine. In certain further embodiments of the Shiga toxin effector polypeptide scaffolds of the invention, the Shiga toxin effector polypeptide component of the scaffold is selected from any one of SEQ ID NOs: 233-756, and the Shiga toxin effector polypeptide scaffold further comprises a linker selected from any one of SEQ ID NOs: 757-761, so long as a single unique cysteine or lysine residue is present in the scaffold outside of the Shiga toxin effector polypeptide. In certain further embodiments of the Shiga toxin effector polypeptide scaffolds of the invention, the Shiga toxin effector polypeptide scaffold comprises or consists essentially of any one of SEQ ID NOs: 762-767.
[0073] In certain embodiments, the Shiga toxin effector polypeptide scaffolds of the invention are fused to linkers known to the skilled artisan.
[0074] In certain embodiments, the Shiga toxin effector polypeptide scaffold of the present invention is fused directly or indirectly to a binding region capable of specifically binding to an extracellular target biomolecule. In certain further embodiments, the binding region is fused to the carboxyl terminus of the Shiga toxin effector polypeptide scaffold.
[0075] For certain embodiments, the Shiga toxin effector polypeptide scaffolds of the invention are capable of exhibiting significant intracellular trafficking from endosomal compartments to the Golgi apparatus, endoplasmic reticulum, and / or cytoplasmic compartments.
[0076] For certain embodiments, the Shiga toxin effector polypeptide scaffolds of the present invention are capable of exhibiting ribosome inhibitory activity (IC 50 values of 10,000 picomolar or less) and / or significant levels of Shiga toxin catalytic activity.
[0077] For certain embodiments of the Shiga toxin effector polypeptide scaffolds of the present invention, the heterologous molecule is selected from the group consisting of: a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection enhancer. For certain further embodiments, the heterologous molecule is capable of specifically binding to at least one extracellular target biomolecule physically coupled to the cell surface. In certain further embodiments, the heterologous molecule comprises a cell targeting polypeptide. In certain further embodiments, the cell targeting polypeptide comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NAR Fragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality.For certain further embodiments, the heterologous molecule is capable of binding to an extracellular target biomolecule selected from the group consisting of: CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gpA33, mucin, TAG-72, carbonic anhydrase IX, folate binding protein, ganglioside GD2, ganglioside GD3, neurotrophic factor 2 (TNF-α), TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α Ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SA RT-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase-related antigen, human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin- 9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54, CD63, CD69, CD123, TLR4, FceRIa, IgE, CD107a, CD203c, CD14, CD68, CD80, CD86, CD105, CD115, F4 / 80, ILT-3, galectin-3, CD11a-c, GITRL, MHC class II, CD284-TLR4, CD107-Mac3, CD195-CCR5, HLA-DR, CD16 / 32, CD282-TLR2, and any immunogenic fragment of any of the foregoing.For certain further embodiments, administration of a Shiga toxin effector polypeptide scaffold to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell-targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide scaffold of the cell-targeting molecule to the cytosol of the cell, (3) disruption of cellular ribosomal function, and (4) killing of the cell. For certain further embodiments, administration of a Shiga toxin effector polypeptide scaffold of the present invention to a cell expressing a biomolecular target, the Shiga toxin effector polypeptide scaffold is capable of causing cell death, i.e., killing the cell.
[0078] In certain embodiments, the Shiga toxin effector polypeptide component of the Shiga toxin effector polypeptide scaffold of the present invention comprises a mutation relative to the naturally occurring A subunit of a member of the Shiga toxin family that alters the enzymatic activity of the Shiga toxin effector polypeptide scaffold, the mutation being selected from at least one amino acid residue deletion, insertion, or substitution, such as, for example, A231E, N75A, Y77S, Y114S, E167D, R170A, R176K, and / or W203A in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. In certain further embodiments, the mutation is selected from at least one amino acid residue deletion, insertion, or substitution that reduces or eliminates catalytic activity but retains at least one other Shiga toxin effector function, such as, for example, inducing cellular internalization and / or directing subcellular trafficking. In certain further embodiments, the mutation reduces or eliminates the cytotoxicity of the Shiga toxin effector polypeptide scaffold.
[0079] Implementation Group #3 - Cell Targeting Molecules
[0080] In certain embodiments, the cell targeting molecule of the present invention and / or as described above comprises (1) a Shiga toxin effector polypeptide of the present invention; and (2) a cell targeting agent or cell targeting binding region capable of specifically binding to at least one extracellular target biomolecule. In certain further embodiments, the cell targeting molecule comprises a conjugated portion. In certain further embodiments, the conjugated portion is selected from the group consisting of: a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection enhancer. In certain further embodiments, the cell targeting binding region comprises a polypeptide. In certain further embodiments, the cell targeting binding region comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (VH H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NAR Fragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. In certain further embodiments, the binding region is capable of binding to an extracellular target biomolecule selected from the group consisting of CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gp A33, mucin, TAG-72, carbonic anhydrase IX, folate-binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TR P-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase phase Related antigens, human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54,CD63, CD69, CD123, TLR4, FceRIa, IgE, CD107a, CD203c, CD14, CD68, CD80, CD86, CD105, CD115, F4 / 80, ILT-3, Galectin-3, CD11a-c, GITRL, MHC class II, CD284-TLR4, CD107-Mac3, CD195-CCR5, HLA-DR, CD16 / 32, CD282-TLR2, and any immunogenic fragment of any of the foregoing. In certain embodiments, the binding region comprises a peptide or polypeptide as set forth in any one of SEQ ID NOs: 844-1100. In certain further embodiments, the cell targeting molecule of the invention comprises or consists essentially of a polypeptide as set forth in any one of SEQ ID NOs: 773-817, 835-837, and 1105-1108. In certain further embodiments, the cell targeting molecule comprises a carboxy-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), ID NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169),KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173), HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ IDNO:1177), HVEL(SEQ ID NO:1178), NDEL(SEQ ID NO:1179), QDEL(SEQ ID NO:1180), REDL(SEQ ID NO:1181), RNEL(SEQ ID NO:1182), RTDL(SEQ ID NO:1183), RTEL(SEQ ID NO:1184), SDEL(SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1187) NO:1189). For certain further embodiments, administration of a cell targeting molecule to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell targeting molecule to the cytosol of the cell, (3) disruption of the ribosome function of the cell, and (4) killing of the cell. For certain further embodiments, the cell targeting molecule of the present invention is capable of killing the cell. For certain further embodiments, after administration of the cell targeting molecule of the present invention to a cell physically coupled to an extracellular target biomolecule, the cell targeting molecule is capable of causing cell death, i.e., killing the cell.
[0081] In certain embodiments, the cell targeting molecule of the present invention comprises (1) a toxin effector protein and (2) a cell targeting agent or cell targeting binding region capable of specifically binding to at least one extracellular target biomolecule. In certain further embodiments, the cell targeting molecule comprises a linker of any one of SEQ ID NOs: 757-761 and 768-772. In certain further embodiments, the cell targeting molecule comprises a conjugated molecule comprising a moiety selected from the group consisting of: a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection enhancer. In certain further embodiments, the cell targeting binding region comprises a polypeptide. In certain further embodiments, the cell targeting binding region comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V Hdomains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NAR Fragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. In certain further embodiments, the binding region is capable of binding to an extracellular target biomolecule selected from the group consisting of CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gp A33, mucin, TAG-72, carbonic anhydrase IX, folate-binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TR P-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase phase Related antigens, human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54,CD63, CD69, CD123, TLR4, FceRIa, IgE, CD107a, CD203c, CD14, CD68, CD80, CD86, CD105, CD115, F4 / 80, ILT-3, Galectin-3, CD11a-c, GITRL, MHC class II, CD284-TLR4, CD107-Mac3, CD195-CCR5, HLA-DR, CD16 / 32, CD282-TLR2, and any immunogenic fragment of any of the foregoing. In certain further embodiments, the cell targeting molecule of the present invention comprises a polypeptide set forth in any one of SEQ ID NOs: 773-817, 835-837, and 844-1108. In certain further embodiments, the cell targeting molecule comprises a carboxyl-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172),HAEL (SEQ ID NO:1173), HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1179) NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1189). For certain further embodiments, administration of a cell targeting molecule to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell targeting molecule to the cytosol of the cell, (3) disruption of the ribosome function of the cell, and (4) killing of the cell. For certain further embodiments, the cell targeting molecule of the present invention is capable of killing the cell. For certain further embodiments, after administration of the cell targeting molecule of the present invention to a cell physically coupled to an extracellular target biomolecule, the cell targeting molecule is capable of causing cell death, i.e., killing the cell.
[0082] In certain embodiments, the cell targeting molecule of the present invention comprises (1) a protein component comprising a polypeptide set forth in any one of SEQ ID NOs: 1-92, 830, 832, and 1109-1140; and (2) a cell targeting agent or cell targeting binding region capable of specifically binding to at least one extracellular target biomolecule. In certain further embodiments, the cell targeting molecule comprises a conjugated portion. In certain further embodiments, the conjugated portion is selected from the group consisting of: a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection facilitator. In certain further embodiments, the cell targeting binding region comprises a polypeptide. In certain further embodiments, the cell targeting binding region comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V Hdomain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NAR Fragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. In certain further embodiments, the binding region is capable of binding to an extracellular target biomolecule selected from the group consisting of CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gp A33, mucin, TAG-72, carbonic anhydrase IX, folate-binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TR P-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase phase Related antigens, human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54,In certain further embodiments, the binding region comprises a peptide or polypeptide as set forth in any one of SEQ ID NOs: 844-1100. In certain further embodiments, the cell targeting molecule of the invention consists essentially of a polypeptide as set forth in any one of SEQ ID NOs: 773-817, 835-837, and 1105-1108. In certain further embodiments, the cell targeting molecule comprises a carboxy-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169),KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173), HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1188) NO:1189). For certain further embodiments, administration of a cell targeting molecule to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell targeting molecule to the cytosol of the cell, (3) disruption of the ribosome function of the cell, and (4) killing of the cell. For certain further embodiments, the cell targeting molecule of the present invention is capable of killing the cell. For certain further embodiments, after administration of the cell targeting molecule of the present invention to a cell physically coupled to an extracellular target biomolecule, the cell targeting molecule is capable of causing cell death, i.e., killing the cell.
[0083] In certain embodiments, the cell targeting molecule of the present invention comprises (1) a Shiga toxin effector polypeptide that does not comprise any cysteine residues; (2) a cell targeting binding region that is capable of specifically binding to at least one extracellular target biomolecule; and (3) a protein linker fused between the Shiga toxin effector polypeptide and the cell targeting binding region to form a continuous polypeptide. In certain further embodiments, the linker comprises one or more cysteine residues. In certain further embodiments, the linker is selected from the group consisting of: any one of SEQ ID NOs: 757-760. In certain other embodiments, the cell targeting binding region comprises one or more cysteine residues. In certain further embodiments, the cell targeting binding region comprises a polypeptide selected from the group consisting of: amino acids 269-499 of any one of SEQ ID NOs: 807-808 and 812-813, amino acids 269-519 of any one of SEQ ID NOs: 814-815 and 818-829, or amino acids 268-386 of any one of SEQ ID NOs: 816-817. In certain further embodiments, the Shiga toxin effector polypeptide comprises or consists essentially of any one of SEQ ID NOs: 721-756. In certain further embodiments, the cell targeting molecule of the present invention comprises only one free cysteine residue (i.e., a unique cysteine residue that can be used for conjugation to a heterologous molecule). In certain further embodiments, the cell targeting molecule comprises a heterologous molecule covalently linked directly or indirectly to a cysteine residue. In certain further embodiments, the heterologous molecule is selected from the group consisting of: a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection enhancer. In certain further embodiments, the cell targeting binding region comprises a polypeptide. In certain further embodiments, the cell targeting binding region comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NAR Fragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. In certain further embodiments, the binding region is capable of binding to an extracellular target biomolecule selected from the group consisting of CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gp A33, mucin, TAG-72, carbonic anhydrase IX, folate-binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TR P-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase phase Related antigens, human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54,CD63, CD69, CD123, TLR4, FceRIa, IgE, CD107a, CD203c, CD14, CD68, CD80, CD86, CD105, CD115, F4 / 80, ILT-3, Galectin-3, CD11a-c, GITRL, MHC class II, CD284-TLR4, CD107-Mac3, CD195-CCR5, HLA-DR, CD16 / 32, CD282-TLR2, and any immunogenic fragment of any of the foregoing. In certain embodiments, the binding region comprises a peptide or polypeptide as set forth in any one of SEQ ID NOs: 844-1100. In certain further embodiments, the cell targeting molecule comprises a carboxyl-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173),HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1188) NO:1189). For certain further embodiments, administration of a cell targeting molecule to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell targeting molecule to the cytosol of the cell, (3) disruption of the ribosome function of the cell, and (4) killing of the cell. For certain further embodiments, the cell targeting molecule of the present invention is capable of killing the cell. For certain further embodiments, after administration of the cell targeting molecule of the present invention to a cell physically coupled to an extracellular target biomolecule, the cell targeting molecule is capable of causing cell death, i.e., killing the cell.
[0084] In certain embodiments, the cell targeting molecules of the present invention comprise (1) a Shiga toxin effector polypeptide that does not comprise any cysteine and / or selenocysteine residues; (2) a cell targeting binding region capable of specifically binding to at least one extracellular target biomolecule; and (3) a protein linker fused between the Shiga toxin effector polypeptide and the cell targeting binding region to form a continuous polypeptide. In certain further embodiments, the linker comprises one or more selenocysteine residues. In certain other embodiments, the cell targeting binding region comprises one or more selenocysteine residues. In certain further embodiments, the Shiga toxin effector polypeptide comprises or consists essentially of any one of SEQ ID NOs: 721–756. In certain further embodiments, the cell targeting molecules of the present invention comprise only one selenocysteine residue. In certain further embodiments, the cell targeting molecule comprises a heterologous molecule covalently linked directly or indirectly to the selenocysteine residue. In certain further embodiments, the heterologous molecule is selected from the group consisting of a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection enhancer. In certain further embodiments, the cell targeting binding region comprises a polypeptide. In certain further embodiments, the cell targeting binding region comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NAR Fragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. In certain further embodiments, the binding region is capable of binding to an extracellular target biomolecule selected from the group consisting of CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gp A33, mucin, TAG-72, carbonic anhydrase IX, folate-binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TR P-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase phase Related antigens, human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54,CD63, CD69, CD123, TLR4, FceRIa, IgE, CD107a, CD203c, CD14, CD68, CD80, CD86, CD105, CD115, F4 / 80, ILT-3, Galectin-3, CD11a-c, GITRL, MHC class II, CD284-TLR4, CD107-Mac3, CD195-CCR5, HLA-DR, CD16 / 32, CD282-TLR2, and any immunogenic fragment of any of the foregoing. In certain embodiments, the binding region comprises a peptide or polypeptide as set forth in any one of SEQ ID NOs: 844-1100. In certain further embodiments, the cell targeting molecule comprises a carboxyl-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173),HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1188) NO:1189). For certain further embodiments, administration of a cell targeting molecule to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell targeting molecule to the cytosol of the cell, (3) disruption of the ribosome function of the cell, and (4) killing of the cell. For certain further embodiments, the cell targeting molecule of the present invention is capable of killing the cell. For certain further embodiments, after administration of the cell targeting molecule of the present invention to a cell physically coupled to an extracellular target biomolecule, the cell targeting molecule is capable of causing cell death, i.e., killing the cell.
[0085] In certain embodiments, the cell targeting molecule of the present invention comprises (1) a Shiga toxin effector polypeptide that does not comprise any cysteine residues; (2) a cell targeting binding region that is capable of specifically binding to at least one extracellular target biomolecule; and (3) a protein linker fused between the Shiga toxin effector polypeptide and the cell targeting binding region to form a continuous polypeptide. In certain further embodiments, the linker comprises one or more lysine residues. In certain further embodiments, the linker is selected from the group consisting of: any one of SEQ ID NOs: 757-761 and 771-772. In certain other embodiments, the cell targeting binding region comprises one or more lysine residues. In certain further embodiments, the cell targeting binding region comprises a polypeptide selected from the group consisting of: amino acids 269-499 of any one of SEQ ID NOs: 807-808 and 812-813, amino acids 269-519 of any one of SEQ ID NOs: 814-815 and 818-829, or amino acids 268-386 of any one of SEQ ID NOs: 816-817. In certain further embodiments, the Shiga toxin effector polypeptide comprises or consists essentially of any one of SEQ ID NOs: 233-720. In certain further embodiments, the cell targeting molecule of the present invention comprises only one lysine residue (a unique lysine residue that can be used for conjugation to a heterologous molecule). In certain further embodiments, the cell targeting molecule comprises a heterologous molecule covalently linked directly or indirectly to a lysine residue. In certain further embodiments, the heterologous molecule is selected from the group consisting of: a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection facilitator. In certain further embodiments, the cell targeting binding region comprises a polypeptide. In certain further embodiments, the cell targeting binding region comprises an immunoglobulin-type binding region. In certain further embodiments, the immunoglobulin-type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NAR Fragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. In certain further embodiments, the binding region is capable of binding to an extracellular target biomolecule selected from the group consisting of CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gp A33, mucin, TAG-72, carbonic anhydrase IX, folate-binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TR P-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase phase Related antigens, human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54,CD63, CD69, CD123, TLR4, FceRIa, IgE, CD107a, CD203c, CD14, CD68, CD80, CD86, CD105, CD115, F4 / 80, ILT-3, Galectin-3, CD11a-c, GITRL, MHC class II, CD284-TLR4, CD107-Mac3, CD195-CCR5, HLA-DR, CD16 / 32, CD282-TLR2, and any immunogenic fragment of any of the foregoing. In certain embodiments, the binding region comprises a peptide or polypeptide as set forth in any one of SEQ ID NOs: 844-1100. In certain further embodiments, the cell targeting molecule comprises a carboxyl-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173),HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1188) NO:1189). For certain further embodiments, administration of a cell targeting molecule to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell targeting molecule to the cytosol of the cell, (3) disruption of the ribosome function of the cell, and (4) killing of the cell. For certain further embodiments, the cell targeting molecule of the present invention is capable of killing the cell. For certain further embodiments, after administration of the cell targeting molecule of the present invention to a cell physically coupled to an extracellular target biomolecule, the cell targeting molecule is capable of causing cell death, i.e., killing the cell.
[0086] In certain embodiments, the cell targeting molecules of the present invention comprise (1) a Shiga toxin effector polypeptide that does not comprise any lysine and / or pyrroline-carboxyl-lysine residues; (2) a cell targeting binding region that is capable of specifically binding to at least one extracellular target biomolecule; and (3) a protein linker fused between the Shiga toxin effector polypeptide and the cell targeting binding region to form a continuous polypeptide. In certain further embodiments, the linker comprises one or more pyrroline-carboxyl-lysine residues. In certain further embodiments, the linker is selected from the group consisting of any one of SEQ ID NOs: 757-761 and 771-772. In certain other embodiments, the cell targeting binding region comprises one or more pyrroline-carboxyl-lysine residues. In certain further embodiments, the cell targeting binding region comprises a polypeptide selected from the group consisting of amino acids 269-499 of any one of SEQ ID NOs: 807-808 and 812-813, amino acids 269-519 of any one of SEQ ID NOs: 814-815 and 818-829, or amino acids 268-386 of any one of SEQ ID NOs: 816-817. In certain further embodiments, the Shiga toxin effector polypeptide comprises or consists essentially of any one of SEQ ID NOs: 233-720. In certain further embodiments, the cell targeting molecule of the present invention comprises only one pyrroline-carboxyl-lysine residue (a unique pyrroline-carboxyl-lysine residue that can be used for conjugation to a heterologous molecule). In certain further embodiments, the cell targeting molecule comprises a heterologous molecule covalently linked directly or indirectly to the pyrroline-carboxyl-lysine residue. In certain further embodiments, the heterologous molecule is selected from the group consisting of a peptide, a protein, a nucleic acid, a protein-nucleic acid complex, a cytotoxic agent, an antibiotic, and a detection enhancer. In certain further embodiments, the cell targeting binding region comprises a polypeptide. In certain further embodiments, the cell targeting binding region comprises an immunoglobulin type binding region. In certain further embodiments, the immunoglobulin type binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NARFragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 thFibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality. In certain further embodiments, the binding region is capable of binding to an extracellular target biomolecule selected from the group consisting of CD20, PD-L1, CD22, CD40, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EpCAM, EphB2, prostate specific membrane antigen, Cripto, endoglin, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, EpCAM, CEA, gp A33, mucin, TAG-72, carbonic anhydrase IX, folate-binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, ganglioside Lewis-Y2, VEGFR, αVβ3, α5β1, ErbB1 / EGFR, Erb3, c-MET, IGF1R, EphA3, TRAIL-R1, TRAIL-R2, RANKL, FAP, tenascin, CD64, mesothelin, BRCA1, MART-1 / MelanA, gp100, tyrosinase, TR P-1, TRP-2, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MUC1, MART-1 / MelanA, gp100, tyrosinase phase Related antigens, human tyrosinase-related protein 1, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder tumor antigen, SAIL, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, FceRIa, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54,CD63, CD69, CD123, TLR4, FceRIa, IgE, CD107a, CD203c, CD14, CD68, CD80, CD86, CD105, CD115, F4 / 80, ILT-3, Galectin-3, CD11a-c, GITRL, MHC class II, CD284-TLR4, CD107-Mac3, CD195-CCR5, HLA-DR, CD16 / 32, CD282-TLR2, and any immunogenic fragment of any of the foregoing. In certain embodiments, the binding region comprises a peptide or polypeptide as set forth in any one of SEQ ID NOs: 844-1100. In certain further embodiments, the cell targeting molecule comprises a carboxyl-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. In certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173),HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ ID NO:1184), SDEL (SEQ ID NO:1185), TDEL (SEQ ID NO:1186), SKEL (SEQ ID NO:1187), STEL (SEQ ID NO:1188), and EDEL (SEQ ID NO:1188) NO:1189). For certain further embodiments, administration of a cell targeting molecule to a cell physically coupled to an extracellular target biomolecule results in one or more of the following: (1) internalization of the cell targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell targeting molecule to the cytosol of the cell, (3) disruption of the ribosome function of the cell, and (4) killing of the cell. For certain further embodiments, the cell targeting molecule of the present invention is capable of killing the cell. For certain further embodiments, after administration of the cell targeting molecule of the present invention to a cell physically coupled to an extracellular target biomolecule, the cell targeting molecule is capable of causing cell death, i.e., killing the cell.
[0087] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide has a Shiga toxin Al fragment-derived region having a carboxyl terminus and further comprises a disrupted furin cleavage motif at the carboxyl terminus of the Al fragment region.
[0088] In certain embodiments of embodiment groups #1 and #3, the molecule comprises a portion of the molecule located carboxy-terminally to the carboxy-terminal end of the Shiga toxin Al fragment region.
[0089] In certain embodiments of embodiment groups #1 to #3, the cell targeting molecule of the present invention or its polypeptide component comprises a carboxy-terminal endoplasmic reticulum retention / recycling signal motif of a KDEL family member. For certain further embodiments, the carboxy-terminal endoplasmic reticulum retention / recycling signal motif is selected from the group consisting of KDEL (SEQ ID NO: 1142), HDEF (SEQ ID NO: 1143), HDEL (SEQ ID NO: 1144), RDEF (SEQ ID NO: 1145), RDEL (SEQ ID NO: 1146), WDEL (SEQ ID NO: 1147), YDEL (SEQ ID NO: 1148), HEEF (SEQ ID NO: 1149), HEEL (SEQ ID NO: 1150), KEEL (SEQ ID NO: 1151), REEL (SEQ ID NO: 1152), KAEL (SEQ ID NO: 1153), KCEL (SEQ ID NO: 1154), KFEL (SEQ ID NO: 1155), KGEL (SEQ ID NO: 1156), KHEL (SEQ ID NO: 1157), KLEL (SEQ ID NO: 1158), KNEL (SEQ ID NO: 1159), NO:1159), KQEL (SEQ ID NO:1160), KREL (SEQ ID NO:1161), KSEL (SEQ ID NO:1162), KVEL (SEQ ID NO:1163), KWEL (SEQ ID NO:1164), KYEL (SEQ ID NO:1165), KEDL (SEQ ID NO:1166), KIEL (SEQ ID NO:1167), DKEL (SEQ ID NO:1168), FDEL (SEQ ID NO:1169), KDEF (SEQ ID NO:1170), KKEL (SEQ ID NO:1171), HADL (SEQ ID NO:1172), HAEL (SEQ ID NO:1173), HIEL (SEQ ID NO:1174), HNEL (SEQ ID NO:1175), HTEL (SEQ ID NO:1176), KTEL (SEQ ID NO:1177), HVEL (SEQ ID NO:1178), NDEL (SEQ ID NO:1179), QDEL (SEQ ID NO:1180), REDL (SEQ ID NO:1181), RNEL (SEQ ID NO:1182), RTDL (SEQ ID NO:1183), RTEL (SEQ IDNO: 1184), SDEL (SEQ ID NO: 1185), TDEL (SEQ ID NO: 1186), SKEL (SEQ ID NO: 1187), STEL (SEQ ID NO: 1188), and EDEL (SEQ ID NO: 1189). In certain further embodiments, the cell targeting molecules of the present invention can exhibit cytotoxicity greater than that of a reference molecule (a reference cell targeting molecule consisting of a cell targeting molecule, except that the reference cell targeting molecule does not contain any carboxyl terminal endoplasmic reticulum retention / recycling signal motif of the KDEL family) when introduced into a cell. In certain further embodiments, the cell targeting molecules of the present invention can exhibit cytotoxicity with better optimized cytotoxic efficacy, such as, for example, 4-fold, 5-fold, 6-fold, 9-fold or greater cytotoxicity compared to a reference molecule, such as a reference cell targeting molecule. In certain further embodiments, as by CD 50 The cytotoxicity of the cell targeting molecule of the present invention to the target-positive cell population is 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more greater than the cytotoxicity of the reference cell targeting molecule to the second target-positive cell population as measured by the cytotoxicity value.
[0090] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide further comprises at least one inserted or embedded heterologous epitope.
[0091] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide further comprises at least one, two, or three disrupted endogenous B cell and / or CD4+ T cell epitope regions. In certain further embodiments, the Shiga toxin effector polypeptide further comprises disruption of at least one, two, or three endogenous B cell and / or T cell epitopes and / or epitope regions. In certain further embodiments, the Shiga toxin effector polypeptide further comprises at least one disrupted endogenous B cell and / or CD4+ T cell epitope region that does not overlap with at least one inserted or embedded heterologous epitope.
[0092] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide further comprises a disruption of a B cell and / or T cell epitope region selected from the group consisting of: 1-15 of SEQ ID NO: 1 or SEQ ID NO: 2; 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 94-115 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 141-153 of SEQ ID NO: 1 or SEQ ID NO: 2; 140-156 of SEQ ID NO: 3; 179-190 of SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 3 NO:3; 179-191 of SEQ ID NO:3; 204 of SEQ ID NO:3; 205 of SEQ ID NO:1 or SEQ ID NO:2 and 210-218 of SEQ ID NO:3; 240-260 of SEQ ID NO:3; 243-257 of SEQ ID NO:1 or SEQ ID NO:2; 254-268 of SEQ ID NO:1 or SEQ ID NO:2; 262-278 of SEQ ID NO:3; 281-297 of SEQ ID NO:3; 285-293 of SEQ ID NO:1 or SEQ ID NO:2; 4-33 of SEQ ID NO:1 or SEQ ID NO:2; 34-78 of SEQ ID NO:1 or SEQ ID NO:2; 77-103 of SEQ ID NO:1 or SEQ ID NO:2; 128-168 of SEQ ID NO:1 or SEQ ID NO:2; SEQ ID NO:1 or SEQ ID NO:2 1 or SEQ ID NO: 2; 236-258 of SEQ ID NO: 1 or SEQ ID NO: 2; and 274-293 of SEQ ID NO: 1 or SEQ ID NO: 2; or the equivalent region in the Shiga toxin A subunit or a derivative thereof. In certain further embodiments, there is no carboxyl-terminal truncation of amino acid residues that overlap with part or all of at least one disrupted endogenous B-cell and / or T-cell epitope and / or epitope region.
[0093] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide further comprises a mutation relative to the wild-type Shiga toxin A subunit in a B cell immunogenic amino acid residue selected from the group consisting of naturally located Shiga toxin A subunit amino acid residues: L49, D197, D198, R204, and R205.
[0094] In certain embodiments of embodiment groups #1 to #3, the embedded or inserted heterologous T cell epitope disrupts an endogenous B cell and / or T cell epitope region of a naturally located Shiga toxin A subunit selected from the group consisting of: (i) 1-15 of SEQ ID NO: 1 or SEQ ID NO: 2; 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; and 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or the equivalent regions in a Shiga toxin A subunit or a derivative thereof, without the following disruptions: amino-terminal truncation of a sequence that overlaps with part or all of at least one of the disrupted epitope regions; (ii) 94-115 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; NO:2; 141-153 of SEQ ID NO:2; 140-156 of SEQ ID NO:3; 179-190 of SEQ ID NO:1 or SEQ ID NO:2; 179-191 of SEQ ID NO:3; 204 of SEQ ID NO:3; 205 of SEQ ID NO:1 or SEQ ID NO:2; and 210-218 of SEQ ID NO:3; (iii) 240-260 of SEQ ID NO:3; 243-257 of SEQ ID NO:1 or SEQ ID NO:2; 254-268 of SEQ ID NO:1 or SEQ ID NO:2; 262-278 of SEQ ID NO:3; 281-297 of SEQ ID NO:3; and 285-293 of SEQ ID NO:1 or SEQ ID NO:2; or the equivalent regions in the Shiga toxin A subunit or its derivatives.
[0095] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide further comprises a mutation relative to a wild-type Shiga toxin A subunit in a B-cell and / or T-cell epitope region selected from the group consisting of: (i) 1-15 of SEQ ID NO: 1 or SEQ ID NO: 2; 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; and 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or the equivalent region in a Shiga toxin A subunit or a derivative thereof, without the following disruptions: an amino-terminal truncation of a sequence overlapping with part or all of at least one of the disrupted epitope regions; (ii) 94-115 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; NO:2; 141-153 of SEQ ID NO:2; 140-156 of SEQ ID NO:3; 179-190 of SEQ ID NO:1 or SEQ ID NO:2; 179-191 of SEQ ID NO:3; 204 of SEQ ID NO:3; 205 of SEQ ID NO:1 or SEQ ID NO:2; and 210-218 of SEQ ID NO:3; (iii) 240-260 of SEQ ID NO:3; 243-257 of SEQ ID NO:1 or SEQ ID NO:2; 254-268 of SEQ ID NO:1 or SEQ ID NO:2; 262-278 of SEQ ID NO:3; 281-297 of SEQ ID NO:3; and 285-293 of SEQ ID NO:1 or SEQ ID NO:2; or the equivalent regions in the Shiga toxin A subunit or a derivative thereof, without the following disruptions: amino-terminal truncation of sequences that overlap with part or all of at least one disrupted epitope region.
[0096] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide comprises a disruption of at least one endogenous epitope region of a naturally located Shiga toxin A subunit selected from the group consisting of: 94-115 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; 141-153 of SEQ ID NO: 1 or SEQ ID NO: 2; 140-156 of SEQ ID NO: 3; 179-190 of SEQ ID NO: 1 or SEQ ID NO: 2; 179-191 of SEQ ID NO: 3; 204 of SEQ ID NO: 3; 205 of SEQ ID NO: 1 or SEQ ID NO: 2; or 210-218 of SEQ ID NO: 3.
[0097] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide does not comprise a heterologous MHC class I restricted T cell epitope. MHC class I restricted T cell epitopes are known in the art or can be predicted by a skilled artisan. The term heterologous refers to an MHC class I restricted T cell epitope that is not naturally present in a wild-type Shiga toxin A subunit, such as, for example, the wild-type Shiga toxin A subunit to which the Shiga toxin effector polypeptide of interest is most closely related.
[0098] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide comprises disruption of at least four, five, six, seven, eight or more endogenous B cell and / or T cell epitope regions.
[0099] In certain embodiments of embodiment groups #1 to #3, one or more disruptions comprise amino acid residue substitutions relative to wild-type Shiga toxin A subunit.
[0100] In certain embodiments of embodiment groups #1 to #3, one or more endogenous B cell and / or T cell epitope regions comprise a plurality of amino acid residue substitutions relative to wild-type Shiga toxin A subunit.
[0101] In certain embodiments of embodiment groups #1 to #3, at least one, two, three, or four disruptions comprise multiple amino acid residue substitutions in the endogenous B cell and / or T cell epitope region relative to the wild-type Shiga toxin A subunit.
[0102] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide of the invention further comprises at least one disruption comprising at least one, two, three, four, five, six, seven, eight or more amino acid residue substitutions relative to the wild-type Shiga toxin A subunit, and optionally wherein at least one substitution occurs at a naturally located Shiga toxin A subunit amino acid residue selected from the group consisting of: 1 of SEQ ID NO: 1 or SEQ ID NO: 2; 4 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 6 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 8 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 9 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 11 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 12 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 33 of SEQ ID NO: 1 or SEQ ID NO: 2; NO:2; 43 of SEQ ID NO:1 or SEQ ID NO:2; 44 of SEQ ID NO:1 or SEQ ID NO:2; 45 of SEQ ID NO:1 or SEQ ID NO:2; 46 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 47 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 48 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 49 of SEQ ID NO:1 or SEQ ID NO:2; 50 of SEQ ID NO:1 or SEQ ID NO:2; 51 of SEQ ID NO:1 or SEQ ID NO:2; 53 of SEQ ID NO:1 or SEQ ID NO:2; 54 of SEQ ID NO:1 or SEQ ID NO:2; 55 of SEQ ID NO:1 or SEQ ID NO:2; 56 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 57 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 58 of SEQ ID NO: 2 or SEQ ID NO: 3; 59 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 60 of SEQ ID NO: 1 or SEQ ID NO: 2;SEQ ID NO: 1 or SEQ ID NO: 61; SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 2; SEQ ID NO: 1 or SEQ ID NO: 3; SEQ ID NO: 1 or SEQ ID NO: 2 ... SEQ ID NO: 1 or SEQ ID NO: 3; 112 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 141 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 147 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 154 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 179 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 180 of SEQ ID NO: 1 or SEQ ID NO: 2; 181 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 183 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 184 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 185 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 186 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 187 of SEQ ID NO: 1 or SEQ ID NO: 2; 188 of SEQ ID NO: 1 or SEQ ID NO: 2; 189 of SEQ ID NO: 1 or SEQ ID NO: 2; 197 of SEQ ID NO: 3; 198 of SEQ ID NO: 1 or SEQ ID NO: 2; 204 of SEQ ID NO: 3; 205 of SEQ ID NO: 1 or SEQ ID NO: 2;247 of SEQ ID NO:1 or SEQ ID NO:2; 247 of SEQ ID NO:3; 248 of SEQ ID NO:1 or SEQ ID NO:2; 250 of SEQ ID NO:3; 251 of SEQ ID NO:1 or SEQ ID NO:2; 264 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; 265 of SEQ ID NO:1 or SEQ ID NO:2; and 286 of SEQ ID NO:1 or SEQ ID NO:2; or the equivalent amino acid residues in the Shiga toxin A subunit or a derivative thereof. In certain further embodiments, at least two disruptions each comprise at least one amino acid residue replacement relative to a wild-type Shiga toxin A subunit selected from the group consisting of: 1 of SEQ ID NO: 1 or SEQ ID NO: 2; 4 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 8 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 9 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 11 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 33 of SEQ ID NO: 1 or SEQ ID NO: 2; 43 of SEQ ID NO: 1 or SEQ ID NO: 2; 45 of SEQ ID NO: 1 or SEQ ID NO: 2; 47 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 48 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 49 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 53 of SEQ ID NO: 1 or SEQ ID NO: 2; 54 of SEQ ID NO: 1 or SEQ ID NO: 2; 55 of SEQ ID NO: 1 or SEQ ID NO: 2; 56 of SEQ ID NO: 1 or SEQ ID NO: 2; 57 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 58 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 SEQ ID NO: 1 or SEQ ID NO: 2; 55 of SEQ ID NO: 1 or SEQ ID NO: 2; 58 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 59 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 60 of SEQ ID NO: 1 or SEQ ID NO: 2; 61 of SEQ ID NO: 1 or SEQ ID NO: 2; 62 of SEQ ID NO: 1 or SEQ ID NO: 2; 94 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 96 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 109 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 110 of SEQ ID NO: 1 or SEQ ID NO: 2;SEQ ID NO: 1 or SEQ ID NO: 3 112; SEQ ID NO: 1 or SEQ ID NO: 3 147; SEQ ID NO: 1 or SEQ ID NO: 3 179; SEQ ID NO: 1 or SEQ ID NO: 3 180; SEQ ID NO: 1 or SEQ ID NO: 2 181; SEQ ID NO: 1 or SEQ ID NO: 2 183; SEQ ID NO: 1 or SEQ ID NO: 3 184; SEQ ID NO: 1 or SEQ ID NO: 2 185; SEQ ID NO: 1 or SEQ ID NO: 2 186; SEQ ID NO: 1 or SEQ ID NO: 3 187; SEQ ID NO: 1 or SEQ ID NO: 2 188; SEQ ID NO: 1 or SEQ ID NO: 2 189; SEQ ID NO: 3 204; SEQ ID NO: 1 or SEQ ID NO: 2 205 of SEQ ID NO: 2; 247 of SEQ ID NO: 1 or SEQ ID NO: 2; 247 of SEQ ID NO: 3; 250 of SEQ ID NO: 3; 264 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; 265 of SEQ ID NO: 1 or SEQ ID NO: 2; and 286 of SEQ ID NO: 1 or SEQ ID NO: 2; or the equivalent amino acid residues in the Shiga toxin A subunit or a derivative thereof.
[0103] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide comprises disruptions of at least three endogenous B-cell and / or T-cell epitope regions selected from the group consisting of: (i) 1-15 of SEQ ID NO: 1 or SEQ ID NO: 2; 3-14 of SEQ ID NO: 3; 26-37 of SEQ ID NO: 3; 27-37 of SEQ ID NO: 1 or SEQ ID NO: 2; 39-48 of SEQ ID NO: 1 or SEQ ID NO: 2; 42-48 of SEQ ID NO: 3; and 53-66 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or the equivalent region in the Shiga toxin A subunit or a derivative thereof, wherein none of the disruptions is an amino-terminal truncation of amino acid residues that overlap with part or all of at least one of the disrupted endogenous B-cell and / or T-cell epitope regions; (ii) 94-115 of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; NO:2; 141-153 of SEQ ID NO:2; 140-156 of SEQ ID NO:3; 179-190 of SEQ ID NO:1 or SEQ ID NO:2; 179-191 of SEQ ID NO:3; 204 of SEQ ID NO:3; 205 of SEQ ID NO:1 or SEQ ID NO:2; and 210-218 of SEQ ID NO:3; (iii) 240-260 of SEQ ID NO:3; 243-257 of SEQ ID NO:1 or SEQ ID NO:2; 254-268 of SEQ ID NO:1 or SEQ ID NO:2; 262-278 of SEQ ID NO:3; 281-297 of SEQ ID NO:3; and 281-298 of SEQ ID NO:1 or SEQ ID NO:2 NO: 285-293; or the equivalent region in the Shiga toxin A subunit or a derivative thereof, wherein the following disruptions are absent: carboxyl-terminal truncation of amino acid residues that overlap partially or completely with at least one disrupted endogenous B-cell and / or T-cell epitope and / or epitope region;
[0104] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide comprises disruptions of at least two endogenous B cell and / or T cell epitope regions, wherein each disruption comprises one or more amino acid residue substitutions, and wherein the endogenous B cell and / or T cell epitope regions are selected from the group of naturally located Shiga toxin A subunit regions consisting of: 3-14 of SEQ ID NO:3; 26-37 of SEQ ID NO:3; 27-37 of SEQ ID NO:1 or SEQ ID NO:2; 39-48 of SEQ ID NO:1 or SEQ ID NO:2; 42-48 of SEQ ID NO:3; 53-66 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3; or the equivalent regions in the Shiga toxin A subunit or a derivative thereof.
[0105] In certain embodiments of embodiment groups #1 to #3, the embedded or inserted heterologous T cell epitope does not disrupt any endogenous B cell and / or CD4+ T cell epitope regions described herein.
[0106] In certain embodiments of embodiment groups #1 to #3, at least one disruption comprises one or more amino acid residue replacements relative to wild-type Shiga toxin A subunit selected from the group consisting of: D to A, D to G, D to V, D to L, D to I, D to F, D to S, D to Q, D to M, D to R, E to A, E to G, E to V, E to L, E to I, E to F, E to S, E to Q, E to N, E to D, E to M, E to R, F to A, F to G, F to V, F to L, F to I, G to A, G to P, H to A, H to G, H to V, H to L, H to I, H to F, H to M, I to A, I to V, I to G, I to C, K to A, K to G, K to V, K to L, K to I, K to M, K to H, L to A, L to V, L to G, L to C, N to A, N to G, N to V, N to L, N to I, N to F, P to A, P to G, P to F, R to A, R to G, R to V, R to L, R to I, R to F, R to M, R to Q, R to S, R to K, R to H, S to A, S to G, S to V, S to L, S to I, S to F, S to M, T to A, T to G, T to V, T to L, T to I, T to F, T to M, T to S, V to A, V to G, Y to A, Y to G, Y to V, Y to L, Y to I, Y to F, Y to M, and Y to T. In certain further embodiments, the one or more amino acid residue substitutions relative to wild-type Shiga toxin A subunit are selected from the group consisting of: D to A, D to G, D to V, D to L, D to I, D to F, D to S, D to Q, E to A, E to G, E to V, E to L, E to I, E to F, E to S, E to Q, E to N, E to D, E to M, E to R, G to A, H to A, H to G, H to V, H to L, H to I, H to F, H to M, K to A, K to G, K to V, K to L, K to I, K to M, K to H, L to A, L to G, N to A, N to G, N to V, N to L, N to I, N to F, P to A, P to G, P to F, R to A, R to G, R to V, R to L, R to I, R to F, R to M, R to Q, R to S, R to K, R to H, S to A, S to G, S to V, S to L, S to I, S to F, S to M, T to A, T to G, T to V, T to L, T to I, T to F, T to M, T to S, Y to A, Y to G, Y to V, Y to L, Y to I, Y to F and Y to M.
[0107] In certain embodiments of embodiment groups #1 to #3, at least one of the disruptions comprises one or more amino acid residue replacements relative to wild-type Shiga toxin A subunit selected from the group consisting of: K1 to A, G, V, L, I, F, M, and H; T4 to A, G, V, L, I, F, M, and S; D6 to A, G, V, L, I, F, S, Q, and R; S8 to A, G, V, I, L, F, and M; T9 to A, G, V, I, L, F, M, and S; S9 to A, G, V, L, I, F, and M; K11 to A, G, V, L, I, F, M, and H; T12 to A, G, V, I, L, F, M, S, and K; S12 to A, G, V, I, L, F, and M; S33 to A, G, V, L, I, F, M, and C; S43 to A, G, V, L, I, F, and M; G44 to A or L; S45 to A, G, V, L, I, F, and M; T45 to A, G, V, L, I, F, and M; G46 to A and P; D47 to A, G, V, L, I, F, S, M, and Q; N48 to A, G, V, L, M, and F; L49 to A, V, C, and G; Y49 to A, G, V, L, I, F, M, and T; F50 to A, G, V, L, I, and T; A51; D53 to A, G, V, L, I, F, S, and Q; V54 to A, G, I, and L; R55 to A, G, V, L, I, F, M, Q, S, K, and H;
[0108] G56 to A and P; I57 to A, G, V, and M; L57 to A, V, C, G, M, and F; D58 to A, G, V, L, I, F, S, and Q; P59 to A, G, and F; E60 to A, G, V, L, I, F, S, Q, N, D, M, T, and R; E61 to A, G, V, L, I, F, S, Q, N, D, M, and R; G62 to A; R84 to A, G, V, L, I, F, M, Q, S, K, and H; V88 to A and G; I88 to A, V, C, and G; D94 to A, G, V, L, I, F, S, and Q; S96 to A, G, V, I, L, F, and M; T104 to A, G, V, L, I, F, M; and N; A105 to L; T107 to A, G, V, L, I, F, M, and P; S107 to A, G, V, L, I, F, M, and P; L108 to A, V, C, and G; S109 to A, G, V, I, L, F, and M; T109 to A, G, V, I, L, F, M, and S; G110 to A; S112 to A, G, V, L, I, F, and M; D111 to A, G, V, L, I, F, S, Q, and T; S112 to A, G, V, L, I, F, and M; D141 to A, G, V, L, I, F, S, and Q; G147 to A; V154 to A and G. R179 to A, G, V, L, I, F, M, Q, S, K, and H; T180 to A, G, V, L, I, F, M, and S; T181 to A, G, V, L, I, F, M, and S; D183 to A, G, V, L, I, F, S, and Q; D184 to A, G, V, L, I, F, S, and Q; L185 to A, G, V, and C; S186 to A, G, V, I, L, F, and M; G187 to A; R188 to A, G, V, L, I, F, M, Q, S, K, and H; S189 to A, G, V, I, L, F, and M; D197 to A, G, V, L, I, F, S, and Q; D198 to A, G, V, L, I , F, S, and Q; R204 to A, G, V, L, I, F, M, Q, S, K, and H; R205 to A, G, V, L, I, F, M, Q, S, K, and H; S247 to A, G, V, I, L, F, and M; Y247 to A, G, V, L, I, F, and M; R248 to A, G, V, L, I, F, M, Q, S, K, and H; R250 to A, G, V, L, I, F, M, Q, S, K, and H; R251 to A, G, V, L, I, F, M, Q, S, K, and H; D264 to A, G, V, L, I, F, S, and Q; G264 to A; and T286 to A, G, V, L, I, F, M, and S.
[0109] In certain embodiments of embodiment groups #1 to #3, the binding region and the Shiga toxin effector polypeptide are linked together, directly or indirectly.
[0110] For certain embodiments of embodiment groups #1 to #3, the molecules of the invention and / or their Shiga toxin effector polypeptides are capable of exhibiting subcellular delivery efficiency comparable to that of a reference cell-targeting molecule comprising a wild-type Shiga toxin A1 fragment or a wild-type Shiga toxin effector polypeptide, and / or are capable of exhibiting a significant level of intracellular delivery activity from an endosomal origin to the endoplasmic reticulum and / or the cytosol of the cell.
[0111] For certain embodiments of embodiment groups #1 to #3, the molecules of the invention are capable of exhibiting (i) a level of catalytic activity comparable to that of wild-type Shiga toxin A1 fragment or wild-type Shiga toxin effector polypeptide, (ii) ribosome inhibitory activity, half-maximal inhibitory concentration (IC 50 ) value of 10,000 picomolar or less, and / or (iii) a significant level of Shiga toxin catalytic activity.
[0112] In certain embodiments of embodiment groups #1 to #3, the molecule comprises a portion of a molecule that associates with the carboxyl terminus of a Shiga toxin effector polypeptide. In certain embodiments, the portion of the molecule comprises or consists of a binding region. In certain embodiments, the portion of the molecule comprises at least one amino acid, and the Shiga toxin effector polypeptide is linked to at least one amino acid residue of the portion of the molecule. In certain further embodiments, the portion of the molecule and the Shiga toxin effector polypeptide are fused to form a continuous polypeptide.
[0113] In certain embodiments of embodiment group #1 to #3, the furin cleavage motif of destruction comprises one or more mutations relative to wild-type Shiga toxin A subunit at the minimum furin cleavage site. In certain embodiments, the furin cleavage motif of destruction is not the amino-terminal truncation of a sequence that is partially or entirely overlapping with at least one amino acid residue of the minimum furin cleavage site. In certain embodiments, the mutation in the minimum furin cleavage site is an amino acid deletion, insertion and / or replacement of at least one amino acid residue in the R / YxxR furin cleavage motif. In certain further embodiments, the furin cleavage motif of destruction comprises at least one mutation relative to wild-type Shiga toxin A subunit, and the mutation changes natural positioning 1) at 248-251 of the A subunit (SEQ ID NO:1) of Shiga-like toxin 1 or Shiga toxin (SEQ ID NO:2), or 2) at 247-250 of the A subunit (SEQ ID NO:3) of Shiga-like toxin 2, or at least one amino acid residue in the region of the equivalent amino acid sequence position in any Shiga toxin A subunit. In certain further embodiments, the mutation is an amino acid residue substitution of an arginine residue with a non-positively charged amino acid residue.
[0114] In certain embodiments of embodiment groups #1 to #3, the molecule portion comprises a peptide and / or polypeptide derived from a Shiga toxin A2 fragment of a naturally occurring Shiga toxin.
[0115] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide comprises one or more mutations relative to a naturally occurring A subunit of a member of the Shiga toxin family, said mutations altering the enzymatic activity of the Shiga toxin effector polypeptide are selected from at least one amino acid residue deletion, insertion or substitution. In certain further embodiments, the mutation relative to the naturally occurring A subunit reduces or eliminates the cytotoxic activity of the Shiga toxin effector polypeptide, but the Shiga toxin effector polypeptide retains at least one other Shiga toxin effector function, such as, for example, promoting cellular internalization and / or directing intracellular delivery to one or more subcellular compartments. In certain further embodiments, the mutation relative to the naturally occurring A subunit is selected from at least one amino acid residue substitution, such as, for example, A231E, R75A, Y77S, Y114S, E167D, R170A, R176K and / or W203A in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.
[0116] For certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide is capable of: (i) localizing to a subcellular compartment selected from the group consisting of the cytosol, endoplasmic reticulum, and lysosome of a cell in which the Shiga toxin effector polypeptide is present; (ii) intracellularly delivering an epitope from an early endosomal compartment to a proteasome in a cell in which the Shiga toxin effector polypeptide is present; and / or (iii) intracellularly delivering an epitope from an early endosomal compartment to an MHC class I molecule in a cell in which the Shiga toxin effector polypeptide is present. In certain further embodiments, the Shiga toxin effector polypeptide is capable of intracellularly delivering a CD8+ T cell epitope for presentation by an MHC class I molecule on the surface of a cell in which the Shiga toxin effector polypeptide is present.
[0117] In certain embodiments, the cell targeting molecules of the present invention comprise a binding region comprising an immunoglobulin-type binding region comprising one or more polypeptides selected from the group consisting of: (a) a heavy chain variable (V H) domain, comprising a HCDR1 comprising or consisting essentially of the amino acid sequence of any one of SEQ ID NOs: 844, 850, 857, 863, 869, 875, 881, 885, 891, 897, 903, 909, 915, 921, 927, 933, 939, 948, 954, 960, 966, 972, 978, 984, 990, 996, 1002, 1008, 1014, 1020, 1026, 1032, 1035, 1041, 1044, 1050, 1056, 1062, 1065, 1071, 1077, 1083, 1089, and 1095; and a HCDR2 comprising or consisting essentially of the amino acid sequence of any one of SEQ ID NOs: 844, 850, 857, , 1072, 1078, 1084, 1090, and 1096; or a HCDR3 comprising or consisting essentially of the amino acid sequence of any one of SEQ ID NO: SEQ ID NO: 845, 851, 856, 858, 864, 876, 886, 892, 898, 904, 910, 916, 922, 928, 934, 940, 949, 955, 961, 967, 973, 979, 985, 991, 997, 1003, 1009, 1015, 1021, 1027, 1036, 1042, 1045, 1051, 1057, 1063, 1066, 1072, 1078, 1084, 1090, and 1096; NO: 846, 852, 859, 865, 870, 872, 877, 882, 887, 893, 899, 905, 911, 917, 923, 929, 935, 941, 950, 956, 962, 968, 974, 980, 982, 986, 992, 998, 1004, 1010, 1016, 1022, 1028, 1037, 1043, 1046, 1064, 1052, 1058, 1067, 1073, 1079, 1085, 1091, and 1097; and / or (b) light chain variable (V L) domain, comprising a LCDR1 comprising or consisting essentially of the amino acid sequence of any one of SEQ ID NOs: 847, 853, 860, 866, 871, 888, 894, 900, 906, 912, 918, 924, 930, 936, 942, 947, 953, 959, 965, 971, 977, 983, 989, 995, 1001, 1007, 1013, 1019, 1025, 1032, 1038, 1047, 1053, 1059, 1068, 1074, 1080, 1086, 1092, and 1098; and a LCDR2 comprising or consisting essentially of the amino acid sequence of any one of SEQ ID NOs: 847, 853, 860, 866, 871, NO: 848, 854, 861, 867, 883, 889, 895, 901, 907, 913, 919, 925, 931, 937, 948, 954, 960, 966, 972, 978, 984, 990, 996, 1002, 1008, 1014, 1020, 1026, 1033, 1039, 1048, 1054, 1060, 1069, 1075, 1081, 1087, 1093 and 1099; or a HCDR3 comprising or consisting essentially of the amino acid sequence of any one of SEQ ID NO: 848, 854, 861, 867, 883, 889, 895, 901, 907, NO:849, 855, 862, 868, 884, 890, 896, 902, 908, 914, 920, 926, 932, 938, 949, 955, 961, 967, 973, 979, 985, 991, 997, 1003, 1009, 1015, 1021, 1027, 1034, 1040, 1049, 1055, 1061, 1070, 1076, 1082, 1088, 1094 and 1100.
[0118] In certain embodiments, a cell targeting molecule of the invention comprises a binding region comprising or consisting essentially of amino acids 269-499 of any one of SEQ ID NOs: 807-808 and 812-813, comprising or consisting essentially of amino acids 269-519 of any one of SEQ ID NOs: 814-815 and 818-829, or comprising or consisting essentially of amino acids 268-386 of any one of SEQ ID NOs: 816-817.
[0119] In certain embodiments of embodiment group #3, the amino terminus of the Shiga toxin effector polypeptide is located at and / or proximal to the amino terminus of the polypeptide component of the cell-targeting molecule. In certain further embodiments, the binding region is not located proximal to the amino terminus of the cell-targeting molecule relative to the Shiga toxin effector polypeptide. In certain further embodiments, the binding region and the Shiga toxin effector polypeptide are physically arranged or oriented within the cell-targeting molecule such that the binding region is not located proximal to the amino terminus of the Shiga toxin effector polypeptide. In certain further embodiments, the binding region is located within the cell-targeting molecule closer to the carboxyl terminus of the Shiga toxin effector polypeptide than to the amino terminus of the Shiga toxin effector polypeptide. For certain further embodiments, the cell targeting molecules of the present invention are not cytotoxic and can exhibit a higher subcellular delivery efficiency from the extracellular space to the subcellular compartments of the endoplasmic reticulum and / or cytosol when introduced into a cell, compared to the cytotoxicity of a reference molecule (such as, for example, a reference cell targeting molecule having an amino terminus and comprising a binding region and a Shiga toxin effector polypeptide, wherein the Shiga toxin effector polypeptide is not located at or proximal to the amino terminus of the reference cell targeting molecule). For certain further embodiments, the cell targeting molecules of the present invention exhibit cytotoxicity with better optimized cytotoxic potency, such as, for example, 4-fold, 5-fold, 6-fold, 9-fold or greater cytotoxicity compared to the cytotoxicity of the reference cell targeting molecule. For certain further embodiments, such as by CD 50 In certain further embodiments, the cell-targeting molecule of the present invention is 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more cytotoxic to a target-positive cell population than the reference cell-targeting molecule is to a second target-positive cell population. In certain further embodiments, the reference cell-targeting molecule does not comprise any carboxy-terminal endoplasmic reticulum retention / recycling signal motif of the KDEL family.
[0120] For certain embodiments of embodiment group #3, the cell-targeting molecules of the invention can exhibit improved in vivo tolerability and / or stability when introduced into chordates compared to a reference molecule (such as, for example, a reference cell-targeting molecule consisting of the cell-targeting molecule, except that all of its Shiga toxin effector polypeptide components each comprise a wild-type Shiga toxin A1 fragment and / or a wild-type Shiga toxin furin cleavage site at the carboxyl terminus of its A1 fragment region). In certain further embodiments, the Shiga toxin effector polypeptide is not cytotoxic, and the molecule portion is cytotoxic.
[0121] In certain embodiments of embodiment group #3, the binding region comprises at least one peptide and / or polypeptide. In certain further embodiments, the binding region is or comprises an immunoglobulin-type binding region. In certain further embodiments, the binding region comprises a polypeptide selected from the group consisting of: an autonomous V H domains, single domain antibody fragments (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H or V H domain fragments), heavy chain antibody domains from cartilaginous fish (V H H or V H domain fragments), immunoglobulin new antigen receptor (IgNAR), V NAR Fragment, single chain variable fragment (scFv), antibody variable fragment (Fv), complementarity determining region 3 fragment (CDR3), constrained FR3-CDR3-FR4 polypeptide (FR3-CDR3-FR4), Fd fragment, small modular immunopharmaceutical (SMIP) domain, antigen binding fragment (Fab), armadillo repeat polypeptide (ArmRP), fibronectin-derived 10 th Fibronectin type III domain (10Fn3), tenascin type III domain (TNfn3), ankyrin repeat motif domain, low-density lipoprotein receptor-derived A domain (LDLR-A), lipocalin (anticalin), Kunitz domain, protein A-derived Z domain, γ-B crystal protein-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide (affitin), Fyn-derived SH2 domain, small protein, C-type lectin-like domain scaffold, engineered antibody mimics, and any of the aforementioned genetically manipulated counterparts that retain binding functionality.
[0122] For certain embodiments of embodiment group #3, wherein a cell targeting molecule of the invention is administered to a cell physically coupled to an extracellular target biomolecule of the binding region of the cell targeting molecule, the cell targeting molecule is capable of causing cell death. In certain further embodiments, a cell targeting molecule of the invention is administered to two different cell type populations that differ in the presence or level of the extracellular target biomolecule, compared to a CD4 T cell population that is not physically coupled to an extracellular target biomolecule of the binding region of the cell targeting molecule. 50 , the cell targeting molecule is capable of at least three times or less CD 50Resulting in the death of a cell type that is physically coupled to an extracellular target biomolecule of a binding region of a cytotoxic cell targeting molecule. For certain embodiments, wherein a cell targeting molecule of the invention is administered to a first cell population (members of which are physically coupled to an extracellular target biomolecule of a binding region of a cell targeting molecule), and a second cell population (members of which are not physically coupled to an extracellular target biomolecule of a binding region), the cytotoxic effect of the cell targeting molecule on members of the first cell population is at least 3-fold greater relative to members of the second cell population. For certain embodiments, wherein a cell targeting molecule of the invention is administered to a first cell population (members of which are physically coupled to a plurality of extracellular target biomolecules of a binding region of a cell targeting molecule), and a second cell population (members of which are not physically coupled to a plurality of extracellular target biomolecules of a binding region), the cytotoxic effect of the cell targeting molecule on members of the first cell population is at least 3-fold greater relative to members of the second cell population. For certain embodiments, wherein a cell targeting molecule of the invention is administered to a first target biomolecule-positive cell population, and a second cell population (whose members do not express a significant amount of the target biomolecule on the cell surface of the binding region of the cell targeting molecule), the cytotoxic effect of the cell targeting molecule on members of the first cell population is at least 3-fold greater relative to members of the second cell population.
[0123] For certain embodiments of the cell-targeting molecules of the present invention, upon administration of the cell-targeting molecule to a first cell population physically coupled to a target biomolecule and a second cell population, the cytotoxic effect of the cell-targeting molecule on members of the first cell population is at least 3-fold greater relative to members of the second cell population. For certain further embodiments, the members of the first cell population are target biomolecule positive cells. For certain embodiments, the members of the first cell population overexpress the extracellular target biomolecule on the cell surface. For certain embodiments, the members of the second cell population are not physically coupled to the extracellular target biomolecule and / or are target biomolecule negative. For certain embodiments of the cell-targeting molecules of the present invention, upon administration of the cell-targeting molecule to a first cell population (members of which are target biomolecule positive) and a second cell population (members of which are not target biomolecule positive), the cytotoxic effect of the cell-targeting molecule on members of the first cell population is at least 3-fold greater relative to members of the second cell population.
[0124] In certain embodiments, the cell targeting molecules of the present invention are capable of inducing cellular internalization more effectively than a reference molecule consisting of a cell targeting molecule without any Shiga toxin effector polypeptide component. For certain further embodiments, administration of the cell targeting molecule to a cell physically coupled to an extracellular target biomolecule results in one or more of: (1) internalization of the cell targeting molecule into the cell, (2) subcellular localization of the Shiga toxin effector polypeptide of the cell targeting molecule to the cytosol of the cell, (3) disruption of ribosomal function of the cell, and (4) killing of the cell. For certain further embodiments, internalization occurs within about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes or less at a physiological temperature suitable for the cell and / or about 37 degrees Celsius. For certain further embodiments, the cell targeting molecule induces cellular internalization of a molecular complex comprising the cell targeting molecule bound to the target biomolecule. For certain further embodiments, the cell is a target positive cell. For certain embodiments, the cell is physically coupled to a plurality of extracellular target biomolecules.
[0125] For certain embodiments of embodiment group #3, the cell targeting molecules of the present invention are capable of exhibiting a half-maximal inhibitory concentration (C 500 nM) or less when introduced into cells. 50 ) values, and / or are capable of exhibiting significant levels of Shiga toxin cytotoxicity.
[0126] For certain embodiments of embodiment group #3, the cell targeting molecules of the invention are capable of delivering an embedded or inserted heterologous CD8+ T cell epitope to the MHC class I presentation pathway of the cell for cell surface presentation of the epitope bound by an MHC class I molecule.
[0127] In certain embodiments of embodiment group #3, the cell-targeting molecule further comprises a cytotoxic molecule portion associated with the carboxyl terminus of the Shiga toxin effector polypeptide. For certain embodiments, the cytotoxic molecule portion is a cytotoxic agent, such as, for example, a small molecule chemotherapeutic agent, an anti-tumor agent, a cytotoxic antibiotic, an alkylating agent, an antimetabolite, a topoisomerase inhibitor, and / or a tubulin inhibitor known to those skilled in the art and / or described herein. For certain further embodiments, the cytotoxic molecule portion is cytotoxic at a concentration of less than 10,000, 5,000, 1,000, 500, or 200 pM.
[0128] In certain embodiments of embodiment set #3, the binding region is directly or indirectly linked to the Shiga toxin effector polypeptide via at least one covalent bond that is not a disulfide bond. In certain further embodiments, the binding region is fused directly or indirectly to the carboxyl terminus of the Shiga toxin effector polypeptide to form a single contiguous polypeptide. In certain further embodiments, the binding region is an immunoglobulin-type binding region.
[0129] In certain embodiments of embodiment group #3, the cell-targeting molecules of the invention are capable of exhibiting cytotoxicity comparable to that of a reference molecule (such as, for example, a reference cell-targeting molecule consisting of the cell-targeting molecule, except that all of its Shiga toxin effector polypeptide components each comprise a wild-type Shiga toxin A1 fragment) when introduced into a cell.
[0130] In certain embodiments of embodiment group #3, the binding region spatially overlaps the carboxyl terminus of the A1 fragment region.
[0131] In certain embodiments of embodiment group #3, the molecular moiety sterically covers the carboxyl terminus of the A1 fragment region. In certain further embodiments, the molecular moiety comprises a binding region.
[0132] In certain embodiments of embodiment group #3, the cell targeting molecules of the present invention comprise a binding region and / or a molecular portion located at the carboxyl terminus of the Shiga toxin A1 fragment region. In certain further embodiments, the binding region and / or molecular portion has a mass of at least 4.5 kDa, 6, kDa, 9 kDa, 12 kDa, 15 kDa, 20 kDa, 25 kDa, 28 kDa, 30 kDa, 41 kDa, 50 kDa, 100 kDa or more.
[0133] In certain embodiments of embodiment groups #1 to #3, the cell targeting molecule comprises a binding region with a mass of at least 4.5 kDa, 6, kDa, 9 kDa, 12 kDa, 15 kDa, 20 kDa, 25 kDa, 28 kDa, 30 kDa, 41 kDa, 50 kDa, 100 kDa or more, so long as the cell targeting molecule retains an appropriate level of Shiga toxin biological activity described herein (e.g., cytotoxicity and / or intracellular delivery).
[0134] In certain embodiments of embodiment group #3, the binding region is contained within a relatively large molecular portion, which comprises, for example, a molecular portion having a mass of at least 4.5kDa, 6, kDa, 9kDa, 12kDa, 15kDa, 20kDa, 25kDa, 28kDa, 30kDa, 41kDa, 50kDa, 100kDa or more, so long as the cell targeting molecule retains an appropriate level of Shiga toxin biological activity as described herein.
[0135] For certain embodiments of embodiment group #3, the cell-targeting molecules of the present invention exhibit low cytotoxic potency (i.e., they are unable to exhibit cytotoxicity resulting in greater than 1% cell death in a cell population at a cell-targeting molecule concentration of 1000 nM, 500 nM, 100 nM, 75 nM, or 50 nM when introduced into certain positive target cell types) and, when introduced into cells, are capable of exhibiting higher subcellular delivery efficiency from the extracellular space to subcellular compartments of the endoplasmic reticulum and / or cytosol than the cytotoxicity of a reference molecule (such as, for example, a reference cell-targeting molecule having an amino terminus and comprising a binding region and a Shiga toxin effector polypeptide, wherein the Shiga toxin effector polypeptide is not located at or proximal to the amino terminus of the reference cell-targeting molecule). In certain further embodiments, the reference cell-targeting molecule does not comprise any carboxy-terminal endoplasmic reticulum retention / recycling signal motif of the KDEL family.
[0136] In certain embodiments of the present invention, a pharmaceutical composition comprises any one of the above-mentioned Shiga toxin effector polypeptides of the present invention, any one of the above-mentioned Shiga toxin effector polypeptide scaffolds of the present invention, and / or any one of the above-mentioned cell targeting molecules of the present invention; and at least one pharmaceutically acceptable excipient or carrier.
[0137] In certain embodiments of the present invention are diagnostic compositions comprising any of the aforementioned Shiga toxin effector polypeptides of the present invention, any of the aforementioned Shiga toxin effector polypeptide scaffolds of the present invention, and / or a cell-targeting molecule of the present invention and a detection-facilitating agent. Certain further embodiments are cell-targeting molecules of the present invention, wherein the detection-facilitating agent is a heterologous epitope and the cell-targeting molecule comprises a heterologous epitope.
[0138] For certain embodiments, the cell targeting molecules of the present invention can express CD 50 Cytotoxic activity with a value of 1,000 nanomolar or less and / or significant levels of Shiga toxin cytotoxicity.
[0139] For certain embodiments of the cell-targeting molecules of the present invention, upon administration of the cell-targeting molecule to a cell expressing a target, the cell-targeting molecule is capable of causing cell death, i.e., killing the cell. For certain embodiments of the cell-targeting molecules of the present invention, upon administration of the cell-targeting molecule to a cell expressing a target that expresses an extracellular target biomolecule, the cell-targeting molecule is capable of causing cell death. For certain further embodiments, the cell is a target biomolecule-positive cell. For certain further embodiments, the cell is physically coupled to a plurality of extracellular target biomolecules. This cell-killing activity may or may not be dependent on the catalytic activity of one or more Shiga toxin effector polypeptides of the cell-targeting molecule.
[0140] In certain embodiments, the cell targeting molecules of the invention comprise only those immunoglobulin regions that lack free cysteine residues. In certain further embodiments, the cell targeting molecules of the invention comprise only those immunoglobulin regions that do not contain any cysteine residues.
[0141] The embodiments of the present invention are not intended to encompass any naturally occurring Shiga holotoxin or Shiga toxin A subunit. In certain embodiments of embodiment groups #1-3, the cell-targeting molecules of the present invention do not comprise a naturally occurring Shiga toxin B subunit. In certain further embodiments, the cell-targeting molecules of the present invention do not comprise any polypeptide comprising or consisting essentially of a functional binding domain of a naturally occurring Shiga toxin B subunit. Rather, in certain embodiments of the cell-targeting molecules of the present invention, a region derived from a Shiga toxin A subunit is functionally associated with a heterologous binding region to achieve cell targeting.
[0142] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide comprises at least two embedded or inserted heterologous epitopes.
[0143] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide does not comprise a group of amino acid residue substitutions relative to the wild-type Shiga toxin A subunit selected from the following groups: (1) R248H and R251H; (2) R248G and R251G; (3) A246G, S247A, A253G, and S254A; and (4) A246G, S247A, R248G, R251G, A253G, and S254A.
[0144] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide does not comprise a deletion of the region naturally located at 247-252 in the wild-type Shiga toxin subunit A. In certain embodiments of embodiment groups #2-11, the Shiga toxin effector polypeptide does not comprise a deletion of the region naturally located at 245-247 and 253-255 in the wild-type Shiga toxin subunit A.
[0145] In certain embodiments, the molecules of the invention do not comprise any additional exogenous material representing antigenic and / or heterologous CD8+ T cell epitope-peptides at the carboxy-terminal position of the Shiga toxin effector polypeptide and / or the carboxy-terminal end of the Shiga toxin A1 fragment region.
[0146] In certain embodiments of embodiment group #3, the cell targeting molecule of the invention does not comprise a carboxy-terminal binding region comprising a fragment of an immune cell surface receptor.
[0147] In certain embodiments of embodiment set #3, the binding region does not comprise a human CD4 fragment corresponding to amino acid residues 19 to 183. In certain further embodiments, the binding region does not comprise a fragment of human CD4, a type I transmembrane glycoprotein. In certain further embodiments, the binding region does not comprise a fragment of a human immune cell surface co-receptor.
[0148] In certain embodiments of embodiment group #3, the binding region does not comprise a ligand. In certain embodiments of embodiment group #3, the binding region does not comprise a chemokine or TNF-related apoptosis-inducing ligand (TRAIL), nor does it comprise a receptor binding fragment thereof. In certain embodiments of embodiment group #3, the binding region does not comprise a human chemokine or human TRAIL, nor does it comprise a receptor binding fragment thereof. In the embodiment of embodiment group #3, the immunoglobulin-type binding region does not comprise a ligand or its receptor binding fragment. In certain embodiments of embodiment group #3, the immunoglobulin-type binding region does not comprise a chemokine or TNF-related apoptosis-inducing ligand (TRAIL), nor does it comprise a receptor binding fragment thereof. In certain embodiments of embodiment group #3, the binding region does not comprise a human CC chemokine or its receptor binding fragment. In certain embodiments of embodiment groups #1 to #3, the binding region does not comprise a human CC chemokine CCL2 (see Bose S, Cho J et al., Arch Pharm Res 36: 1039-50 (2013)). In certain embodiments of embodiment groups #1 to #3, the binding region does not comprise human CC chemokine CCL2, nor a receptor binding fragment thereof, and a carboxy-terminal Shiga toxin effector polypeptide consisting of amino acids 75-247 of StxA. In certain embodiments of the cell-targeting molecules of the present invention, the binding region does not comprise human CC chemokine CCL2 fused to a carboxy-terminal Shiga toxin effector polypeptide consisting of amino acids 75-247 of StxA (SEQ ID NO: 2), nor a receptor binding fragment thereof. In embodiments of embodiment group #3, the binding region does not comprise human TRAIL or a receptor binding fragment thereof.
[0149] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide does not comprise an amino acid replacement at native position 242 of SLT-1A (SEQ ID NO: 1) or StxA (SEQ ID NO: 2) or at an equivalent position in a Shiga toxin effector polypeptide derived from SLT-1A (SEQ ID NO: 1) and / or StxA (SEQ ID NO: 2). In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide does not comprise any combination of: C242A, C261A, C242S, and / or C261S. In certain embodiments, the Shiga toxin effector polypeptide comprises all endogenous native cysteine residues at their native positions or at equivalent positions in a Shiga toxin effector polypeptide derived from SLT-1A (SEQ ID NO: 1), StxA (SEQ ID NO: 2), or SLT-2 (SEQ ID NO: 3).
[0150] In certain embodiments of embodiment groups #1 to #3, wherein the Shiga toxin effector polypeptide and / or Shiga toxin effector polypeptide scaffold of the molecule of the invention is linked to a heterologous molecule (e.g., a cargo or cell targeting molecule), the heterologous molecule is not linked to the free amine group at the amino terminus of the polypeptide of the molecule of the invention.
[0151] In certain embodiments of embodiment groups #1 to #3, wherein the Shiga toxin effector polypeptide and / or Shiga toxin effector polypeptide scaffold of the molecule of the invention is linked to a heterologous molecule (e.g., a cargo or cell targeting molecule), the heterologous molecule is not linked to the free carboxyl group at the carboxyl terminus of the polypeptide of the molecule of the invention.
[0152] In certain embodiments of embodiment groups #1 to #3, the Shiga toxin effector polypeptide and / or Shiga toxin effector polypeptide scaffold of the present invention is linked to a heterologous molecule via a functional group of a unique amino acid residue that is not an amine or carboxyl group.
[0153] In certain embodiments, the cell-targeting molecules of the present invention do not comprise an immunoglobulin Fc region or Fc region effector that retains Fc region functions (such as, for example, those involved in extracellular signaling to immune system factors, cells and / or tissues). Non-limiting examples of Fc region functions include activation of T cells, stimulation of the release of inflammatory mediators such as cytokines such as TNF-α, initiation of complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and phagocytosis of cells extracellularly bound by molecules comprising an Fc region.
[0154] In certain embodiments, the cell targeting molecules of the present invention do not comprise any immunoglobulin heavy chain constant region, immunoglobulin light chain constant region, immunoglobulin C L domain, immunoglobulin CH 1 domain, immunoglobulin C H 2 domains and / or immunoglobulin C H In certain further embodiments, the cell targeting molecule does not comprise any immunoglobulin domain other than an immunoglobulin domain selected from the group consisting of: (1) CDRs, (2) ABRs and / or (3) domains present in autonomous V H any immunoglobulin domain, single domain antibody domain (sdAb), heavy chain antibody domain fragment (V H H fragment or V H In certain embodiments, the cell targeting molecules of the present invention do not comprise any immunoglobulin domain or any polypeptide derived from an immunoglobulin.
[0155] For certain embodiments of the cell targeting molecule, the cell targeting molecule can be used to deliver additional exogenous substances into the cell. In certain embodiments, the cell targeting molecule of the present invention comprises a conjugated molecule representing an additional exogenous substance. For certain embodiments of the cell targeting molecule of the present invention (which comprises an additional exogenous substance); after the cell targeting molecule is administered to one or more cells physically coupled to the extracellular target biomolecule, the cell targeting molecule is internalized into the one or more cells at a physiological temperature suitable for the cell and / or about 37 degrees Celsius within about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes or less. For certain further embodiments, the one or more cells are target positive cells. For certain embodiments, the one or more cells are physically coupled to a large number of extracellular target biomolecules.
[0156] For certain embodiments of the cell-targeting molecules of the present invention (which include additional exogenous substances); after the cell-targeting molecule is administered to one or more cells physically coupled to the extracellular target biomolecule, the cell-targeting molecule is internalized into the one or more cells and delivers the additional exogenous substance to the interior of the cells within about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes or less at a physiological temperature suitable for the cells and / or about 37 degrees Celsius. For certain further embodiments, the one or more cells are target-positive cells. For certain embodiments, the one or more cells are physically coupled to a plurality of extracellular target biomolecules.
[0157] For certain embodiments of the cell targeting molecules of the present invention (which include additional exogenous substances); Thus, after administering the cell targeting molecule to a plurality of cells physically coupled to an extracellular target biomolecule at a cell targeting molecule concentration equivalent to 5 percent or 38 to 50 percent cell surface occupancy, a majority of the cell targeting molecule is internalized into the plurality of cells within about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes or less at a physiological temperature suitable for the cells and / or about 37 degrees Celsius. For certain further embodiments, members of the plurality of cells are target-positive cells. For certain embodiments, members of the plurality of cells are physically coupled to a plurality of extracellular target biomolecules.
[0158] For certain embodiments of the cell targeting molecules of the present invention (which contain additional exogenous substances); therefore, after administering the cell targeting molecule to a plurality of cells physically coupled to an extracellular target biomolecule at a cell targeting molecule concentration equivalent to 5% or 38% to 50% cell surface occupancy, the majority of the cell targeting molecule is internalized into the plurality of cells and delivers the additional exogenous substance to the interior of the cells within about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes or less at a physiological temperature suitable for the cells and / or about 37 degrees Celsius. For certain further embodiments, members of the plurality of cells are target-positive cells. For certain embodiments, members of the plurality of cells are physically coupled to a large number of extracellular target biomolecules.
[0159] In certain embodiments, the cell targeting molecule of the present invention comprises a conjugate molecule representing an additional exogenous substance selected from the group consisting of: an antibiotic, a cytotoxic agent, a detection facilitator, a peptide, a polypeptide, a protein, a polynucleotide, and / or a protein-nucleic acid complex. In certain further embodiments, the additional exogenous substance is a protein comprising an enzyme. In certain other embodiments, the additional exogenous substance is a polynucleotide that acts as a small inhibitory RNA (siRNA) or microRNA (miRNA). In certain embodiments, the additional exogenous substance is a peptide that is an antigen from, for example, a pathogen. In certain embodiments, the antigen is derived from a molecule selected from the group consisting of: a bacterial protein, a protein mutated in cancer, a protein abnormally expressed in cancer, a T cell complementarity determining region polypeptide, and / or a viral protein. In certain embodiments, the cytotoxic agent is a chemotherapeutic agent, a cytotoxic antibiotic, an alkylating agent, an antimetabolite, a topoisomerase inhibitor, and / or a tubulin inhibitor.
[0160] The present invention also provides pharmaceutical compositions comprising a Shiga toxin effector polypeptide of the invention and / or a cell-targeting molecule of the invention and at least one pharmaceutically acceptable excipient or carrier, and uses of such cell-targeting molecules or compositions comprising the same in the preparation of such pharmaceutical compositions and in the methods of the invention, as further described herein. Certain embodiments of the invention are pharmaceutical compositions comprising any cell-targeting molecule of the invention and at least one pharmaceutically acceptable excipient or carrier.
[0161] In certain embodiments of the invention are diagnostic compositions comprising a cell-targeting molecule of the invention, further comprising a detection-facilitating agent for collecting information about a cell, cell type, tissue, organ, disease, disorder, condition, subject and / or patient.
[0162] In addition to the Shiga toxin effector polypeptides and cell-targeting molecules of the present invention and compositions thereof, polynucleotides encoding Shiga toxin effector polypeptides and / or cell-targeting molecules of the present invention or polypeptide components thereof are also within the scope of the present invention, as well as expression vectors comprising the polynucleotides of the present invention and host cells comprising the expression vectors of the present invention. Host cells comprising the expression vectors of the present invention can be used, for example, in methods for producing the cell-targeting molecules or polypeptide components of the present invention or fragments thereof by recombinant expression. Similarly, host cells comprising the expression vectors of the present invention can be used, for example, in methods for producing the compositions of the present invention or polypeptide components thereof.
[0163] The present invention also includes any composition of the invention immobilized on a solid substrate. Such arrangements of the invention composition of matter can be used, for example, in methods for screening molecules as described herein.
[0164] In addition, the present invention provides a method for killing cells, the method comprising the step of contacting one or more cells with a cell targeting molecule of the present invention and / or a pharmaceutical composition of the present invention. For certain embodiments, the step of contacting one or more cells occurs in vitro. For certain other embodiments, the step of contacting one or more cells occurs in vivo. For certain embodiments of the method of killing cells of the present invention, when contacting a cell mixture comprising different cells (which differ in the cell surface presence and / or expression level of the extracellular target biomolecule bound by the binding region of the cell targeting molecule), the method is able to selectively kill one or more cells and / or cell types over other one or more cells and / or cell types.
[0165] In addition, the present invention provides a method for inducing cellular internalization of a cell-targeting molecule into one or more cells physically coupled to an extracellular target biomolecule, the method comprising the step of contacting the one or more cells with a cell-targeting molecule of the present invention, a pharmaceutical composition of the present invention, and / or a diagnostic composition of the present invention. For certain further embodiments of the method for inducing cellular internalization, the step of contacting the one or more cells occurs in vitro. For certain other embodiments, the step of contacting the one or more cells occurs in vivo, such as, for example, in a patient. For certain further embodiments of the method for inducing cellular internalization, cellular internalization of the cell-targeting molecule occurs at a physiological temperature suitable for the cell and / or at about 37 degrees Celsius within about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less. For certain further embodiments, the cell is a target-positive cell. For certain embodiments, the cell is physically coupled to a plurality of extracellular target biomolecules.
[0166] For certain embodiments, the present invention provides a method for inducing cellular internalization of a cell-targeting molecule into a plurality of cells physically coupled to an extracellular target biomolecule, the method comprising the step of contacting the plurality of cells with a cell-targeting molecule of the invention, a pharmaceutical composition of the invention, and / or a diagnostic composition of the invention. For certain further embodiments of the method for inducing cellular internalization, the step of contacting one or more cells occurs in vitro. For certain other embodiments, the step of contacting one or more cells occurs in vivo, such as, for example, in a patient. For certain further embodiments of the method for inducing cellular internalization, cellular internalization of the cell-targeting molecule occurs at a physiological temperature suitable for the cell and / or at about 37 degrees Celsius within about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less. For certain embodiments, members of the plurality of cells are physically coupled to a plurality of extracellular target biomolecules.
[0167] Similarly, the present invention provides methods for internalizing a cell surface-localized target bound by a cell targeting molecule of the present invention, the method comprising the step of contacting one or more cells having a cell surface-localized target biomolecule with a targeting molecule of the present invention, a pharmaceutical composition of the present invention, and / or a diagnostic composition of the present invention. For certain further embodiments of the method for internalizing a cell surface-localized target, the step of contacting one or more cells occurs in vitro. For certain other embodiments, the step of contacting one or more cells occurs in vivo, such as, for example, in a patient. For certain further embodiments of the method for internalizing a cell surface-localized target, internalization of the cell surface-localized target biomolecule occurs at a physiological temperature suitable for the cell and / or at about 37 degrees Celsius in about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less. For certain further embodiments, the cell is a target-positive cell. For certain embodiments, the cell is physically coupled to a large number of extracellular target biomolecules.
[0168] For certain embodiments, the present invention provides a method for internalizing a cell surface-localized target biomolecule bound by a cell targeting molecule of the present invention, the method comprising the step of contacting a plurality of cells having a cell surface-localized target biomolecule with a targeting molecule of the present invention, a pharmaceutical composition of the present invention, and / or a diagnostic composition of the present invention. For certain further embodiments of the method for internalizing a cell surface-localized target biomolecule, the step of contacting the plurality of cells occurs in vitro. For certain other embodiments, the step of contacting the plurality of cells occurs in vivo, such as, for example, in a patient. For certain further embodiments of the method for internalizing a cell surface-localized target biomolecule, internalization of the cell surface-localized target biomolecule occurs in a majority of the plurality of cells at a physiological temperature suitable for the cell and / or at about 37 degrees Celsius within about 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less. For certain further embodiments, members of the plurality of cells are target-positive cells. For certain embodiments, members of the plurality of cells are physically coupled to a plurality of extracellular target biomolecules.
[0169] For certain embodiments, the present invention provides a method for inducing cellular internalization of a cell surface-localized target biomolecule bound by a cell targeting molecule in a subject, the method comprising the step of administering to the subject a cell targeting molecule of the present invention, a pharmaceutical composition of the present invention, and / or a diagnostic composition of the present invention.
[0170] In addition, the present invention provides a method for delivering an exogenous substance to the interior of a cell, the method comprising contacting one or more cells in vitro or in vivo with a cell-targeting molecule comprising another exogenous substance of the present invention, a pharmaceutical composition of the present invention (which comprises: a cell-targeting molecule comprising another exogenous substance of the present invention), and / or a diagnostic composition of the present invention (which comprises: a cell-targeting molecule comprising another exogenous substance of the present invention). For certain further embodiments, the cell is physically coupled to the extracellular target biomolecule. For certain further embodiments, the cell is a target-positive cell. For certain embodiments, the cell is physically coupled to a plurality of extracellular target biomolecules.
[0171] For certain embodiments, the present invention provides a method for delivering an exogenous substance to the interior of a cell, the method comprising administering to a subject a cell-targeting molecule of the present invention comprising an additional exogenous substance, a pharmaceutical composition of the present invention (which comprises: a cell-targeting molecule of the present invention comprising an additional exogenous substance), and / or a diagnostic composition of the present invention (which comprises: a cell-targeting molecule of the present invention comprising an additional exogenous substance). For certain further embodiments, the cell is physically coupled to an extracellular target biomolecule. For certain further embodiments, the cell is a target-positive cell. For certain embodiments, the cell is physically coupled to a plurality of extracellular target biomolecules.
[0172] For certain further embodiments, cells, multiple cells, and cell populations referred to as (1) a "cell"; (2) a "cell physically coupled to a target biomolecule"; (3) a "cell expressing a target biomolecule on the cell surface"; (4) a "target-positive cell"; (5) a "multiple cells"; (6) a "multiple cells physically coupled to a target biomolecule"; (7) a "cell population"; (8) a "target-positive cell population"; or (9) "one or more cells" are cells, multiple cells, or cell populations that (a) are physically coupled to an extracellular target biomolecule; (b) express a target biomolecule on the cell surface that (i) has an extracellular portion that is bound by a binding region of a cell-targeting molecule, (ii) has a transmembrane domain, and (iii) remains physically coupled to one or more cells; (c) are target-positive; and / or (d) are physically coupled to a plurality of extracellular target biomolecules that have an extracellular portion that is bound by a binding region of a cell-targeting molecule.
[0173] The use of any composition of the present invention for the diagnosis, prognosis and / or characterization of a disease, disorder and / or condition is within the scope of the present invention. In certain embodiments of the present invention, one or more compositions of matter of the present invention (e.g., pharmaceutical compositions of the present invention) are used in the treatment or prevention of cancer, tumors, abnormal growth conditions and / or immune disorders. In certain embodiments of the present invention, one or more compositions of matter of the present invention (e.g., pharmaceutical compositions of the present invention) are used in the preparation of a medicament for the treatment or prevention of cancer, tumors, abnormal growth conditions and / or immune disorders.
[0174] The present invention further provides methods of treating a disease, condition, and / or disorder in a subject, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a cell-targeting molecule of the present invention and / or a pharmaceutical composition of the present invention. For certain embodiments of these treatment methods of the present invention, the disease, condition, or disorder treated using the methods of the present invention involves cells, cancer cells, tumor cells, and / or immune cells that express the target biomolecule on their cell surface. For certain embodiments of these treatment methods of the present invention, the disease, condition, or disorder treated using the methods of the present invention is cancer, a tumor, an abnormal growth disorder, and / or an immune disorder.For certain embodiments of these treatment methods of the invention, the disease to be treated is selected from the group consisting of bone cancer (e.g., multiple myeloma or Ewing's sarcoma), breast cancer, central / peripheral nervous system cancer (e.g., brain cancer, neurofibromatosis, or glioblastoma), gastrointestinal cancer (e.g., gastric cancer or colorectal cancer), germ cell cancer (e.g., ovarian cancer and testicular cancer), adenocarcinoma (e.g., pancreatic cancer, parathyroid cancer, pheochromocytoma, salivary gland cancer, or thyroid cancer), head and neck cancer (e.g., nasopharyngeal cancer, oral cancer, or pharyngeal cancer), hematological cancer (e.g., leukemia, lymphoma, or myeloma), renal urinary system cancer (e.g., kidney cancer and bladder cancer), liver cancer, lung / pleural cancer (e.g., mesothelioma, small cell lung cancer, or non-small cell lung cancer), prostate cancer, sarcoma (e.g., vascular endothelial cell carcinoma), ovarian cancer (e.g., pancreatic cancer, parathyroid cancer, pheochromocytoma, salivary gland cancer, or thyroid cancer), head and neck cancer (e.g., nasopharyngeal cancer, oral cancer, or pharyngeal cancer), hematological cancer (e.g., leukemia, lymphoma, or myeloma), renal urinary system cancer (e.g., kidney cancer and bladder cancer), liver cancer, lung / pleural cancer (e.g., mesothelioma, small cell lung cancer, or non-small cell lung cancer), prostate cancer, sarcoma, fibrosarcoma, Kaposi's sarcoma, or synovial sarcoma), skin cancer (such as basal cell carcinoma, squamous cell carcinoma, or melanoma), uterine cancer, AIDS, amyloidosis, ankylosing spondylitis, asthma, autism, heart development, Crohn's disease, diabetes, lupus erythematosus, gastritis, transplant rejection, graft-versus-host disease (GVHD), Graves' disease, Hashimoto's thyroiditis, hemolytic uremic syndrome, HIV-related diseases, lupus erythematosus, lymphoproliferative disorders, multiple sclerosis, myasthenia gravis, neuroinflammation, polyarteritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleroderma, septic shock, Sjögren's syndrome, systemic lupus erythematosus, ulcerative colitis, vasculitis, cell proliferation, inflammation, leukocytes Cell activation, leukocyte adhesion, leukocyte chemotaxis, leukocyte maturation, leukocyte migration, neuronal differentiation, acute lymphoblastic leukemia (ALL), T acute lymphoblastic leukemia / lymphoma (ALL), acute myeloid leukemia, acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia (B-CLL), B-cell prolymphocytic lymphoma, Burkitt lymphoma (BL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML-BP), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia (HCL), Hodgkin lymphoma (HL), intravascular large B-cell lymphoma, lymphomatoid granulomatosis, lymphoplasmacytic lymphoma In some embodiments, the method includes but is not limited to: hematologic malignancies, leukemias, lymphomas, myelodysplastic syndromes (MDS), multiple myeloma, and Waldenstrom's macroglobulinemia. In some embodiments, the method includes but is not limited to: hematologic malignancies, leukemias, lymphomas, melanomas, and myeloma.For certain embodiments of these treatment methods of the invention, the immune disorder to be treated is selected from the group consisting of amyloidosis, ankylosing spondylitis, asthma, Crohn's disease, diabetes, transplant rejection, graft-versus-host disease, Graves' disease, Graves' ophthalmopathy, Hashimoto's thyroiditis, hemolytic uremic syndrome, HIV-related diseases, lupus erythematosus, multiple sclerosis, neuromyelitis optica spectrum disorder, N-methyl D-aspartate (NMDA) receptor encephalitis, oculomyoclonic syndrome (OMS), paroxysmal nocturnal hemoglobinuria, polyarteritis nodosa, polyarthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, scleroderma, septic shock, Sjorgren's syndrome, ulcerative colitis, and vasculitis. For certain embodiments of these treatment methods of the invention, the cancer to be treated is selected from the group consisting of acute myeloid leukemia (acute myeloid leukemia or AML), acute non-lymphocytic leukemia, B-cell chronic lymphocytic leukemia (B-cell CLL), B-cell lymphoma, B-cell non-Hodgkin lymphoma (B-cell NHL), B-cell precursor acute lymphoblastic leukemia (BCP-ALL or B-ALL), B-cell lymphocytic leukemia (B-PLL), Burkitt lymphoma (BL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL or DLBL), Follicular lymphoma (FL), hairy cell leukemia (HCL), Hodgkin lymphoma (HL or HD), immunoblastic large cell lymphoma, mantle cell lymphoma (MCL), multiple myeloma (MM), nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), non-Hodgkin lymphoma (NHL), plasmablastic lymphoma, plasma cell neoplasms, plasma cell myeloma, precursor B-lymphoblastic lymphoma (B-LBL), small lymphocytic lymphoma (SLL), T-cell large granular lymphocytic leukemia (T-LGLL), T-cell lymphoma (TCL), T-cell lymphocytic leukemia (T-PLL), and Waldenstrom's macroglobulinemia (WM). macroglobulinemia, WM).
[0175] In certain embodiments of the present invention are methods of producing a cell targeting molecule and / or Shiga toxin effector polypeptide conjugate of the present invention, comprising the step of conjugating a cell targeting molecule or Shiga toxin effector polypeptide of the present invention to a heterologous molecule and / or another exogenous substance.
[0176] In certain embodiments of the present invention are methods of using the cell-targeting molecules of the present invention, the methods comprising a detection facilitator for collecting information that can be used for the diagnosis, prognosis, or characterization of a disease, disorder, or condition. In certain embodiments of the present invention are methods of detecting cells using the cell-targeting molecules and / or diagnostic compositions of the present invention, the methods comprising the steps of contacting cells with the cell-targeting molecules and / or diagnostic compositions of the present invention and detecting the presence of the cell-targeting molecules and / or diagnostic compositions. For certain embodiments, the step of contacting one or more cells occurs in vitro and / or ex vivo. For certain embodiments, the step of contacting one or more cells occurs in vivo. For certain embodiments, the step of detecting one or more cells occurs in vitro and / or ex vivo. For certain embodiments, the step of detecting one or more cells occurs in vivo.For certain further embodiments, the information can be used to diagnose, prognose, or characterize one or more of the following: bone cancer (e.g., multiple myeloma or Ewing's sarcoma), breast cancer, central / peripheral nervous system cancer (e.g., brain cancer, neurofibromatosis, or glioblastoma), gastrointestinal cancer (e.g., gastric cancer or colorectal cancer), germ cell cancer (e.g., ovarian cancer and testicular cancer), adenocarcinoma (e.g., pancreatic cancer, parathyroid cancer, pheochromocytoma, salivary gland cancer, or thyroid cancer), head and neck cancer (e.g., nasopharyngeal cancer, oral cancer, or pharyngeal cancer), hematologic cancer (e.g., leukemia, lymphoma, or myeloma), renal urinary system cancer (e.g., kidney cancer and bladder cancer), liver cancer, lung / pleural cancer (e.g., mesothelioma, small cell lung cancer, or non-small cell lung cancer), Lung cancer, prostate cancer, sarcomas (such as angiosarcoma, fibrosarcoma, Kaposi's sarcoma, or synovial sarcoma), skin cancer (such as basal cell carcinoma, squamous cell carcinoma, or melanoma), uterine cancer, AIDS, amyloidosis, ankylosing spondylitis, asthma, autism, heart development, Crohn's disease, diabetes, lupus erythematosus, gastritis, transplant rejection, graft-versus-host disease, Graves' disease, Hashimoto's thyroiditis, hemolytic uremic syndrome, HIV-related diseases, lupus erythematosus, lymphoproliferative disorders, multiple sclerosis, myasthenia gravis, neuroinflammation, polyarteritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleroderma, septic shock, Sjögren's syndrome, systemic Lupus erythematosus, ulcerative colitis, vasculitis, cell proliferation, inflammation, leukocyte activation, leukocyte adhesion, leukocyte chemotaxis, leukocyte maturation, leukocyte migration, neuronal differentiation, acute lymphoblastic leukemia (ALL), T acute lymphoblastic leukemia / lymphoma (ALL), acute myeloid leukemia, acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia (B-CLL), B-cell prolymphocytic lymphoma, Burkitt lymphoma (BL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML-BP), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia (HCL) ), Hodgkin lymphoma (HL), intravascular large B-cell lymphoma, lymphomatoid granulomatosis, lymphoplasmacytic lymphoma, MALT lymphoma, mantle cell lymphoma, multiple myeloma (MM), natural killer cell leukemia, nodal marginal B-cell lymphoma, non-Hodgkin lymphoma (NHL), plasma cell leukemia, plasmacytoma, primary effusion lymphoma, prolymphocytic leukemia, promyelocytic leukemia, small lymphocytic lymphoma, splenic marginal zone lymphoma, T-cell lymphoma (TCL), heavy chain disease, monoclonal gammopathy, monoclonal immunoglobulin deposition disease, myelodysplastic syndrome (MDS), suppressed multiple myeloma, and Waldenstrom's macroglobulinemia.
[0177] In certain embodiments of the present invention, a kit is provided, comprising the composition of matter of the present invention, and optionally instructions for use, other one or more reagents and / or one or more drug delivery devices. The kit may further comprise reagents and other tools for detecting cell types (e.g., tumor cells) in a sample or subject.
[0178] These and other features, aspects and advantages of the present invention will be better understood with reference to the following description, appended claims and accompanying drawings. The above elements of the present invention may be combined individually or freely removed to produce other embodiments of the present invention without any statement in the following opposing such combination or removal. BRIEF DESCRIPTION OF THE DRAWINGS
[0179] Figure 1 depicts an exemplary Shiga toxin A subunit effector polypeptide of the present invention; a cell targeting molecule comprising the same; a cell targeting molecule comprising a linker and / or cell targeting binding region of the present invention; and a cell targeting molecule linked to a conjugate of the present invention. The depiction of the exemplary molecules in Figure 1 is for illustrative purposes of certain general arrangements of structural features of a limited set of embodiments of the present invention. It should be understood that these exemplary molecules are not intended to, and should not be interpreted as, fully defining the arrangement of any structural features and / or components of the molecules of the present invention. The relative sizes, positions, or number of features shown in the schematic diagram of Figure 1 are simplified. For example, the relative positions of the X, Y, and Z features are not fixed. Similarly, the total number of X, Y, and Z features is not fixed. The schematic diagram in Figure 1 is not intended to accurately depict any information about the relative sizes of the molecular structures in any embodiment of the present invention, for example, the relative sizes of Y or Z to the Shiga toxin effector polypeptide and / or cell targeting molecule or the relative sizes of the linker of the Shiga toxin effector domain to the cell targeting binding domain. Figure 1-A Depicted are Shiga toxin A subunit effector domains having one or more engineered amino acid residues for site-specific conjugation, such as, for example, one or more cysteine, lysine, and / or histidine residues. Figure 1-A In the Figures, "X" represents an ectopic amino acid residue and / or a unique amino acid residue relative to wild-type Shiga toxin that has been engineered into the Shiga toxin effector domain without impairing the desired function(s) of the Shiga toxin effector domain. Figure 1-A Also depicted are Shiga toxin A subunit effector domains conjugated to one or more molecules (labeled "Y" or "Z"), such as, for example, one or more cargoes such as drugs or one or more property-altering agents such as serum albumin and / or one or more polyethylene glycol molecules. Figure 1-B Depicted are exemplary cell targeting molecules of the invention, each comprising one or more amino acid residues for site-specific conjugation, e.g., where the residues are located in a Shiga toxin effector domain, a linker, and / or a cell targeting domain. Figure 1-AAs shown, Figure 1-B Also depicted are molecules conjugated to one or more other molecules labeled "Y" or "Z," such as, for example, one or more cargoes such as drugs or one or more property-altering agents such as serum albumin and / or one or more polyethylene glycol molecules. Figure 1-B An "X" in the molecule indicates that an amino acid residue has been engineered into the molecule for site-specific conjugation and / or other amino acid residues of the same type have been engineered from the molecule for uniqueness, such as, for example, site-specific cysteine, lysine, histidine, or selenocysteine residues, without compromising the desired function(s) of the cell targeting molecule.
[0180] Figure 2 The graph shows that the exemplary cell targeting molecule SLT-1A-Cys(p)::scFv1 of the present invention exhibits potent and specific cell targeting cytotoxicity. The percentage of cell viability for each cell line is plotted relative to the base 10 logarithm of the cell targeting molecule concentration (in nM) administered to each cell. Figure 2 The results show that the cell targeting molecule SLT-1A-Cys(p)::scFv1 of the present invention exhibits no cytotoxicity towards target-negative cell types at the concentrations tested. The cytotoxicity results of the assay for the non-targeted wild-type Shiga toxin A1 fragment are also shown.
[0181] Figure 3 The graph shows that the exemplary cell-targeting molecule of the present invention, SLT-1A-Cys(p)-D1::scFv2, exhibits potent cytotoxicity comparable to that of the reference molecule, SLT-1A-D1::scFv2 (SEQ ID NO: 838). The percentage of cell viability is plotted relative to the base-10 logarithm of the concentration of the cell-targeting molecule administered to the cells (in nM). Also shown are the cytotoxicity results of this assay for a non-targeted, deimmunized Shiga toxin A1 fragment with zero cysteine residues.
[0182] Figure 4The graph shows that exemplary cell-targeting molecules of the invention, SLT-1A-D1::Linker-Cys1::scFv2 (SEQ ID NO: 803), SLT-1A-D1::scFv2-Linker-Cys1 (SEQ ID NO: 807), and SLT-1A-D1::scFv2-Binding Domain-Cys2 (SEQ ID NO: 812), exhibit comparable cytotoxicity against target-positive cell types as the reference cell-targeting molecule, SLT-1A-D1::scFv2 (SEQ ID NO: 838). The percentage of cell viability is plotted relative to the base 10 logarithm of the concentration of the cell-targeting molecule administered to the cells (in nM). Also shown are the cytotoxicity results of this assay for a non-targeted, deimmunized Shiga toxin A1 fragment with zero cysteine residues.
[0183] Figure 5-6 Shown are images of repeated Coomassie-stained sodium dodecyl sulfate (SDS) polyacrylamide gels after electrophoresis of reduced or non-reduced samples to analyze the presence of non-covalently reduced species compared to covalently reduced species in the various samples. Figure 5-6 In the figure, the left side shows a Coomassie-stained SDS-PAGE gel run under reducing and denaturing conditions, and the right side shows a duplicate Coomassie-stained SDS-PAGE gel run under non-reducing denaturing conditions. The legend lists the samples loaded and run in each lane of the duplicate gel. The first lane, labeled "MW marker," shows the migration pattern of the protein molecular weight ladder, and the approximate size of each ladder protein band is labeled in kilodaltons (kDa). The molecular weight bands representing larger molecules that are visible in the non-reducing gel but not visible in the reducing gel indicate that reducible disulfide bonds are formed between protein species in the sample. This suggests that a unique cysteine residue of one molecule can be used for intermolecular bonding with another unique cysteine residue of a second molecule to form homodimers and multimeric complexes.
[0184] Figure 5 Shown are the sizes of different protein species present in exemplary cell targeting molecule compositions of the present invention as analyzed by gel electrophoresis of protein molecules present in different exemplary compositions of the present invention. Figure 5In the figure, samples loaded and run in lanes numbered 2-6 indicate the preparation of the cell-targeting molecule name-x in the legend (lane number #n): #2) SLT-1A-D1::scFv3 (SEQ ID NO:839), #3) SLT-1A-D1-C242::scFv3 (SEQ ID NO:837), #4) SLT-1A-Cys5-D1::scFv3 (SEQ ID NO:778), #5) SLT-1A-Cys3-D1::scFv3 (SEQ ID NO:779), and #6) SLT-1A-Cys2-D1::scFv3 (SEQ ID NO:780).
[0185] Figure 6 Shown are the sizes of different protein species present in exemplary cell targeting molecule compositions of the present invention as analyzed by gel electrophoresis of protein molecules present in different exemplary compositions of the present invention. Figure 6 In the figure, samples loaded and run in lanes numbered 2-10 are indicated in the legend (lane number #n) as follows: #2) SLT-1A-Cys2-D1::scFv2 (SEQ ID NO: 773), #3) SLT-1A-Cys6-D1::scFv2 (SEQ ID NO: 774), #4) SLT-1A-Cys8-D1::scFv2 (SEQ ID NO: 776), #5) SLT-1A-Cys9-D1::scFv2 (SEQ ID NO: 777), #6) SLT-1A-D1::linker-Cys1::scFv2 (SEQ ID NO: 803), #7) SLT-1A-D1::scFv2-linker-Cys1 (SEQ ID NO: 804). NO:807), #8)SLT-1A-D1::scFv2-Cys-C2 (SEQ ID NO:812), #9)SLT-1A-Cys7-D1::scFv2 (SEQ ID NO:775), and #10)SLT-1A-D1::scFv2 (SEQ ID NO:838). Figure 6 The analyzed SLT-1A-Cys2-D1::scFv2 (SEQ ID NO: 773) sample was shown to be composed primarily of non-covalent dimeric complexes, and the protein in the SLT-1A-Cys7-D1::scFv2 (SEQ ID NO: 775) sample was primarily composed of redox-sensitive proteins.
[0186] Figure 7Graphed are the sizes of different molecular species present in a sample of an exemplary composition of the invention comprising an exemplary cell targeting molecule of the invention, SLT-1A-Cys2-D1::scFv2 (SEQ ID NO:773), as analyzed by size exclusion chromatography (SEC). Figure 7 The absorbance of the material eluted after passing through the SEC column in milli-absorbance units (mAU) at 280 nanometers (nm) is plotted against the elution volume (mL) (indicated by the marker below the x-axis). The numbers above the x-axis represent the fractions. Figure 7 The purity of the cell targeting molecule of this exemplary composition of the invention analyzed by SEC is shown.
[0187] Figure 8 Graphed are the sizes of different molecular species present in a sample of an exemplary composition of the invention comprising an exemplary cell targeting molecule of the invention, SLT-1A-Cys7-D1::scFv2 (SEQ ID NO:775), as analyzed by size exclusion chromatography (SEC). Figure 7 The absorbance of the material eluted after passing through the SEC column in milli-absorbance units (mAU) at 280 nanometers (nm) is plotted against the elution volume (mL) (indicated by the marker below the x-axis). The numbers above the x-axis represent the fractions. Figure 8 The purity of the cell targeting molecule of this exemplary composition of the invention analyzed by SEC is shown.
[0188] Figure 9 Figure 11 shows an overlay of fluorescence activated cell sorting (FACS) profiles of cell samples treated with an exemplary cargo-linked cell-targeting molecule of the invention or a control molecule. Cell counts or "events" (y-axis) are plotted against fluorescence intensity measured as mean fluorescence intensity (MFI) in relative fluorescence units (RFU) detected by the FACS FL1-A channel (x-axis). The black line shows data from cells treated with cargo-linked cell-targeting molecules or antibody controls, and the gray line shows data from a negative cell population (isotype control sample). Figure 9-10 It was shown that cargo-linked variants of SLT-1A-Cys5-D1::scFv2 (SEQ ID NO: 789), whether catalytically active or impaired, bound to target-2 positive cells in two different cell types. Figure 9-10 It was shown that cargo-linked variants of SLT-1A-Cys5-D1::scFv2 (SEQ ID NO:789), both catalytically active and impaired, bound to Target-2 positive cells with a profile similar to the monoclonal antibody positive control "anti-Target2 mAb-FITC". Figure 11It was shown that cargo-linked variants of SLT-1A-Cys5-D1::scFv2 (SEQ ID NO:789), whether catalytically active or impaired, bound to target-2 negative cells comparable to the isotype negative control, i.e., these molecules did not show specific binding to this cell type.
[0189] Figure 12-14 Microscope images showing the localization of the dye-linked cell targeting molecules of the present invention, SLT-1A-Cys5-D1::scFv2_Alexa-555 and IA-SLT-1A-Cys5-D1::scFv2_Alexa-555, after administration to different cell types. The image is a merged image of two fluorescent signals, one for detecting the emission of 4',6-diamidino-2-phenylindole (DAPI) shown in blue and the other for detecting the emission of red. The emission of 555 (Alexa-555). Figure 12 In the assay, the cells tested were target-2 positive cells of cell line C. Figure 13 In this assay, the cells tested were target-2 positive cells of cell line G. Figure 12-13 The images in show that two cell targeting molecules enter the target cells within one hour of administration of two target-2 positive cell types (cells of cell line C and cell line G). Figure 14 In this assay, the cells tested were target-2 negative cells of cell line H. Figure 14 These cell-targeting molecules were shown to neither bind to nor enter target-negative cells in detectable amounts under the conditions tested.
[0190] Figure 15 Photographs of a Coomassie-stained SDS-polyacrylamide gel following electrophoresis of an exemplary cell-targeting molecule of the present invention (SLT-1A-Cys5-D1::scFv2) before and after conjugation to a cargo molecule are shown. The legend lists the sample loaded and run in each lane of the gel. The first and last lanes show the migration pattern of a protein molecular weight ladder, and the approximate size of each ladder protein band is marked in kDa on the left. Lane #4 shows the cell-targeting molecule alone, while lanes #3 and #5 show the same cell-targeting molecule linked to two different cargoes.
[0191] Figure 16The graph shows that the exemplary cell targeting molecule of the present invention, SLT-1A-Cys5-D1::scFv2 (SEQ ID NO: 789), whether or not linked to a cargo, exhibits potent and specific cell-targeted cytotoxicity that is comparable to the cytotoxic potency and specificity of the reference molecule, SLT-1A-D1::scFv2 (SEQ ID NO: 838). The percentage of cell viability for each cell line is plotted relative to the base 10 logarithm of the concentration of the cell targeting molecule administered to each cell (in ng / mL). Figure 16 It was shown that the cell targeting molecule of the present invention, SLT-1A-Cys5-D1::scFv2 (SEQ ID NO: 789), whether linked to a cargo or not, exhibited no cytotoxicity towards target-negative cell types at the concentrations tested, similar to the reference molecule SLT-1A-D1::scFv2 (SEQ ID NO: 838).
[0192] Figure 17 The diagram shows that exemplary cell targeting molecules of the present invention, SLT-1A-Lys1-D3-variant-1::scFv4 (SEQ ID NO: 818), SLT-1A-Lys1-D3-variant-2::scFv4 (SEQ ID NO: 819), SLT-1A-Lys1-D3-variant::scFv4 (SEQ ID NO: 820), SLT-1A-Lys2-D3-variant-1::scFv4 (SEQ ID NO: 821), SLT-1A-Lys2-D3-variant::scFv4 (SEQ ID NO: 822), and SLT-1A-Lys2-D3-variant-5::scFv4 (SEQ ID NO: 823), exhibit potent and specific cell targeting cytotoxicity that is comparable to the cytotoxic potency and specificity of the reference molecule SLT-1A-D3::scFv4 (SEQ ID NO: 828). In addition, Figure 17 The graph shows that exemplary cell-targeting molecules of the invention, SLT-1A-Lys(null)-D3-variant-21::scFv4 (SEQ ID NO: 824), SLT-1A-Lys(null)-D3-variant-27::scFv4 (SEQ ID NO: 825), and SLT-1A-Lys(null)-D3-variant-40::scFv4 (SEQ ID NO: 826), exhibit potent and specific cell-targeting cytotoxicity comparable to the cytotoxic potency and specificity of the reference molecule, SLT-1A-D3::scFv4 (SEQ ID NO: 828). The percentage of cell viability for each cell line is plotted relative to the base 10 logarithm of the cell-targeting molecule concentration (in ng / mL) administered to each cell.
[0193] Figure 18 The cell targeting molecules of the present invention are shown as follows: SLT-1A-Lys1-D3-variant-1::scFv4 (SEQ ID NO: 818), SLT-1A-Lys1-D3-variant-2::scFv4 (SEQ ID NO: 819), SLT-1A-Lys1-D3-variant-4::scFv4 (SEQ ID NO: 820), SLT-1A-Lys2-D3-variant-1::scFv4 (SEQ ID NO: 821), SLT-1A-Lys2-D3-variant 2::scFv4 (SEQ ID NO: 822), SLT-1A-Lys2-D3-variant-5::scFv4 (SEQ ID NO: 823), SLT-1A-Lys(inactive)-D3-variant-21::scFv4 (SEQ ID NO: NO: 824), SLT-1A-Lys(null)-D3-variant-27::scFv4 (SEQ ID NO: 825), and SLT-1A-Lys(null)-D3-variant-40::scFv4 (SEQ ID NO: 826) showed no cytotoxicity against target-negative cell types at the concentrations tested, similar to the reference molecule SLT-1A-D3::scFv4 (SEQ ID NO: 828). The percentage of cell viability for each cell line was plotted relative to the base 10 logarithm of the concentration of the cell-targeting molecule administered to each cell (in ng / mL).
[0194] Figure 19 The graph shows that the exemplary cell-targeting molecule of the present invention, SLT-1A-Lys(null)-D4-variant-42::scFv4 (SEQ ID NO: 827), exhibits potent and specific cell-targeting cytotoxicity that is comparable to the cytotoxic potency and specificity of the reference molecules, SLT-1A-D3::scFv4 (SEQ ID NO: 828) and SLT-1A-D5::scFv4 (SEQ ID NO: 829). The percentage of cell viability for each cell line is plotted relative to the base 10 logarithm of the cell-targeting molecule concentration (in ng / mL) administered to each cell. DETAILED DESCRIPTION
[0195] The present invention is described more fully below using illustrative, non-limiting embodiments and reference to the accompanying drawings. However, the present invention can be implemented in many different forms and should not be construed as limited to the embodiments set forth below. Instead, these embodiments are provided to make this disclosure thorough and convey the scope of the invention to those skilled in the art.
[0196] In order to make the present invention more easily understood, certain terms are defined below. Additional definitions can be found in the detailed description of the invention.
[0197] As used in the specification and the appended claims, the terms "a," "an," and "the" include singular and plural referents unless the context clearly dictates otherwise.
[0198] As used in the specification and the appended claims, when referring to two species A and B, the term "and / or" means at least one of A and B. As used in the specification and the appended claims, when referring to more than two species, such as A, B, and C, the term "and / or" means at least one of A, B, or C, or at least one of any combination of A, B, or C (with each species in either single or plural possibilities).
[0199] Throughout the specification, the word "comprise" or variations such as "comprising" or "containing" will be understood to imply the inclusion of a stated integer (or component) or group of integers (or components) but not the exclusion of any other integer (or component) or group of integers (or components).
[0200] Throughout the specification, the term "including" is used to mean "including but not limited to." "Including" and "including but not limited to" are used interchangeably.
[0201] The term "amino acid residue" or "amino acid" includes reference to an amino acid incorporated into a protein, polypeptide, or peptide. The term "polypeptide" includes any polymer of amino acids or amino acid residues. The term "polypeptide sequence" refers to the series of amino acids or amino acid residues that physically make up a polypeptide. A "protein" is a macromolecule comprising one or more polypeptides or polypeptide "chains." A "peptide" is a small polypeptide having a size of less than about 15 to 20 amino acid residues. The term "amino acid sequence" refers to the series of amino acids or amino acid residues that physically comprise a peptide or polypeptide in terms of length. Unless otherwise indicated, the polypeptide and protein sequences disclosed herein are written from left to right, representing their order from amino terminus to carboxyl terminus.
[0202] For the purposes of the claimed invention and with respect to Shiga toxin protein sequences or Shiga toxin-derived polypeptides, the term "wild-type" generally refers to a naturally occurring Shiga toxin protein sequence found in a living species (such as, for example, a pathogenic bacterium), where the Shiga toxin protein sequence is one of the most frequently occurring variants. This is in contrast to sporadic Shiga toxin protein sequences, which, while still naturally occurring, are found in less than 1% of the individual organisms of a particular species when a statistically significant number of naturally occurring individuals of the species are sampled that contain at least one Shiga toxin protein variant. Clonal expansion of a natural isolate outside of its natural environment (regardless of whether the isolate is an organism or a molecule containing biological sequence information) does not alter the naturally occurring requirement, as long as the clonal expansion does not introduce new sequence variants not already present in the naturally occurring population of the species and / or does not alter the ratio of sequence variants relative to one another.
[0203] The terms "amino acid", "amino acid residue", "amino acid sequence" or polypeptide sequence include naturally occurring amino acids (including L and D isomers) and, unless otherwise limited, also include known analogs of twenty common natural amino acids that can function in a similar manner, such as, for example, selenocysteine, pyrrolysine, N-formylmethionine, γ-carboxyglutamic acid, hydroxyproline tail, pyrroglutamic acid and selenomethionine (see, for example, Nagata K et al., Bioinformatics 30: 1681-9 (2014)). The amino acids mentioned herein are described as follows by the abbreviated names in Table A:
[0204] Table A. Amino acid nomenclature
[0205] name 3-letter 1-Letter Alanine Ala A Arginine Arg R Asparagine Asn N Aspartic Acid or Aspartate Asp D Cysteine Cys C Glutamic Acid or Glutamate Glu E Glutamine Gln Q Glycine Gly G Histidine His H Isoleucine Ile I Leucine Leu L Lysine Lys K Methionine Met M Phenylalanine Phe F Proline Pro P Pyrroline-carboxyl-lysine Pcl Selenocysteine Sec Serine Ser S Threonine Thr T Tryptophan Trp W Tyrosine Tyr Y Valine Val V
[0206] The term "conservative substitution" with respect to a protein, polypeptide, or polypeptide region refers to a change in the amino acid composition of a polypeptide that does not substantially alter the function and structure of the entire protein, polypeptide, or polypeptide region (see Creighton, Proteins: Structures and Molecular Properties (WH Freeman and Company, New York (2nd ed., 1992)).
[0207] As used herein, the term "expressed," "expressing," or "expression" and grammatical variations thereof refer to the translation of a polynucleotide or nucleic acid into a protein. The expressed protein may be retained within the cell, become a component of the cell surface membrane, or be secreted into the extracellular space.
[0208] As used herein, the phrase "target-expressing cell" includes any cell that expresses on the cell surface a target biomolecule that is bound by the binding region of the cell targeting molecule of the present invention.
[0209] As used herein, a cell that expresses a high amount of an extracellular target biomolecule on at least one cell surface is a "target positive cell" or "target+ cell" and is a cell that is physically coupled to a designated extracellular target biomolecule.
[0210] As used herein, a cell that expresses a high amount of a target biomolecule on at least one cell surface is a "target positive cell" or "target+ cell" and is physically coupled to the extracellular target biomolecule. High amounts of target biomolecules are defined below.
[0211] As used herein, the symbol "α" is shorthand for an immunoglobulin-type binding region that is capable of binding to the biomolecule following the symbol. The symbol "α" is used to refer to the functional characteristics of an immunoglobulin-type binding region based on its ability to bind to the biomolecule following the symbol, where the binding affinity is expressed as 10 -5 or lower dissociation constant (K D )describe.
[0212] The terms "associated," "associated," "connected," or "connected" with respect to the claimed invention refer to the act of two or more components of a molecule being joined, attached, connected, or otherwise coupled to form a single molecule or to the act of associating two molecules with each other to form a single molecule by creating a key, bond, attachment, and / or any other connection between the two molecules. For example, the term "connected" may refer to two or more components that are associated through one or more atomic interactions so as to form a single molecule, and wherein the atomic interactions may be covalent and / or non-covalent. Non-limiting examples of covalent associations between two components include peptide bonds and cysteine-cysteine disulfide bonds. Non-limiting examples of non-covalent associations between two molecular components include ionic bonds.
[0213] For the purposes of the present invention, the term "linked" refers to two or more molecular components that are associated by one or more atomic interactions so as to form a single molecule, and wherein the atomic interactions include at least one covalent bond. For the purposes of the present invention, the term "linking" refers to the act of producing a linked molecule as described above.
[0214] For the purposes of the present invention, the term "fusion" refers to the association of two or more protein components by at least one covalent bond, which is a peptide bond, whether the peptide bond involves the participation of a carbon atom of a carboxylic acid group or involves another carbon atom, such as, for example, an α-carbon, a β-carbon, a γ-carbon, a σ-carbon, etc. Non-limiting examples of two protein components fused together include, for example, an amino acid, a peptide, or a polypeptide fused to a polypeptide via a peptide bond such that the resulting molecule is a single continuous polypeptide. For the purposes of the present invention, the term "fusion" refers to the act of producing a fusion molecule as described above, such as, for example, a fusion protein produced by recombinant fusion of genetic regions that, when translated, produces a single protein molecule.
[0215] The symbol “::” indicates that the protein molecules before and after the symbol are physically linked together to form a continuous polypeptide.
[0216] The symbol "_" with respect to a cell targeting molecule indicates that the molecules preceding and following the symbol are covalently linked together, directly or indirectly.
[0217] For the purposes of the present invention, the term "effector" means an polypeptide that provides a biological activity, such as cytotoxicity, biological signaling, enzymatic catalysis, subcellular trafficking, and / or intermolecular binding, resulting in the recruitment and / or allosteric effects of one or more factors. For example, a Shiga toxin effector polypeptide provides one or more biological activities present in a Shiga toxin, a Shiga toxin component, and / or a fragment thereof.
[0218] As used herein, the phrase "multivalent target binding molecule" refers to a target binding molecule or a plurality of target binding molecules comprising two or more high affinity binding regions, such as, for example, a protein comprising two or more binding regions, wherein each individual binding region has a 10 affinity for the extracellular portion of a target biomolecule. -5 to 10 -12 The dissociation constant is expressed in mol / L.
[0219] For the purposes of the present invention, the phrase "derived from" when referring to a polypeptide or polypeptide region means that the polypeptide or polypeptide region comprises the amino acid sequence originally found in the "parent" protein, and that it may now contain certain amino acid residue additions, deletions, truncations, rearrangements or other changes relative to the original polypeptide or polypeptide region, as long as one or more functions and one or more structures of the "parent" molecule are substantially conserved. A skilled person will be able to identify the parent molecule of the derived polypeptide or polypeptide region using techniques known in the art, such as protein sequence alignment software.
[0220] For the purposes of the present invention, Shiga toxin effector function is a biological activity conferred by the polypeptide region derived from the Shiga toxin A subunit. Non-limiting examples of Shiga toxin effector function include cellular internalization, subcellular delivery, catalytic activity and cytotoxicity. Shiga toxin catalytic activity includes, for example, ribosome inactivation, protein synthesis inhibition, N-glycosidase activity, polynucleotide: adenosine glycosidase activity, RNA enzyme activity and DNA enzyme activity. Shiga toxin is a ribosome inactivating protein (RIP). RIP can depurinate nucleic acids, polynucleosides, polynucleotides, rRNA, ssDNA, dsDNA, mRNA (and polyA) and viral nucleic acids (see, for example, Brigotti M et al., Toxicon 39:341-8 (2001); Brigotti M et al., FASEB J 16:365-72 (2002)). Some RIPs show antiviral activity and superoxide dismutase activity. Shiga toxin catalytic activity has been observed in vitro and in vivo. Non-limiting examples of assays for Shiga toxin effector activity measure protein synthesis inhibition activity, depurination activity, cell growth inhibition, cytotoxicity, supercoiled DNA relaxation activity, and nuclease activity.
[0221] As used herein, retention of Shiga toxin effector function refers to the ability to exhibit a level of Shiga toxin functional activity comparable to that of a wild-type Shiga toxin effector polypeptide control (e.g., a Shiga toxin A1 fragment) or a cell-targeting molecule comprising a wild-type Shiga toxin effector polypeptide control (e.g., a Shiga toxin A1 fragment) under identical conditions, as measured by a suitable quantitative assay with reproducibility. Retention of Shiga toxin effector function exhibits an IC of 10,000 picomolar (pM) or less in vitro for ribosome-inactivated or ribosome-inhibited Shiga toxin effector function, such as, for example, by using assays known to those skilled in the art and / or described herein. 50 Retained Shiga toxin effector function exhibits a CD40 of 1,000 nanomolar (nM) or less as shown for Shiga toxin effector cytotoxicity in a target-positive cell killing assay, e.g., by using assays known to the skilled artisan and / or described herein. 50 , which depends on the cell type and its expression of appropriate extracellular target biomolecules.
[0222] As used herein, "significant" retention of Shiga toxin effector function refers to a level of Shiga toxin functional activity comparable to a wild-type Shiga toxin effector polypeptide control as measured by a reproducible, appropriate quantitative assay. For in vitro ribosome inhibition, significant Shiga toxin effector function exhibits an IC of 300 pM or less. 50, depending on the origin of the ribosomes (e.g., bacteria, archaea, or eukaryotes (algae, fungi, plants, or animals)). Approximate IC of 100,000 pM for the catalytically inactive SLT-1A 1-251 double mutant (Y77S / E167D) 50 This is a significantly greater inhibition than that of the cytotoxicity in target-positive cell killing assays in laboratory cell culture. Significant Shiga toxin effector function was demonstrated with CD400 of 100, 50, or 30 nM or less. 50 , depending on the cell line and its expression of an appropriate extracellular target biomolecule. Compared to the SLT-1A subunit alone without the cell targeting binding domain, this is significantly more cytotoxic to appropriate target cell lines, which have a CD of 100-10,000 nM. 50 , which depends on the cell line.
[0223] For some samples, IC 50 or CD 50 The exact value of may not be obtained because the required data points cannot be collected to obtain an accurate curve fit. For example, in theory, if no more than 50% ribosomal inhibition or cell death occurs, respectively, in a concentration series for a given sample, then the IC cannot be determined. 50 and CD 50 The data as described in the data analysis from exemplary Shiga toxin effector function assays (such as the assays described in the Examples) were insufficient to accurately fit the curves and should not be considered representative of actual Shiga toxin effector function.
[0224] Failure to detect activity in Shiga toxin effector function may be due to improper expression, polypeptide folding and / or polypeptide stability rather than lack of cellular entry, subcellular trafficking and / or enzymatic activity. Assays for Shiga toxin effector function may not require too many cell-targeting molecules of the present invention to measure a large number of Shiga toxin effector function activities. If the underlying cause of low or ineffective effector function is determined empirically to be related to protein expression or stability, one skilled in the art can use protein chemistry and molecular engineering techniques known in the art to compensate for these factors, so that Shiga toxin effector function activity can be restored and measured. For example, improper cell-based expression can be compensated by using different expression control sequences; improper polypeptide folding and / or stability can benefit from stabilizing terminal sequences, or compensatory mutations in non-effector regions that stabilize the three-dimensional structure of the protein, etc. As new assays for individual Shiga toxin functions become available, Shiga toxin effector regions or polypeptides can be analyzed for any level of those Shiga toxin effector functions (e.g., within a specific multiple activity of the wild-type Shiga toxin effector polypeptide). Examples of meaningful differences in activity are, for example, a Shiga toxin effector domain that has 1000-fold or 100-fold or less activity than a wild-type Shiga toxin effector polypeptide; or a Shiga toxin effector domain that has 3-fold to 30-fold or more activity compared to a functionally knocked-down or knocked-out Shiga toxin effector polypeptide.
[0225] Some Shiga toxin effector functions are not easily measured, such as subcellular delivery. Currently, there are no routine quantitative assays to distinguish whether the failure of a Shiga toxin effector peptide to be cytotoxic is due to improper subcellular delivery, but when this can be done, Shiga toxin effector peptides can be assayed for any significant level of subcellular delivery compared to the appropriate wild-type Shiga toxin effector domain.
[0226] It should be noted that even if the cytotoxicity of the Shiga toxin effector polypeptide is reduced relative to the wild type, in fact, the use of attenuated Shiga toxin effector polypeptides may be the same as or more effective than those using wild-type Shiga toxin effector polypeptides. Because the most potent variants may exhibit adverse effects, these adverse effects are minimized or reduced in the variants with reduced potency. Wild-type Shiga toxin effector polypeptides are very effective and can kill when only one molecule reaches the cytosol or when 40 molecules are internalized (Tam P, Lingwood C, Microbiology 153: 2700-10 (2007)). Compared to wild-type Shiga toxin effector polypeptides, Shiga toxin effector polypeptides with even significantly reduced Shiga toxin effector function (such as, for example, subcellular delivery or cytotoxicity) may still be sufficiently effective for practical applications involving targeted cell killing and / or detection of certain subcellular compartments of specific cell types. And such effector polypeptides can also be used to deliver cargo (e.g., additional exogenous substances) to certain intracellular locations or subcellular compartments.
[0227] The term "selective cytotoxicity" with respect to the cytotoxic activity of a cytotoxic cell-targeting molecule refers to the relative level of cytotoxicity between a targeted cell population and a non-targeted bystander cell population, which can be expressed as a half-maximal cytotoxic concentration (CD 50 ) compared to CD of non-targeted cell types 50 The ratio of α to β was used as a measure of selectivity to show the preferential killing of the targeted cell type.
[0228] As used in this specification and claims, the phrase "physiological temperature suitable for cells" refers to a temperature known in the art and / or recognizable by a skilled artisan as falling within a range suitable for healthy growth, reproduction, and / or function of a particular cell or cell type. This corresponds to the core temperature of the species from which the cell is derived; and / or corresponds to the healthy, living organism containing the cell. For example, a temperature of approximately 37°C is suitable for many mammalian cells, depending on the species.
[0229] For the purposes of the present invention, the phrase "internalization of a molecular complex comprising a cell targeting molecule bound to a target biomolecule" means that the cellular internalization of the cell targeting molecule is target-mediated in that internalization begins with the formation of a complex between the cell targeting molecule and the cell surface target biomolecule at an extracellular location and ends with the entry of both the cell targeting molecule and the target biomolecule into the cell, followed by dissociation of the cell targeting molecule from the target biomolecule to which the cell targeting molecule has bound.
[0230] For the purposes of the present invention, the phrase "target biomolecule naturally occurring on the surface of a cell" means that the cell uses its own internal mechanisms to express the target biomolecule and uses its own internal machinery to localize the target biomolecule to the cell surface such that the target biomolecule is physically coupled to the cell and at least a portion of the target biomolecule is accessible in the extracellular space, i.e., on the cell surface.
[0231] For purposes of the present invention, the phrase "cell targeting molecule altering agent" refers to any of a number of different types of atoms or molecules known to the skilled artisan and / or described herein that can be conjugated to a molecule of the invention to alter one or more properties of the molecule of the invention.
[0232] For purposes of certain embodiments of the present invention, cellular internalization is considered rapid if the time for internalization to occur due to binding of a cell targeting molecule of the invention is reduced compared to the time for internalization of a prior art reference molecule at the same percentage target biomolecule occupancy as determined by the same assay at the same temperature using the same cell type.
[0233] As used in this specification and claims, the phrase "rapid cellular internalization" refers to the ability of a cell targeting molecule of the present invention to reduce the average time for cellular internalization of an extracellular target antigen or a cell surface-localized target biomolecule as compared to the average time required for cellular internalization of the extracellular target antigen or cell surface-localized target biomolecule as measured by any of a number of cell internalization assays known in the art or described herein.
[0234] As used in this specification and claims, the phrase "rapid internalization" includes internalization that can be measured in comparison to the basal target biomolecule internalization rate and / or the target biomolecule internalization rate induced by molecule binding following administration of an immunoglobulin-type binding molecule (e.g., a monoclonal antibody) known in the art that binds to the extracellular portion of the target biomolecule. The phrase "rapid cellular internalization" is intended to encompass an average internalization rate that is faster than that observed when testing target-specific antibodies or immunoglobulin-derived protein molecules with an Fc region. Generally, the internalization rate constant can be defined as the time after administration of a target-specific binding molecule of interest to target-positive cells at which 50% of the cell surface target antigen, target biomolecule, and / or target-specific binding molecule is internalized into a particular cell type at a given administered concentration, mass, molar concentration, or target biomolecule occupancy-adjusted concentration and a specific temperature. Cell surface target biomolecule internalization, whether basal or in response to administration of a target binding molecule, can be measured by various methods known to those of skill in the art.
[0235] For the purposes of certain embodiments of the present invention, cellular internalization is considered rapid if the time for internalization to occur due to binding of a cell targeting molecule of the present invention is reduced compared to the time for internalization of a target biomolecule in the presence of binding of a well-characterized antibody that recognizes an extracellular target biomolecule antigen. The term "rapid" as used throughout this specification is intended to mean that the cell targeting molecule of the present invention enters one or more target-expressing cells and / or target-positive cells in less than 6 hours. In certain embodiments, rapid can be as fast as less than about 30 minutes, but can also include about 1 hour to about 2 hours, about 3 hours, about 4 hours, about 5 hours; about 2 hours to about 3 hours, about 4 hours, about 5 hours; about 3 hours to about 4 hours, about 5 hours; and about 4 hours to about 5 hours.
[0236] For the purposes of the present invention, with respect to molecules comprising two or more components linked together, the phrase "one or more non-covalent bonds" includes the type of bonds linking the components, which in certain molecules can be observed to be eliminated (i.e., "no longer linking the two or more components") when the molecule is altered from native protein folding conditions to protein denaturing conditions. For example, when the size of a protein molecule is determined using techniques known in the art and / or described herein (such as, for example, electrophoresis and / or chromatography), a multicomponent molecule that appears as a single size species under native protein folding conditions (e.g., a pH buffered environment intended to resemble the lumen of the endoplasmic reticulum of a eukaryotic cell or the extracellular environment within an organism) may also be observed to be composed of two or more smaller sized protein molecules under denaturing conditions and / or after being subjected to denaturing conditions. Protein denaturing conditions are known to those of skill in the art and include conditions that differ significantly from native protein folding conditions, such as, for example, an environment having an elevated temperature (e.g., greater than 50 degrees Celsius) and / or characterized by the presence of chemical denaturants and / or detergents (e.g., 1-10% sodium lauryl sulfate, polysorbate, X-100, sarkosyl and other detergents, whether ionic, nonionic, zwitterionic and / or chaotropic).
[0237] As used herein, the term "monomer" with respect to describing proteins and / or protein molecules refers to a molecule comprising only one polypeptide component consisting of a single continuous polypeptide (regardless of secondary or tertiary structure, which can be synthesized by the ribosome from a single polynucleotide template, including a continuous linear polypeptide that subsequently forms a circular structure). In contrast, a multimeric molecule comprises two or more polypeptides (e.g., subunits) that do not together form a single continuous polypeptide that can be synthesized by the ribosome from a single polynucleotide template.
[0238] As used herein, the term "multimer" with respect to describing proteins and / or protein molecules refers to a molecule comprising two or more separate polypeptide components that are associated and / or linked together, such as, for example, a molecule composed of two components, each of which is itself a continuous polypeptide. For example, the association or bonding between the components of the molecule can include 1) one or more non-covalent interactions; 2) one or more post-translational covalent interactions; 3) one or more covalent chemical conjugations; and / or 4) one or more covalent interactions, resulting in a single molecule comprising a non-linear polypeptide (e.g., a branched or cyclic polypeptide structure resulting from the arrangement of two or more polypeptide components). A molecule comprising two discontinuous polypeptides produced by proteolytic cleavage of one or more peptide bonds in a single continuous polypeptide synthesized by the ribosome from a single polynucleotide template is a "multimer" rather than a "monomer."
[0239] As used herein, with respect to a polypeptide region or feature within a polypeptide, the terms "disrupted," "disruption," or "disrupting," and grammatical variations thereof, refer to a change in at least one amino acid within the region or comprising the disrupted feature. Amino acid changes include various mutations, such as, for example, deletions, inversions, insertions, or substitutions, which alter the amino acid sequence of a polypeptide. Amino acid changes also include chemical changes, such as, for example, changes in one or more atoms in an amino acid functional group or additions of one or more atoms in an amino acid functional group.
[0240] As used herein, "deimmunization" means a reduced antigenicity and / or immunogenic potential after administration to a chordate compared to a reference molecule (such as, for example, a wild-type peptide region, polypeptide region, or polypeptide). This includes a reduction in overall antigenicity and / or immunogenic potential compared to a reference molecule despite the introduction of one or more de novo antigenic and / or immunogenic epitopes. For certain embodiments, "deimmunization" refers to a molecule that exhibits reduced antigenicity and / or immunogenicity after administration to a mammal compared to the "parent" molecule from which it is derived (such as, for example, a wild-type Shiga toxin A1 fragment). In certain embodiments, the deimmunized Shiga toxin effector polypeptides of the present invention can exhibit relative antigenicity compared to a reference molecule that is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more lower than the antigenicity of the reference molecule as measured under the same conditions by the same assay (e.g., an assay known to a skilled artisan and / or described herein, such as a quantitative ELISA or Western blot analysis). In certain embodiments, the deimmunized Shiga toxin effector polypeptides of the invention can exhibit relative immunogenicity compared to a reference molecule that is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99% or more lower than the immunogenicity of a reference molecule as measured by the same assay under the same conditions (such as, for example, an assay known to those of skill in the art and / or described herein, such as quantitative measurement of anti-molecule antibodies produced in a mammal after parenteral administration of a molecule at a given time point). The relative immunogenicity of exemplary cell-targeting molecules can be determined using an assay of the in vivo antibody response to the cell-targeting molecule after repeated parenteral administration over a number of time periods.
[0241] For the purposes of the present invention, the term "terminus," "amino terminus," or "carboxyl terminus" with respect to a cell targeting molecule generally refers to the last amino acid residue of a polypeptide chain of a cell targeting molecule (e.g., a single continuous polypeptide chain). A cell targeting molecule may comprise more than one polypeptide or protein, and thus, a cell targeting molecule of the present invention may comprise multiple amino termini and carboxyl termini. For example, the "amino terminus" of a cell targeting molecule may be defined by the first amino acid residue of a polypeptide chain representing the amino terminus of a polypeptide, which is generally characterized by the initial amino acid residue not having any amino acid residues bonded to the primary amino group of the initial amino acid residue or to the equivalent nitrogen of the initial amino acid residue (which is a member of the class of N-alkylated α-amino acid residues). Similarly, the "carboxyl terminus" of a cell targeting molecule may be defined by the last amino acid residue of a polypeptide chain representing the carboxyl terminus of a polypeptide, which is generally characterized by the final amino acid residue not having any amino acid residues bonded to the α-carbon of its primary carboxyl group by a peptide bond.
[0242] For the purposes of the present invention, the terms "terminal," "amino-terminal," or "carboxyl-terminal" with respect to a polypeptide region refer to the region boundary of that region, regardless of whether other amino acid residues are linked by peptide bonds outside of that region. In other words, the terminus of a polypeptide region refers to the region boundary regardless of whether the region is fused to another peptide or polypeptide. For example, a fusion protein comprising two protein regions (e.g., a binding region comprising a peptide or polypeptide and a Shiga toxin effector polypeptide) can have a Shiga toxin effector polypeptide region whose carboxyl-terminus ends at amino acid residue 251 of the Shiga toxin effector polypeptide region, even though a peptide bond participates in a peptide bond between residue 251 and an amino acid residue at position 252 (representing the beginning of another protein region, such as a binding region). In this example, the carboxyl-terminal end of the Shiga toxin effector polypeptide region refers to residue 251, which is not the end of the fusion protein, but rather represents an internal region boundary. Thus, with respect to polypeptide regions, the terms "terminal," "amino-terminal," and "carboxyl-terminal" are used to refer to the boundary of a polypeptide region, regardless of whether the boundary is a physical terminus or an internal position embedded within a larger polypeptide chain.
[0243] For purposes of the present invention, the phrase "resistance to furin cleavage" refers to a molecule or a specific polypeptide region thereof that exhibits reproducibly less furin cleavage compared to (i) the carboxyl terminus of the Shiga toxin A1 fragment in wild-type Shiga toxin A subunit or (ii) the carboxyl terminus of a Shiga toxin A1 fragment-derived region of a construct in which the naturally occurring furin cleavage site at the junction between the A1 and A2 fragments is not disrupted. This determination can be made by any method available to the skilled artisan, including using the methods described herein.
[0244] For purposes of the present invention, phrase " the furin cleavage motif of destruction " refers to (i) specific furin cleavage motif as described in part IB herein, (ii) it comprises mutation and / or truncation, and described mutation and / or truncation can give molecule the furin cleavage reduction compared to reference molecule, such as for example, compared to the furin cleavage of the reference molecule observed in the same assay under the same conditions, the furin cleavage that can be observed repeatedly reduces 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99% or less (including 100% not cutting).Compared to reference molecule, the percentage ratio of furin cleavage can be expressed as the cutting of target molecule: the ratio of the material of uncut divided by the cutting of reference molecule: the ratio of the material of uncut (see, for example, WO 2015 / 191764). Non-limiting examples of suitable reference molecules include molecules comprising the wild-type Shiga toxin furin cleavage motif and / or furin cleavage site described in WO 2015 / 191764 and WO 2016 / 196344.
[0245] introduce
[0246] The present invention provides Shiga toxin effector polypeptides and cell targeting molecules comprising specific attachment sites for conjugation to other molecules. Unique amino acid residues and / or one or more heterotopic residues in the Shiga toxin effector polypeptide or cell targeting molecule scaffolds having unique solvent accessible functional groups provide attachment points for site-specific linkage of various atoms. The atoms or molecules can function as (1) cargo designed for intracellular delivery, including for controlled release once inside the target cell, and / or (2) agents with one or more extracellular functions, such as, for example, a biologically inert moiety that extends vertebrate half-life, masks immunogenic portions of the scaffold and / or blocks proteolytic cleavage. The Shiga toxin effector polypeptides and cell targeting molecules of the present invention can be conjugated to a variety of atoms and molecules in a controlled and convenient manner using conventional methods to obtain homogenous products.
[0247] The present invention also provides Shiga toxin effector polypeptides and cell targeting molecules conjugated with other molecules, such as, for example, molecular cargoes or cell targeting molecule altering agents for intracellular delivery. Certain cell targeting molecules of the present invention and compositions thereof can be used to selectively deliver conjugated one or more cargoes to one or more target-expressing cell types based on their cell targeting and cell internalization activity in the presence of one or more other cell types, such as, for example, cargoes with desired intracellular functions. In addition, certain cell targeting molecules of the present invention and compositions thereof can be used to selectively kill target-expressing cells based on their cell targeting and cell internalization activity in the presence of one or more other cell types, such as, for example, by delivering a component of a cell targeting molecule (which has cytotoxicity at an intracellular location) to the interior of a targeted target-expressing cell. Conjugated atoms, molecules, cargoes and / or cell targeting molecule altering agents contemplated for use in the present invention include linkers, cell targeting moieties, antibiotics, peptides, nucleic acids, proteins, protein-nucleic acid complexes, cytotoxic agents, solubility modifiers, pharmacokinetic modifiers, immunogenicity modifiers, and pharmacodynamic modifiers.
[0248] The molecules of the invention and compositions thereof have utility, for example, for the selective delivery of cargo to cells expressing a target, and as therapeutic agents for the treatment of a variety of diseases, disorders, and conditions.
[0249] I. General Structure of Shiga Toxin Effector Polypeptides and Cell Targeting Molecules of the Invention
[0250] Certain embodiments of the present invention are Shiga toxin A subunit effector polypeptides, such as, for example, (1) a Shiga toxin effector polypeptide conjugated to a heterologous molecule; and (2) a Shiga toxin effector polypeptide comprising one or more ectopic amino acid residues relative to a wild-type Shiga toxin polypeptide. The present invention provides cell targeting molecules comprising (1) a cell targeting moiety (e.g., a cell targeting agent and / or binding region) and (2) a toxin effector polypeptide region. Certain further embodiments are cell targeting molecules comprising a Shiga toxin effector polypeptide of the present invention. In addition, the present invention provides cell targeting molecules (e.g., immunoglobulin-type polypeptides) that lack any Shiga toxin effector polypeptide but comprise a linker or binding region comprising one or more functional groups for site-specific attachment of other molecules. All molecules of the present invention can optionally be conjugated to another molecule, such as, for example, a cargo for cell-targeted delivery, a cell targeting molecule-altering agent and / or another exogenous substance.
[0251] A. Shiga toxin effector A subunit polypeptides of the present invention
[0252] The Shiga toxin effector polypeptides of the present invention are polypeptides derived from the Shiga toxin A subunit of at least one member of the Shiga toxin family, wherein the Shiga toxin effector region is capable of exhibiting at least one Shiga toxin function. Shiga toxin functions include, for example, promoting cell entry, deforming lipid membranes, stimulating clathrin-mediated endocytosis, directing retrograde transport, directing subcellular delivery, avoiding intracellular degradation, catalytically inactivating ribosomes, achieving cytotoxicity, and achieving cytostasis.
[0253] There are many Shiga toxin effector polypeptides known to those skilled in the art (see, e.g., Cheung M et al., Mol Cancer 9:28 (2010); WO 2014 / 164693; WO 2015 / 113005; WO 2015 / 113007; US20150259428; WO 2015 / 191764; US20160177284; WO 2016 / 126950) that are suitable for use in the present invention or as parent polypeptides that are modified into Shiga toxin effector polypeptides of the present invention using techniques known in the art.
[0254] The Shiga toxin effector polypeptides of the present invention comprise or consist essentially of a polypeptide derived from a Shiga toxin A subunit that is dissociated in any manner from its native Shiga toxin B subunit. Furthermore, the cell-targeting molecules of the present invention need not comprise any polypeptide comprising or consisting essentially of a functional binding domain of a native Shiga toxin B subunit. Rather, the Shiga toxin effector polypeptides of the present invention may be functionally associated with a heterologous binding domain to achieve cell targeting.
[0255] In certain embodiments, the Shiga toxin effector polypeptide of the invention may comprise or consist essentially of a full-length Shiga toxin A subunit (e.g., SLT-1A (SEQ ID NO: 1), StxA (SEQ ID NO: 2), or SLT-2A (SEQ ID NO: 3)), noting that the naturally occurring Shiga toxin A subunit may comprise a precursor form containing a signal sequence of approximately 22 amino acids at its amino terminus (which is removed to produce a mature Shiga toxin A subunit and which can be recognized by a skilled artisan). In other embodiments, the Shiga toxin effector polypeptide of the invention comprises or consists essentially of a truncated Shiga toxin A subunit that is shorter than the full-length Shiga toxin A subunit, such as, for example, truncations known in the art (see, e.g., WO 2014 / 164693; WO 2015 / 113005; WO 2015 / 113007; WO 2015 / 138452; WO 2015 / 191764; US20160177284; WO 2016 / 126950).
[0256] While derived from a wild-type Shiga toxin A subunit polypeptide, for certain embodiments of the molecules of the invention, the Shiga toxin effector polypeptide differs from the naturally occurring Shiga toxin A subunit by as many as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or more amino acid residues (but not more than such number that retains at least 85%, 90%, 95%, 99% or more amino acid sequence identity).
[0257] In certain embodiments, the Shiga toxin effector polypeptides of the present invention comprise only one lysine residue. The cytotoxic activity of the SLT-1 holotoxin is not affected by the removal of all lysine residues in the A subunit (McCluskey, AJ, "Shiga-like Toxin 1: Molecular Mechanism of Toxicity and Discovery of Inhibitors", thesis, University of Toronto, (2012), Appendix B). Furthermore, removal of the two amino-terminal lysines of the SLT-1A subunit does not affect its cytotoxicity (McCluskey, AJ, "Shiga-like Toxin 1: Molecular Mechanism of Toxicity and Discovery of Inhibitors", thesis, University of Toronto, (2012), Appendix B). Thus, all but one of the naturally occurring lysine residues in SLT-1A, StxA, and / or SLT-2A can be removed by amino acid residue substitution, thereby leaving only one naturally occurring lysine residue in the Shiga toxin effector polypeptide. Alternatively, all naturally occurring lysine residues in SLT-1A, StxA and / or SLT-2A can be removed from the Shiga toxin effector polypeptide by amino acid residue substitution, and ectopic lysine residues can be engineered into positions suitable for site-specific conjugation and retention of one or more Shiga toxin functions.
[0258] B. Cell Targeting Molecules of the Invention
[0259] The cell-targeting molecules of the present invention each comprise a cell-targeting agent or moiety, such as a binding region as described herein. The cell-targeting agent or moiety of the cell-targeting molecules of the present invention comprises a molecular structure that, when linked to a polypeptide of the present invention, enables the cell-targeting molecule to be brought into close proximity with specific cells based on molecular interactions on the surface of these specific cells. Cell-targeting moieties include ligands and polypeptides that bind to cell-surface targets.
[0260] One type of cell targeting moiety is a protein binding region. The binding region of the cell targeting molecules of the present invention comprises one or more polypeptides capable of selectively and specifically binding to an extracellular target biomolecule. The binding region may comprise one or more different polypeptide moieties, such as ligands (whether synthetic or naturally occurring and derivatives thereof), immunoglobulin-derived domains, synthetically engineered scaffolds (as an alternative to immunoglobulin domains), and the like. The use of a protein binding region in the cell targeting molecules of the present invention allows for the generation of cell targeting molecules that are single-chain cell targeting proteins.
[0261] Certain embodiments of the cell-targeting molecules of the present invention comprise a cell-targeting binding region that is capable of specifically binding to an extracellular portion of a target biomolecule that is physically coupled to a cell. The binding region of the cell-targeting molecules of the present invention comprises a peptide or polypeptide region that is capable of specifically binding to a target biomolecule. In certain embodiments, the binding region of the cell-targeting molecules of the present invention comprises one or more polypeptides that are capable of selectively and specifically binding to an extracellular target biomolecule. The binding region can comprise one or more different peptide or polypeptide portions, such as randomly generated peptide sequences, naturally occurring ligands or derivatives thereof, immunoglobulin-derived domains, synthetically engineered scaffolds (as alternatives to immunoglobulin domains), and the like.
[0262] It is known in the art that many binding regions can be used to target polypeptides (e.g., ligands, monoclonal antibodies, engineered antibody derivatives, and engineered alternatives to antibodies) to specific cell types via their binding characteristics (see, e.g., Cheung M et al., Mol Cancer 9:28 (2010); WO 2014 / 164680; WO 2014 / 164693; WO 2015 / 113005; WO 2015 / 113007; WO 2015 / 138435; WO 2015 / 138452; US20150259428; WO 2015 / 191764; US20160177284; WO 2016 / 126950).
[0263] According to one specific but non-limiting aspect, the binding region of the molecule of the invention comprises a naturally occurring ligand or a derivative thereof that retains binding function to an extracellular target biomolecule (typically a cell surface receptor). For example, various cytokines, growth factors, and hormones known in the art can be used to target cell targeting molecules to the cell surface of a specific cell type expressing a cognate cytokine receptor, growth factor receptor, or hormone receptor.
[0264] According to certain other embodiments, the binding region comprises a synthetic ligand capable of binding an extracellular target biomolecule.
[0265] According to one specific but non-limiting aspect, the binding region may comprise an immunoglobulin-type binding region. As used herein, the term "immunoglobulin-type binding region" refers to a polypeptide region that is capable of binding to one or more target biomolecules (e.g., antigens or epitopes). Binding regions can be functionally defined by their ability to bind to target molecules. Immunoglobulin-type binding regions are typically derived from antibodies or antibody-like structures; however, alternative scaffolds from other sources are considered within the scope of this term.
[0266] Immunoglobulin (Ig) proteins have domains called Ig domains. The length of the Ig domain ranges from about 70-110 amino acid residues and has a characteristic Ig fold, in which usually 7 to 9 antiparallel β strands are arranged into two β folds, forming a sandwich-like structure. The Ig fold is stabilized by hydrophobic amino acid interactions on the inner surface of the sandwich and highly conserved disulfide bonds between cysteine residues in the chain. The Ig domain can be variable (IgV or V-group), constant (IgC or C-group) or intermediate (IgI or I-group). Some Ig domains can be associated with complementarity determining regions or complementarity determining regions (CDRs) (which are important for the specificity of antibodies binding to their epitopes). Ig-like domains are also present in non-immunoglobulins and, on this basis, are classified as members of the protein Ig superfamily. The HUGO Gene Nomenclature Committee (HGNC) provides a list of family members containing the Ig family.
[0267] As used herein, the term "heavy chain variable (V H ) domain" or "light chain variable (V L ) domains” refer to any antibody V H or V L Domain (e.g. human V H or V L domain) and any derivatives thereof (e.g., derived from natural mouse V H or V L Humanized V domain H or V L domain), said derivative retains at least the qualitative antigen-binding ability of the corresponding natural antibody. H or V L The structural domain consists of a "framework" region interrupted by three CDRs or ABRs. The framework region is used to enable the CDRs to bind specifically to the antigen epitope. From the amino terminus to the carboxyl terminus, the V H and V L The domains all contain the following framework (FR) and CDR regions: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. H H fragment, cartilaginous fish IgNAR, V NAR The fragments and their derivatives present a single heavy chain variable domain comprising the same basic arrangement: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
[0268] The immunoglobulin-type binding region can be a polypeptide sequence of an antibody or antigen-binding fragment thereof, wherein the amino acid sequence is different from the amino acid sequence of the Ig-like domain of a natural antibody or non-immunoglobulin protein due to molecular engineering or library screening selection. Due to the relevance of recombinant DNA technology and in vitro library screening in the generation of immunoglobulin-type binding regions, antibodies can be redesigned to obtain desired characteristics, such as smaller size, cell entry or other therapeutic improvements. The possible changes are numerous and can range from changes in just one amino acid to, for example, a complete redesign of the variable region. Typically, changes in the variable region will be made to improve antigen binding characteristics, improve variable region stability or reduce the likelihood of an immunogenic response.
[0269] There are many immunoglobulin-type binding regions that are contemplated as components of the molecules of the invention, such as, for example, the cell-targeting molecules of the invention. An immunoglobulin binding region generally comprises one or more CDRs. In certain embodiments, the immunoglobulin-type binding region is derived from an immunoglobulin binding region, such as an antibody paratope capable of binding an extracellular target biomolecule. In certain other embodiments, the immunoglobulin-type binding region comprises an engineered polypeptide that is not derived from any immunoglobulin domain but functions as an immunoglobulin binding region by providing high-affinity binding to an extracellular target biomolecule. The engineered polypeptide may optionally include a polypeptide scaffold comprising or consisting essentially of a complementarity determining region from an immunoglobulin as described herein.
[0270] There are also many binding regions in the prior art that can be used to target polypeptides to specific cell types through their high affinity binding characteristics. In certain embodiments, the binding region of the protein of the present invention is selected from the group consisting of single domain antibody domains (sdAb), nanobodies, heavy chain antibody domains from Camelidae (V H H fragment), bivalent nanobodies, heavy chain antibody domains from cartilaginous fish, immunoglobulin new antigen receptors (IgNAR), V NAR fragments, single-chain variable (scFv) fragments, autonomous V H domains, single domain antibody domains (sdAb), heavy chain antibody domains from Camelidae (V H H fragment or V H domain fragment), derived from Camelidae V H H fragment or V H Heavy chain antibody domain of domain fragment, heavy chain antibody domain from cartilaginous fish, immunoglobulin new antigen receptor (IgNAR), V NAR Fragments, single chain variable (scFv) fragments, nanobodies, composed of heavy chain and C H 1 domain composed of Fd fragment, single-chain Fv-C H 3 microantibodies, dimer C H2 domain fragment (C H 2D), Fc antigen binding domain (Fcab), isolated complementarity determining region 3 (CDR3) fragment, constrained framework region 3, CDR3, framework region 4 (FR3-CDR3-FR4) polypeptide, small modular immunopharmaceutical (SMIP) domain, multimeric V H H fragments, scFv-Fc fusions, multimeric scFv fragments (diabodies, triabodies, tetrabodies), disulfide-stabilized antibody variable (Fv) fragments, disulfide-stabilized antigen-binding (Fab) fragments (composed of V L 、V H 、C L and C H 1 domain composition), bivalent nanobodies, bivalent minibodies, bivalent F(ab')2 fragments (Fab dimers), bispecific tandem V HH fragments, bispecific tandem scFv fragments, bispecific nanobodies, bispecific minibodies and any genetically manipulated counterparts of any of the foregoing that retain their paratope and binding function (see, e.g., Ward E et al., Nature 341:544-6 (1989); Davies J, Riechmann L, Biotechnology (NY) 13:475-9 (1995); Reiter Y et al., Mol Biol 290:685-98 (1999); Riechmann L, Muyldermans S, J Immunol Methods 231:25-38 (1999); Tanha J et al., J Immunol Methods 263:97-109 (2002); Vranken W et al., Biochemistry 41:8570-9 (2002); Dottorini T et al., Biochemistry 43:622-8 (2004); Jespers et al., Biochemistry 51:576-57 (2005); L et al., J Mol Biol 337:893-903 (2004); Jespers L et al., Nat Biotechnol 22:1161-5 (2004); To R et al., J Biol Chem 280:41395-403 (2005); Spinelli S et al., FEBS Lett 564:35-40 (2004); Saerens D et al., Curr Opin Pharmacol 8:600-8 (2008); Dimitrov D, MAbs 1:26-8 (2009); Baral T et al., PLoS One 7:e30149 (2012); Ahmad Z et al., Clin Dev Immunol 2012:980250 (2012); Weiner L, Cell 148:1081-4 (2012); Richard G et al., PLoS One 8:e69495 (2013). There are a variety of binding regions comprising polypeptides derived from immunoglobulin constant regions, such as, for example, engineered dimeric Fc domains, monomeric Fcs (mFcs), V H H-Fc fusion, scFv-Fc fusion, C H 2 domains, monomer C H 3s domain (mC H3s), synthetically reprogrammed immunoglobulin domains, and / or hybrid fusions of immunoglobulin domains with ligands (Hofer T et al., Proc Natl Acad Sci USA 105:12451-6 (2008); Xiao J et al., J Am Chem Soc 131:13616–13618 (2009); Xiao X et al., Biochem Biophys Res Commun 387:387-92 (2009); Wozniak-Knopp G et al., Protein Eng Des Sel 23 289-97 (2010); Gong R et al., PLoS ONE 7:e42288 (2012); Wozniak-Knopp G et al., PLoS ONE 7:e30083 (2012); Ying T et al., J Biol Chem 287: 19399-408 (2012); Ying T et al., J Biol Chem 288: 25154-64 (2013); Chiang M et al., J Am Chem Soc 136: 3370-3 (2014); Rader C, Trends Biotechnol 32: 186-97 (2014); Ying T et al., Biochimica Biophys Acta 1844: 1977-82 (2014).
[0271] According to certain other embodiments, the binding region comprises an engineered alternative scaffold to an immunoglobulin domain that exhibits similar functional characteristics, such as high affinity and specific binding to a target biomolecule, and can be engineered to improve characteristics, such as greater stability or reduced immunogenicity. For certain embodiments of the cell-targeting molecules of the present invention, the binding region is selected from the group consisting of engineered armadillo repeat polypeptides (ArmRPs), engineered fibronectin-derived 10 th Fibronectin type III (10Fn3) domain (monomer, AdNectins TM or AdNexins TM ); engineered tenascin-derived tenascin type III domains (Centryns™); engineered ankyrin repeat-containing peptides (DARPins TM ); engineered low-density lipoprotein receptor-derived A domain (LDLR-A) (Avimers TM); Lipocalins (anticalins); Engineered protease inhibitor-derived Kunitz domains; Engineered protein A-derived Z domains (Affibodies TM ); engineered γ-B crystal-derived scaffolds or engineered ubiquitin-derived scaffolds (Affilins); Sac7d-derived polypeptides ( or affitins); engineered Fyn-derived SH2 domain and engineered antibody mimetics and any genetically manipulated counterparts of the foregoing that retain their binding function ( A, Plückthun A, J Mol Biol 305:989-1010 (2001); Xu L et al., Chem Biol 9:933-42 (2002); Wikman M et al., Protein Eng Des Sel 17:455-62 (2004); Binz H et al., Nat Biotechnol 23:1257-68 (2005); Holliger P, Hudson P, Nat Biotechnol 23:1126-36 (2005); Gill D, Damle N, Curr Opin Biotech 17:653-8 (2006); Koide A, Koide S, Methods Mol Biol 352:95-109 (2007); Byla P et al., J Biol Chem 285:12096 (2010); Zoller F et al., Molecules 16:2467-85 (2011); Alfarano P et al., Protein Sci 21:1298-314 (2012); Madhurantakam C et al., Protein Sci 21:1015-28 (2012); Varadamsetty G et al., J Mol Biol 424:68-87 (2012)).
[0272] In certain embodiments of the invention, the immunoglobulin-type binding region is derived from a nanobody or a single domain immunoglobulin-derived region V H H. Typically, nanobodies are constructed from fragments of naturally occurring single, monomeric variable domain antibodies (sdAbs) found in camelids and cartilaginous fish (elasmobranchs). Nanobodies are engineered from these naturally occurring antibodies by truncating the single, monomeric variable domains to produce smaller and more stable molecules, such as, for example, IgNAR, V H H and V NARDue to their small size, nanobodies are able to bind antigens that are inaccessible to whole antibodies.
[0273] In certain embodiments of the cell targeting molecules of the present invention, the binding region comprises one or more polypeptides selected from the group consisting of: a) heavy chain variable (V H ) domain comprising (i) HABR1 or HCDR1, (ii) HABR2 or HCDR2, and (iii) HABR3 or HCDR3; and / or b) a light chain variable (V L ) domain, comprising (i) LABR1 or LCDR1, (ii) LABR2 or LCDR2, and (iii) LABR3 or LCDR3; wherein each of the above-mentioned ABRs and / or CDRs is selected from a polypeptide comprising or consisting essentially of one of the amino acid sequences set forth in SEQ ID NOs: 844-1100. In certain further embodiments, the binding region comprises or consists essentially of amino acids 269-499 of any one of SEQ ID NOs: 807-808 and 812-813, comprises or consists essentially of amino acids 269-519 of any one of SEQ ID NOs: 814-815 and 818-829, or comprises or consists essentially of amino acids 268-386 of any one of SEQ ID NOs: 816-817.
[0274] In certain embodiments of the invention, the binding region polypeptide comprises a free cysteine residue suitable for conjugation to another molecule, wherein the cysteine is located at or proximal to the carboxyl terminus of the binding region polypeptide. In certain further embodiments, the binding region of the cell targeting molecule of the invention comprises a series of amino acid residues represented by (X)nCX or (X)nC, wherein X refers to any amino acid, (X)n refers to the polypeptide comprising the binding domain, and C refers to a cysteine residue.
[0275] In certain embodiments of the invention, the binding region polypeptide comprises a free cysteine residue suitable for conjugation to another molecule, wherein the cysteine is located at or proximal to the amino terminus of the binding region polypeptide. In certain further embodiments, the binding region of the cell targeting molecule of the invention comprises a series of amino acid residues represented by C-(X)n or MC-(X)n, wherein X refers to any amino acid, (X)n refers to the polypeptide comprising the binding domain, C refers to a cysteine residue, and M refers to an initial methionine.
[0276] In certain embodiments of the invention, the molecules of the invention comprise immunoglobulin binding domains lacking cysteine residues. Such immunoglobulin binding domain structures are known to those skilled in the art and / or can be produced using conventional methods (see, e.g., Proba K, J Mol Biol 275:245-53 (1998)).
[0277] Any of the above binding regions can be used as a component of the cell targeting molecule of the present invention, as long as the dissociation constant of the binding region component for the extracellular target biomolecule is less than 10 -5 to 10 -12 Mole / L, preferably less than 200 nanomoles (nM).
[0278] Cell-specific targeting can be achieved by attaching the molecules of the invention to cell-targeting carriers, such as liposomes, polymers, nanocarriers, microspheres, nanospheres, dendrimers, polymer micelles, silicon or carbon materials, such as, for example, nanotubes, nanorods and nanohorns, magnetic nanoparticles, microemulsions and other nanostructures (Sinha R et al., Molecular Cancer Therapeutics 5:1909–17 (2006); L Brinton et al., Journal of the National Cancer Institute 100:1643-8 (2008); Tanaka T et al., Biomed Micro Devices 11:49-63 (2009)). Attachment can be accomplished using one or more covalent bonds and / or encapsulation.
[0279] Extracellular target biomolecules
[0280] The binding region of the molecules of the invention comprises a polypeptide region capable of specifically binding an extracellular target biomolecule, preferably physically coupled to the surface of a cell type of interest (e.g., a cancer cell, a tumor cell, a plasma cell, an infected cell, or a host cell harboring an intracellular pathogen).
[0281] The term "target biomolecule" refers to a biomolecule, typically a protein or a protein modified by a post-translational modification (e.g., glycosylation), that can be bound by a binding region to target the protein to a specific cell type or location within an organism. Extracellular target biomolecules can include a variety of epitopes, including unmodified polypeptides, polypeptides modified by the addition of biochemical functional groups, and glycolipids.
[0282] Numerous extracellular target biomolecules are known to those skilled in the art, which can be targeted by the binding regions of the cell targeting molecules of the present invention and polypeptide binding domains known to bind to such target biomolecules (see, for example, WO 2014 / 164680; WO 2014 / 164693; WO 2015 / 113005; WO 2015 / 113007; WO 2015 / 138435; WO 2015 / 138452; US20150259428; WO 2015 / 191764; US20160177284; WO 2016 / 126950).
[0283] For the purposes of the present invention, the term "extracellular" with respect to a target biomolecule for modification refers to a biomolecule whose structure is at least partially exposed to the extracellular environment. Extracellular target biomolecules include cell membrane components, transmembrane spanning proteins, cell membrane anchored biomolecules, cell surface bound biomolecules, and secreted biomolecules.
[0284] With respect to the present invention, the phrase "physically coupled" when used to describe a target biomolecule refers to covalent and / or non-covalent intermolecular interactions that couple the target biomolecule or a portion thereof to the exterior of the cell, e.g., multiple non-covalent interactions between the target biomolecule and the cell, wherein the energy of each single interaction is approximately 1-5 kilocalories (e.g., electrostatic bonds, hydrogen bonds, van der Waals interactions, hydrophobic forces, etc.). All integral membrane proteins can be found physically coupled to cell membranes, as well as peripheral membrane proteins. For example, an extracellular target biomolecule can comprise a transmembrane spanning region, a lipid anchor, a glycolipid anchor, and / or be non-covalently associated with a factor comprising any of the foregoing (e.g., via non-specific hydrophobic interactions and / or lipid binding interactions).
[0285] The binding region of the cell-targeting molecules of the present invention can be designed or selected based on a number of criteria, such as the cell type-specific expression of its target biomolecule and / or the physical localization of its target biomolecule with respect to a particular cell type. For example, certain cell-targeting molecules of the present invention comprise a binding domain capable of binding to a cell surface target that is expressed by only one cell type on the cell surface.
[0286] In certain embodiments of the present invention, the cell targeting molecule comprises a binding region derived from an immunoglobulin-type polypeptide that is selected to bind specifically and with high affinity to a surface antigen on the cell surface of a cancer cell, wherein expression of the antigen is restricted to cancer cells (see Glokler J et al., Molecules 15:2478-90 (2010); Liu Y et al., Lab Chip 9:1033-6 (2009)). According to other embodiments, the binding region is selected to bind specifically and with high affinity to a surface antigen on the cell surface of a cancer cell, wherein the antigen is overexpressed or preferentially expressed by cancer cells compared to non-cancerous cells. Some representative target biomolecules include, but are not limited to, the targets listed below that are associated with cancer and / or specific immune cell types.
[0287] There are many immunoglobulin-type binding regions in the prior art that recognize epitopes associated with cancer cells, for example, binding regions targeting the following: annexin AI, B3 melanoma antigen, B4 melanoma antigen, B7-H3 (CD276, B7RP-2), B cell maturation antigens (BCMA, BCM, TNRSF17, CD269), CD2, CD3, CD4, CD19, CD20 ...
Claims
1. A cell targeting molecule comprising: (a) a Shiga toxin effector polypeptide consisting of an amino acid sequence, wherein the amino acid sequence is obtained by introducing amino acid substitutions S45I, V54I, R55L, I57F, P59F, E60T, E61L, G110A, R188A, C242S, R248A and R251A into amino acids 1-251 of SEQ ID NO: 1; (b) a binding region capable of specifically binding to at least one extracellular target biomolecule; and (c) a linker peptide between the Shiga toxin effector polypeptide and the binding region; wherein the cell targeting molecule comprises a cysteine residue having a functional group suitable for chemical conjugation to a heterologous molecule, wherein the cysteine residue is located at position 8, 16, 33, 43, 146 or 186 of SEQ ID NO: 1 in the Shiga toxin effector polypeptide.
2. A cell targeting molecule comprising: (a) a Shiga toxin effector polypeptide consisting of an amino acid sequence, wherein the amino acid sequence is obtained by introducing amino acid substitutions S45I, V54I, R55L, I57F, P59F, E60T, E61L, G110A, R188A, C242S, R248A and R251A into amino acids 1-251 of SEQ ID NO: 1; (b) a binding region capable of specifically binding to at least one extracellular target biomolecule; and (c) a linker peptide between the Shiga toxin effector polypeptide and the binding region; wherein the cell targeting molecule comprises a cysteine residue having a functional group suitable for chemical conjugation to a heterologous molecule, wherein the cysteine residue is located in the binding region, wherein the binding region is a single-chain variable fragment, the single-chain variable fragment comprises a heavy chain variable domain VH and a light chain variable domain VL, and the cysteine residue is located in the linker between the VH and the VL, wherein, The linker between the VH and the VL comprises the amino acid sequence of any one of SEQ ID NOs: 769-772.
3. A cell targeting molecule comprising: (a) a Shiga toxin effector polypeptide consisting of an amino acid sequence, wherein the amino acid sequence is obtained by introducing amino acid substitutions S45I, V54I, R55L, I57F, P59F, E60T, E61L, G110A, R188A, C242S, R248A and R251A into amino acids 1-251 of SEQ ID NO: 1; (b) a binding region capable of specifically binding to at least one extracellular target biomolecule; and (c) a linker peptide between the Shiga toxin effector polypeptide and the binding region; wherein the cell targeting molecule comprises a cysteine residue having a functional group suitable for chemical conjugation to a heterologous molecule, wherein the cysteine residue is located in a linker peptide comprising an amino acid sequence of any one of SEQ ID NOs:757-760, wherein the cysteine is located at position 6 of SEQ ID NO:757, position 12 of SEQ ID NO:758, position 4 of SEQ ID NO:759, or position 9 of SEQ ID NO:
760.
4. The cell targeting molecule of any one of claims 1 to 3, wherein the Shiga toxin effector polypeptide comprises an asparagine at amino acid residue 75 corresponding to SEQ ID NO: 1, a tyrosine at amino acid residue 114 corresponding to SEQ ID NO: 1, an arginine at amino acid residue 170 corresponding to SEQ ID NO: 1, an arginine at amino acid residue 176 corresponding to SEQ ID NO: 1, and a tryptophan at amino acid residue 203 corresponding to SEQ ID NO:
1.
5. The cell targeting molecule of any one of claims 1 to 3, wherein the Shiga toxin effector polypeptide further comprises at least one of the following amino acid substitutions in SEQ ID NO: 1: Y77S and E167D.
6. The cell targeting molecule of any one of claims 1 to 3, wherein the binding region is located at the C-terminus of the Shiga toxin effector polypeptide.
7. The cell targeting molecule of any one of claims 1 to 3, wherein the Shiga toxin effector polypeptide comprises the amino acid substitution S8C in SEQ ID NO:
1.
8. The cell targeting molecule according to any one of claims 1 to 3, wherein the amino acid residue having the functional group comprises a reactive chemical group.
9. The cell targeting molecule of any one of claims 1-3, wherein the Shiga toxin effector polypeptide consists of SEQ ID NO: 86 or 106.
10. The cell targeting molecule of claim 1 or 3, wherein the binding region is a single-chain variable fragment.
11. The cell targeting molecule of any one of claims 1 to 3, wherein the extracellular target biomolecule is: B7-H3, BCMA, CD20, PD-L1, CD22, CD40, CD45, CD79, CD25, CD30, HER2 / neu / ErbB2, EGFR, EphB2, prostate-specific membrane antigen, Cripto, endoglin / CD105, fibroblast activation protein, Lewis-Y, CD19, CD21, CS1 / SLAMF7, CD33, CD52, CD74, EpCAM, gpA33, mucin, TAG-72, carbonic anhydrase IX, folate binding protein, ganglioside GD2, ganglioside GD3, ganglioside GM2, VEGFR, αVβ3, α 5β1, Erb3, c-MET, IGF1R, EphA3, LMP1, TRAIL-R1, TRAIL-R2, RANKL, tenascin, CD64, mesothelin, BRCA1, tyrosinase, MAGE-1, MAGE-3, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE6, SART-1, PRAME, carcinoembryonic antigen, prostate-specific antigen, prostate stem cell antigen, human aspartyl (asparaginyl) β-hydroxylase, EphA2, HER3 / ErbB-3, MART-1 / MelanA, gp100, tyrosinase-related antigen, HPV-E7, Epstein-Barr virus antigen, Bcr-Abl, alpha-fetoprotein antigen, 17-A1, bladder Tumor antigens, CD38, CD15, CD23, CD53, CD88, CD129, CD183, CD191, CD193, CD244, CD294, CD305; C3AR, galectin-9, mrp-14, siglec-8, siglec-10, CD49d, CD13, CD44, CD54, CD63, CD69, CD123, TLR4 , FceRIa, IgE, CD107a, CD203c, CD14, CD68, CD80, CD86, CD115, F4 / 80, ILT-3, galectin-3, CD11a-c, GITRL, MHC class II, CD284 / TLR4, CD107 / Mac3, CD195 / CCR5, HLA-DR, CD16 / 32, or CD282 / TLR2.
12. The cell targeting molecule of any one of claims 1 to 3, wherein the extracellular target biomolecule is TRP-2.
13. The cell targeting molecule of any one of claims 1 to 3, which is covalently linked to a heterologous molecule via the functional group. The cell targeting molecule of claim 13 , wherein the heterologous molecule is an antibiotic. The cell targeting molecule of claim 13 , wherein the heterologous molecule is an antigen. The cell targeting molecule of claim 13 , wherein the heterologous molecule is an antigenic substance.
17. The cell targeting molecule of claim 13, wherein the heterologous molecule is a cytotoxic agent.
18. The cell targeting molecule of claim 13, wherein the heterologous molecule is a radionuclide.
19. The cell targeting molecule of claim 13, wherein the heterologous molecule is a solubility altering agent.
20. The cell targeting molecule of claim 13, wherein the heterologous molecule is a pharmacokinetic altering agent.
21. The cell targeting molecule of claim 13, wherein the heterologous molecule is an immunogenicity altering agent.
22. The cell targeting molecule of claim 13, wherein the heterologous molecule is a pharmacodynamics altering agent.
23. The cell targeting molecule of claim 13, wherein the heterologous molecule is a detection enhancer.
24. The cell targeting molecule of claim 13, wherein the heterologous molecule is a dye.
25. The cell targeting molecule of claim 13, wherein the heterologous molecule is a T cell epitope.
26. The cell targeting molecule of claim 13, wherein the heterologous molecule is a fluorophore.
27. The cell targeting molecule of claim 13, wherein the heterologous molecule is an immunogen.
28. The cell targeting molecule of claim 13, wherein the heterologous molecule is an immunogenic substance.
29. The cell targeting molecule of claim 13, wherein the heterologous molecule is an enzyme.
30. The cell targeting molecule of claim 13, wherein the heterologous molecule is a zymoxin.
31. The cell targeting molecule of claim 13, wherein the heterologous molecule is a lipid.
32. The cell targeting molecule of claim 13, wherein the heterologous molecule is a polymer.
33. The cell targeting molecule of claim 13, wherein the heterologous molecule is polyethylene glycol.
34. The cell targeting molecule of claim 13, wherein the heterologous molecule is a serum albumin binder.
35. The cell targeting molecule of claim 13, wherein the heterologous molecule is a small molecule chemotherapeutic agent.
36. The cell targeting molecule of claim 13, wherein the heterologous molecule is a prodrug.
37. The cell targeting molecule of claim 13, wherein the heterologous molecule is a nucleic acid.
38. The cell targeting molecule of claim 13, wherein the heterologous molecule is a protein-nucleic acid complex.
39. The cell targeting molecule according to claim 13, wherein The heterologous molecule is a protein.
40. The cell targeting molecule according to claim 13, wherein The heterologous molecule is a peptide.
41. The cell targeting molecule of claim 13, wherein the heterologous molecule is auristatin, pyrrolebenzodiazepine, or pyrrolebenzodiazepine dimer.
42. A pharmaceutical composition comprising the cell targeting molecule according to any one of claims 1 to 41, and a pharmaceutically acceptable excipient or carrier.
43. A polynucleotide encoding the cell targeting molecule of any one of claims 1-41.
44. An expression vector comprising the polynucleotide of claim 43.
45. A host cell comprising the polynucleotide of claim 43.
46. Use of the cell targeting molecule of any one of claims 1-41 or the pharmaceutical composition of claim 42 for the preparation of a medicament for treating a disease, disorder or condition in a patient; wherein the disease, disorder or condition is a tumor.
47. Use of the cell targeting molecule of any one of claims 1-41 or the pharmaceutical composition of claim 42 for the preparation of a medicament for treating a disease, disorder or condition in a patient; wherein the disease, disorder or condition is cancer.
